CN1403479A - Human protein with function of suppressing cancer cell growth and its coding sequence - Google Patents

Abstract

The present invention discloses one kind of human protein with cancer suppressing function, polynucleotides encoding the polypeptide and the recombinant process of producing the polypeptide. The present invention also discloses the method of using the polypeptide in treating various diseases, such as cancer. The present invention also discloses the agonist resisting the polypeptide and its treatment effect. The present invention also discloses the application of the polynucleotides encoding the human protein with cancer suppressing function.

Description

New people's albumen and encoding sequence thereof with anticancer growth function

Technical field

The invention belongs to biological technical field, specifically, the present invention relates to new coding and have the proteic polynucleotide of people of cancer suppressing function and the polypeptide of this polynucleotide encoding.The invention still further relates to the purposes and the preparation of these polynucleotide and polypeptide.

Background technology

The research of people's gene group is international focus at present, removes human chromosome DNA large scale sequencing, outside the method for expressed sequence order-checking (EST), also lacks the screening that begins from function and has the high-throughout method of functional gene.

Cancer is one of principal disease of harm humans health.In order to treat effectively and prophylaxis of tumours, people more and more pay close attention to genetic treatment of tumor at present.Therefore, this area presses for people's albumen and the agonist/inhibitor thereof that development research has cancer suppressing function.

Summary of the invention

The purpose of this invention is to provide the new people's protein polypeptide of a class with cancer suppressing function with and fragment, analogue and derivative.

Another object of the present invention provides the polynucleotide of these polypeptide of coding.

Another object of the present invention provides the method for these polypeptide of production and the purposes of this polypeptide and encoding sequence.

In a first aspect of the present invention, novel isolated protein polypeptide with cancer suppressing function is provided, it comprises the polypeptide of the aminoacid sequence with the group of being selected from down: SEQ ID NO:2,5,8,11,14,17,20,23,26,29,32,35; Or its conservative property variation polypeptide or its active fragments or its reactive derivative.

Preferably, this polypeptide is the polypeptide with aminoacid sequence of the group of being selected from down: SEQ ID NO:2,5,8,11,14,17,20,23,26,29,32,35.

In a second aspect of the present invention, a kind of isolating polynucleotide are provided, it comprises a nucleotide sequence, and this nucleotide sequence is shown at least 85% homogeny with a kind of nucleotides sequence that is selected from down group: the polynucleotide of the above-mentioned protein polypeptide with cancer suppressing function of (a) encoding; (b) with polynucleotide (a) complementary polynucleotide.Preferably, the polypeptide of this polynucleotide encoding has the aminoacid sequence of the group of being selected from down: SEQ ID NO:2,5,8,11,14,17,20,23,26,29,32,35.More preferably, the sequence of these polynucleotide is selected from down group: SEQ ID NO:3,6,9,12,15,18,21,24,27,30,33,36 coding region sequence or full length sequence.

In a third aspect of the present invention, the carrier that contains above-mentioned polynucleotide is provided, and has been transformed or host cell of transduceing or the host cell that is directly transformed or transduce by above-mentioned polynucleotide by this carrier.

In a fourth aspect of the present invention, the preparation method who prepares the polypeptide of the protein-active with cancer suppressing function is provided, this method comprises: (a) have under the proteic condition of cancer suppressing function suitable the expression, cultivate the above-mentioned host cell that is transformed or transduce; (b) from culture, isolate the polypeptide of protein-active with cancer suppressing function.

In a fifth aspect of the present invention, provide and above-mentioned protein polypeptide specificity bonded antibody with cancer suppressing function.The nucleic acid molecule that can be used for detecting also is provided, and it contains, and continuous 10 Nucleotide are to full length nucleotide in the above-mentioned polynucleotide, and preferably it contains the about 10-800 of a successive Nucleotide.

In a sixth aspect of the present invention, a kind of pharmaceutical composition is provided, it contains the protein polypeptide and the pharmaceutically acceptable carrier with cancer suppressing function of the present invention of safe and effective amount.These pharmaceutical compositions can be treated illnesss such as cancer and cellular abnormality propagation.

Others of the present invention are because the disclosure of this paper is conspicuous to those skilled in the art.

Embodiment

The present invention adopts large-scale cDNA clone transfection cancer cells, has on the basis of cancer suppressing action in acquisition, proves new gene through order-checking, further obtains full length cDNA clone.DNA transfection evidence, the albumen with cancer suppressing function of the present invention has the effect that suppresses clone's formation to cancer cells (liver cancer cell), and its inhibiting rate is more than 50% or 50%.

As used herein, " isolating " is meant that material separates (if natural substance, primal environment promptly is a natural surroundings) from its primal environment.Do not have separation and purification as polynucleotide under the native state in the active somatic cell and polypeptide, but same polynucleotide or polypeptide as from native state with in other materials that exist separately, then for separation and purification.

As used herein, " isolating albumen or polypeptide with cancer suppressing function " is meant that the protein polypeptide with cancer suppressing function is substantially free of natural relative other albumen, lipid, carbohydrate or other material.Those skilled in the art can have the albumen of cancer suppressing function with the purified technology of protein purifying of standard.Basically pure polypeptide can produce single master tape on non-reduced polyacrylamide gel.

Polypeptide of the present invention can be recombinant polypeptide, natural polypeptides, synthetic polypeptide, preferred recombinant polypeptide.Polypeptide of the present invention can be the product of natural purifying, or the product of chemosynthesis, or uses recombinant technology to produce from protokaryon or eucaryon host (for example, bacterium, yeast, higher plant, insect and mammalian cell).The host used according to the recombinant production scheme, polypeptide of the present invention can be glycosylated, maybe can be nonglycosylated.Polypeptide of the present invention also can comprise or not comprise initial methionine residues.

The present invention also comprises the proteic fragment of the people with cancer suppressing function, derivative and analogue.As used herein, term " fragment ", " derivative " are meant with " analogue " and keep natural identical biological function or the active polypeptide of people's albumen with cancer suppressing function of the present invention basically.Polypeptide fragment of the present invention, derivative or analogue can be that (i) has one or more conservative or substituted polypeptide of non-conservation amino-acid residue (preferred conservative amino acid residue), and the amino-acid residue of such replacement can be also can not encoded by genetic code, or (ii) in one or more amino-acid residues, has a polypeptide of substituted radical, or (iii) mature polypeptide and another compound (such as the compound that prolongs the polypeptide transformation period, polyoxyethylene glycol for example) merge formed polypeptide, or (iv) additional aminoacid sequence is fused to this peptide sequence and the polypeptide that forms (as leader sequence or secretion sequence or be used for the sequence or the proteinogen sequence of this polypeptide of purifying).According to the instruction of this paper, these fragments, derivative and analogue belong to the known scope of those skilled in the art.

Polynucleotide of the present invention can be dna form or rna form.Dna form comprises the DNA of cDNA, genomic dna or synthetic.DNA can be strand or double-stranded.DNA can be coding strand or noncoding strand.Be example with PP10187 albumen (in this application, its clone numbering is adopted in proteinic name), the coding region sequence of encoding mature polypeptide can be identical with the coding region sequence shown in the SEQ ID NO:3 or the varient of degeneracy.As used herein, " varient of degeneracy " is meant that in the present invention coding has the protein of SEQ ID NO:2, but with the differentiated nucleotide sequence of coding region sequence shown in the SEQ IDNO:3.Be example with PP12104 albumen (in this application, its clone numbering is adopted in proteinic name) again, the coding region sequence of encoding mature polypeptide can be identical with the coding region sequence shown in the SEQ ID NO:6 or the varient of degeneracy.As used herein, " varient of degeneracy " is meant that in the present invention coding has the protein of SEQ ID NO:5, but with the differentiated nucleotide sequence of coding region sequence shown in the SEQ ID NO:6.Have the albumen of cancer suppressing function for of the present invention other, can the rest may be inferred.

The polynucleotide of encoding mature polypeptide comprise: the encoding sequence of an encoding mature polypeptide; The encoding sequence of mature polypeptide and various additional code sequence; Encoding sequence of mature polypeptide (with optional additional code sequence) and non-coding sequence.

Term " polynucleotide of coded polypeptide " can be the polynucleotide that comprise this polypeptide of encoding, and also can be the polynucleotide that also comprise additional code and/or non-coding sequence.

The invention still further relates to the varient of above-mentioned polynucleotide, its coding has the polypeptide of identical aminoacid sequence or fragment, analogue and the derivative of polypeptide with the present invention.The varient of these polynucleotide can be the allelic variant of natural generation or the varient that non-natural takes place.These nucleotide diversity bodies comprise and replace varient, deletion mutation body and insert varient.As known in the art, allelic variant is the replacement form of polynucleotide, and it may be replacement, disappearance or the insertion of one or more Nucleotide, but can be from not changing the function of its encoded polypeptides in fact.

The invention still further relates to and above-mentioned sequence hybridization and two sequences between have at least 50%, preferably at least 70%, the polynucleotide of at least 80% homogeny more preferably.The present invention be more particularly directed under stringent condition and the interfertile polynucleotide of polynucleotide of the present invention.In the present invention, " stringent condition " is meant: (1) than hybridization under low ionic strength and the comparatively high temps and wash-out, as 0.2 * SSC, and 0.1%SDS, 60 ℃; Or (2) hybridization the time is added with denaturing agent, as 50% (v/v) methane amide, 0.1% calf serum/0.1%Ficoll, 42 ℃ etc.; Or (3) only at the homogeny between the two sequences at least more than 95%, be more preferably 97% and just hybridize when above.And the polypeptide of interfertile polynucleotide encoding has identical biological function (is example with PP10187 albumen) and activity with the mature polypeptide shown in the SEQ IDNO:2.

The invention still further relates to nucleic acid fragment with above-mentioned sequence hybridization.As used herein, the length of " nucleic acid fragment " contains 15 Nucleotide at least, better is at least 30 Nucleotide, is more preferably at least 50 Nucleotide, preferably more than at least 100 Nucleotide.The amplification technique (as PCR) that nucleic acid fragment can be used for nucleic acid has the proteic polynucleotide of cancer suppressing function to determine and/or to separate to encode.

Polypeptide among the present invention and polynucleotide preferably provide with isolating form, more preferably are purified to homogeneous.

Dna sequence dna of the present invention can obtain with several method.For example, with hybridization technique DNA isolation well known in the art.These technology including, but not limited to: 1) with probe and genome or the hybridization of cDNA library to detect homology nucleotide sequence and 2) antibody screening of expression library to be to detect the dna fragmentation of the clone with common structure feature.

The proteic specific DNA fragment sequence that coding has cancer suppressing function produces also and can obtain with following method: 1) separate double chain DNA sequence from genomic dna; 2) the chemical synthesising DNA sequence is to obtain the double-stranded DNA of required polypeptide.

In the above-mentioned method of mentioning, isolation of genomic DNA is least commonly used.When the whole aminoacid sequence of the polypeptide product of needs was known, the direct chemical of dna sequence dna is synthetic to be the method for often selecting for use.When if required amino acid whose whole sequence is not known, the direct chemical of dna sequence dna is synthetic to be impossible, and the method for selecting for use is the separation of cDNA sequence.The standard method that separates interested cDNA is from the donorcells separating mRNA of this gene of high expression level and carries out reverse transcription, forms plasmid or phage cDNA library.Extract the existing multiple proven technique of method of mRNA, test kit also can obtain (Qiagene) from commercial channels.And the construction cDNA library also is usual method (Sambrook, et al., Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory.New York, 1989).Also can obtain the cDNA library of commercial offers, as the different cDNA library of Clontech company.When being used in combination the polymeric enzyme reaction technology, even few expression product also can be cloned.

Available ordinary method is screened gene of the present invention from these cDNA libraries.These methods include, but is not limited to: (1) DNA-DNA or DNA-RNA hybridization; (2) function of marker gene occurs or forfeiture; (3) mensuration has the level of the proteic transcript of cancer suppressing function; (4), detect the protein product of genetic expression by immunological technique or mensuration biologic activity.Aforesaid method can singly be used, but also several different methods combined utilization.

In (1) kind method, hybridizing used probe is and any a part of homology of polynucleotide of the present invention that at least 15 Nucleotide of its length better are at least 30 Nucleotide, are more preferably at least 50 Nucleotide, preferably at least 100 Nucleotide.In addition, the length of probe within 2kb, preferably is within the 1kb usually.Probe used herein is the dna sequence dna of chemosynthesis on the basis of gene DNA sequence information of the present invention normally.Gene of the present invention itself or fragment are certainly as probe.The mark of dna probe can be used radio isotope, fluorescein or enzyme (as alkaline phosphatase) etc.

In (4) kind method, detect the protein product of protein gene expression and can use immunological technique such as Western blotting, radioimmunoprecipitation, enzyme-linked immunosorbent assay (ELISA) etc. with cancer suppressing function.

Use method (Saiki, the et al.Science 1985 of round pcr DNA amplification/RNA; 230:1350-1354) be optimized for acquisition gene of the present invention.When particularly being difficult to obtain the cDNA of total length from the library, can preferably use RACE method (the terminal rapid amplifying method of RACE-cDNA), the primer that is used for PCR can suitably be selected according to sequence information of the present invention disclosed herein, and available ordinary method is synthetic.Available ordinary method is as the DNA/RNA fragment by gel electrophoresis separation and purifying amplification.

The gene of the present invention that obtains as mentioned above, perhaps the available ordinary method of mensuration of the nucleotide sequence of various dna fragmentations etc. such as dideoxy chain termination (Sanger et al.PNAS, 1977,74:5463-5467).This class nucleotide sequencing is available commercial sequencing kit etc. also.In order to obtain the cDNA sequence of total length, order-checking need be carried out repeatedly.Sometimes need to measure a plurality of clones' cDNA sequence, just can be spliced into the cDNA sequence of total length.

The present invention also relates to comprise the carrier of polynucleotide of the present invention, and the host cell that produces through genetically engineered with carrier of the present invention or albumen coded sequence with cancer suppressing function, and the method that produces polypeptide of the present invention through recombinant technology.

Recombinant DNA technology (Science, 1984 by routine; 224:1431), can utilize polymerized nucleoside acid sequence of the present invention to can be used to express or produce the protein polypeptide with cancer suppressing function of reorganization.In general following steps are arranged:

(1). have the proteic polynucleotide of people (or varient) of cancer suppressing function with coding of the present invention, or transform or the transduction proper host cell with the recombinant expression vector that contains these polynucleotide;

(2). the host cell of in suitable medium, cultivating;

(3). separation, protein purification from substratum or cell.

Among the present invention, the people's albumen polynucleotide sequence with cancer suppressing function can be inserted in the recombinant expression vector.Term " recombinant expression vector " refers to that bacterial plasmid well known in the art, phage, yeast plasmid, vegetable cell virus, mammalian cell virus are as adenovirus, retrovirus or other carriers.The carrier of Shi Yonging includes but not limited in the present invention: and the expression vector based on T7 of in bacterium, expressing (Rosenberg, et al.Gene, 1987,56:125); The pMSXND expression vector of in mammalian cell, expressing (Lee and Nathans, J Bio Chem.263:3521,1988) and at the carrier that derives from baculovirus of expressed in insect cells.In a word, as long as can duplicate in host and stablize, any plasmid and carrier can be used.A key character of expression vector is to contain replication orgin, promotor, marker gene and translation controlling elements usually.

Method well-known to those having ordinary skill in the art can be used to make up and contains people's encoding histone dna sequence dna with cancer suppressing function and suitable transcribing/the translate expression vector of control signal.These methods comprise (Sambroook, et al.) such as extracorporeal recombinant DNA technology, DNA synthetic technology, the interior recombinant technologys of body.Described dna sequence dna can effectively be connected on the suitable promotor in the expression vector, and is synthetic to instruct mRNA.The representative example of these promotors has: colibacillary lac or trp promotor; Lambda particles phage P _LPromotor; Eukaryotic promoter comprises LTRs and some other known may command gene expression promoter in protokaryon or eukaryotic cell or its virus of CMV immediate early promoter, early stage and late period SV40 promotor, retrovirus.Expression vector also comprises ribosome bind site and the transcription terminator that translation initiation is used.

In addition, expression vector preferably comprises one or more selected markers, to be provided for selecting the phenotypic character of transformed host cells, cultivate Tetrahydrofolate dehydrogenase, neomycin resistance and the green fluorescent protein (GFP) of usefulness as eukaryotic cell, or be used for colibacillary tsiklomitsin or amicillin resistance.

Comprise the carrier of above-mentioned suitable dna sequence dna and suitable promotor or control sequence, can be used to transform appropriate host cell, so that it can marking protein.

Host cell can be a prokaryotic cell prokaryocyte, as bacterial cell; Or eukaryotic cell such as low, as yeast cell; Or higher eucaryotic cells, as mammalian cell.Representative example has: intestinal bacteria, streptomyces; The bacterial cell of Salmonella typhimurium; Fungal cell such as yeast; Vegetable cell; The insect cell of fruit bat S2 or Sf9; The zooblast of CHO, COS or Bowes melanoma cells etc.

When polynucleotide of the present invention are expressed in higher eucaryotic cells, be enhanced if will make to transcribe when in carrier, inserting enhancer sequence.Enhanser is the cis acting factor of DNA, and nearly 10 to 300 base pairs act on promotor transcribing with enhancing gene usually.Can for example be included in the SV40 enhanser of 100 to 270 base pairs of replication origin side in late period one, at the polyoma enhanser of replication origin side in late period one and adenovirus enhanser etc.

Persons skilled in the art all know how to select appropriate carriers, promotor, enhanser and host cell.

Can carry out with routine techniques well known to those skilled in the art with the recombinant DNA transformed host cell.When the host was prokaryotic organism such as intestinal bacteria, the competent cell that can absorb DNA can be used CaCl in exponential growth after date results ₂Method is handled, and used step is well-known in this area.Alternative is to use MgCl ₂If desired, transforming also the method for available electroporation carries out.When the host is an eukaryote, can select following DNA transfection method for use: coprecipitation of calcium phosphate method, conventional mechanical method such as microinjection, electroporation, liposome packing etc.

The transformant that obtains can be cultivated with ordinary method, expresses the polypeptide of coded by said gene of the present invention.According to used host cell, used substratum can be selected from various conventional substratum in the cultivation.Under the condition that is suitable for the host cell growth, cultivate.After host cell grows into suitable cell density, induce the promotor of selection with suitable method (as temperature transition or chemical induction), cell is cultivated for some time again.

Recombinant polypeptide in the above methods can wrap by in cell, extracellular or on cytolemma, express or be secreted into the extracellular.If desired, can utilize its physics, the separating by various separation methods with other characteristic and the albumen of purification of Recombinant of chemistry.These methods are well-known to those skilled in the art.The example of these methods includes, but are not limited to: conventional renaturation handles, with protein precipitant handle (salt analysis method), centrifugal, the broken bacterium of infiltration, superly handle, the combination of super centrifugal, sieve chromatography (gel-filtration), adsorption chromatography, ion exchange chromatography, high performance liquid chromatography (HPLC) and other various liquid chromatography (LC) technology and these methods.

The people's albumen or the polypeptide with cancer suppressing function of reorganization are of use in many ways.These purposes include, but is not limited to: directly have the disease (as cancer) due to the low or forfeiture of the protein function of cancer suppressing function as pharmacological agent and be used to screen and promote or antagonism has antibody, polypeptide or other part of the protein function of cancer suppressing function.For example, antibody can be used for activating or suppressing to have the proteic function of people of cancer suppressing function.The people's protein screening peptide library that has a cancer suppressing function with the reorganization of expressing can be used for seeking the peptide molecule that can suppress or stimulate the people's protein function with cancer suppressing function of therapeutic value.

The present invention also provides screening of medicaments to improve (agonist) or check the method that (antagonist) has the proteic medicament of people of cancer suppressing function to identify.Agonist improves the biological function such as stimulate cellular proliferation of the people's albumen with cancer suppressing function, and antagonist prevention disorder such as the various cancer relevant with cell hyperproliferation with treatment.For example, can be in the presence of medicine, the proteic film preparation of people that mammalian cell or expression is had cancer suppressing function is cultivated with the people's albumen with cancer suppressing function of mark.Measure the medicine raising then or check this interactional ability.

The proteic antagonist of people with cancer suppressing function comprises antibody, compound, acceptor disappearance thing and the analogue etc. that filter out.Described antagonist can and be eliminated its function with the people's protein binding with cancer suppressing function, or suppresses to have the proteic generation of people of cancer suppressing function, or combines with the avtive spot of polypeptide and to make polypeptide can not bring into play biological function.The proteic antagonist of people with cancer suppressing function can be used for therepic use.

In screening during as the compound of antagonist, albumen of the present invention can be added during bioanalysis measures, determine by measuring albumen and the interaction between its acceptor that compounds affect has cancer suppressing function whether compound is antagonist.With the same quadrat method of above-mentioned SCREENED COMPOUND, can filter out the acceptor disappearance thing and the analogue of antagonist action.

Polypeptide of the present invention can be directly used in disease treatment, for example, and various malignant tumours and cellular abnormality propagation etc.

Polypeptide of the present invention, and fragment, derivative, analogue or their cell can be used as antigen to produce antibody.These antibody can be polyclone or monoclonal antibody.Polyclonal antibody can obtain by the method with this polypeptide direct injection animal.The technology of preparation monoclonal antibody comprises hybridoma technology, three knurl technology, people B-quadroma technology, EBV-hybridoma technology etc.

Can be with polypeptide of the present invention and antagonist and suitable pharmaceutical carrier combination back use.These carriers can be water, glucose, ethanol, salt, damping fluid, glycerine and their combination.Composition comprises the polypeptide or the antagonist of safe and effective amount and carrier and the vehicle that does not influence effect of drugs.These compositions can be used as medicine and are used for disease treatment.

The present invention also provides medicine box or the test kit that contains one or more containers, and one or more medicinal compositions compositions of the present invention are housed in the container.With these containers, can have by the given indicative prompting of government authorities of making, using or selling medicine or biological products, the government authorities that this prompting reflects production, uses or sells permits it to use on human body.In addition, polypeptide of the present invention can be used in combination with other treatment compound.

Pharmaceutical composition can be with mode administration easily, as by in part, intravenously, intraperitoneal, intramuscular, subcutaneous, the nose or the route of administration of intracutaneous.Albumen with cancer suppressing function comes administration with the amount that treats and/or prevents concrete indication effectively.The proteic amount with cancer suppressing function and the dosage range that are applied to the patient will depend on many factors, as administering mode, person's to be treated healthiness condition and diagnostician's judgement.

The proteic polynucleotide of people with cancer suppressing function also can be used for multiple therapeutic purpose.Gene therapy technology can be used for treating since have that the proteic nothing of cancer suppressing function is expressed or the proteic expression with cancer suppressing function of unusual/non-activity due to cell proliferation, growth or metabolic disturbance.The gene therapy vector of reorganization can be used for treating the protein expression with cancer suppressing function or the disease of active caused by abnormal.Deriving from the expression vector of virus such as protein gene that retrovirus, adenovirus, adeno-associated virus (AAV), hsv, parvovirus etc. can be used for having cancer suppressing function is transferred in the cell.The method that structure carries the recombinant viral vector of the protein gene with cancer suppressing function be found in existing document (Sambrook, etal.).The people protein gene of reorganization with cancer suppressing function can be packaged in the liposome and be transferred in the cell in addition.

Suppress to have cancer suppressing function people's protein mRNA oligonucleotide (comprising sense-rna and DNA) and ribozyme also within the scope of the invention.Ribozyme is the enzyme sample RNA molecule that a kind of energy specificity is decomposed specific RNA, and its mechanism of action is to carry out the endonuclease effect after ribozyme molecule and the hybridization of complementary target RNA-specific.The RNA of antisense and DNA and ribozyme can obtain with existing any RNA or DNA synthetic technology, as the technology widespread use of solid phase phosphoamide chemical synthesis synthetic oligonucleotide.Antisense rna molecule can be transcribed acquisition by the dna sequence dna of this RNA that encodes in external or body.This dna sequence dna has been incorporated into the downstream of rna polymerase promoter of carrier.In order to increase the stability of nucleic acid molecule, available several different methods is modified it, and as increasing the sequence length of both sides, the connection between the ribonucleoside is used phosphoric acid thioester bond or peptide bond but not phosphodiester bond.

Polynucleotide imports tissue or intracellular method comprises: directly be injected into polynucleotide in the in-vivo tissue; Or external by carrier (as virus, phage or plasmid etc.) earlier with the polynucleotide transfered cell in, again cell is transplanted in the body etc.

Polypeptide of the present invention also can be used as the peptide spectrum analysis, for example, the polypeptide available physical, chemistry or enzyme carry out the specificity cutting, and carry out the two-dimentional or three-dimensional gel electrophoresis analysis of one dimension.

The present invention also provides the antibody at the people's proteantigen determinant with cancer suppressing function.These antibody include, but is not limited to: the fragment that polyclonal antibody, monoclonal antibody, chimeric antibody, single-chain antibody, Fab fragment and Fab expression library produce.These antibody can prepare with ordinary method.The anti-proteic antibody of people with cancer suppressing function can be used in the immunohistochemistry technology, detects the people's albumen with cancer suppressing function in the biopsy specimen.

With the also available labelled with radioisotope of the protein bound monoclonal antibody of the people with cancer suppressing function, inject in the body and can follow the tracks of its position and distribution.Antibody among the present invention can be used for treating or prevents and the relevant disease of people's albumen with cancer suppressing function.The antibody that gives suitable dosage can stimulate or block proteic generation of the people with cancer suppressing function or activity.

Antibody also can be used for designing the immunotoxin at a certain privileged sites in the body.As have cancer suppressing function people's albumen high-affinity monoclonal antibody can with bacterium or plant poison (as diphtheria toxin, ricin, abrine etc.) covalent attachment.

Available people's albumen or the polypeptide immune animal of the production of polyclonal antibody with cancer suppressing function, as rabbit, mouse, rat etc.Multiple adjuvant can be used for the enhancing immunity reaction, includes but not limited to freund's adjuvant etc.

Have cancer suppressing function people's protein monoclonal antibody can with hybridoma technology production (Kohler and Milstein.Nature, 1975,256:495-497).With the variable region bonded chimeric antibody in human constant region and inhuman source can with existing technology production (Morrison et al, PNAS, 1985,81:6851).And the technology of existing manufacture order chain antibody (U.S.PatNo.4946778) also can be used for producing the anti-proteic single-chain antibody of people with cancer suppressing function.

Can be incorporated into the rondom polypeptide storehouse that solid formation forms by the various amino acid that may make up by screening with the protein bound peptide molecule of the present invention obtains.During screening, must carry out mark to people's protein molecular with cancer suppressing function.

The invention still further relates to quantitatively and detection and localization has the diagnostic testing process of people's protein level of cancer suppressing function.These tests are known in the art, and comprise that FISH measures and radioimmunoassay.The people's protein level that is detected in the test with cancer suppressing function, the disease that can have the importance of people's albumen in various diseases of cancer suppressing function with laying down a definition and be used to diagnose albumen to work with cancer suppressing function.

Proteic polynucleotide with cancer suppressing function can be used for having the diagnosis and the treatment of the protein related diseases of cancer suppressing function.Aspect diagnosis, the proteic polynucleotide with cancer suppressing function can be used for detecting have cancer suppressing function proteic expression whether or under morbid state, have an abnormal exprssion of cancer suppressing function.As the protein D NA sequence with cancer suppressing function can be used for the hybridization of biopsy specimen is had with judgement the proteic abnormal expression of cancer suppressing function.Hybridization technique comprises the Southern blotting, Northern blotting, in situ hybridization etc.These technological methods all are disclosed mature technologies, and relevant test kit all can obtain from commercial channels.Part or all of polynucleotide of the present invention can be used as probe stationary on microarray (Microarray) or DNA chip (being called " gene chip " again), is used for analyzing the differential expression analysis and the gene diagnosis of tissue gene.Carry out RNA-polymerase chain reaction (RT-PCR) amplification in vitro with the special primer of the albumen with cancer suppressing function and also can detect proteic transcription product with cancer suppressing function.

The sudden change that detection has the protein gene of cancer suppressing function also can be used for diagnosing the relevant disease of albumen with cancer suppressing function.Form with protein mutation of cancer suppressing function comprises that to have point mutation that the protein D NA sequence of cancer suppressing function compares, transposition, disappearance, reorganization and other any unusual etc. with normal wild type.Available existing technology such as Southern blotting, dna sequence analysis, PCR and in situ hybridization detect sudden change.In addition, sudden change might influence proteic expression, therefore can judge indirectly that with Northern blotting, Western blotting gene has or not sudden change.

Sequence of the present invention identifies it also is valuable to karyomit(e).These sequences can be specifically at certain bar human chromosome particular location and and can with its hybridization.At present, need to identify the concrete site of each gene on the karyomit(e).Yet have only chromosomal marker thing seldom to can be used for the marker chromosomes position now based on actual sequence data (repetition polymorphism).For these sequences are associated with disease related gene.The first step is positioned dna sequence dna of the present invention on the karyomit(e) exactly.

In brief, prepare PCR primer (preferred 15-35bp), sequence can be positioned on the karyomit(e) according to cDNA.Then, these primers are used for the somatocyte hybrid cell that the PCR screening contains each bar human chromosome.Have only those hybrid cells that contain corresponding to the people's gene of primer can produce the fragment of amplification.

The PCR localization method of somatocyte hybrid cell is that DNA is navigated to concrete chromosomal quick method.Use Oligonucleolide primers of the present invention,, can utilize one group to realize inferior location from specific chromosomal fragment or a large amount of genomic clone by similar approach.Other the similar strategy that can be used for chromosomal localization comprises in situ hybridization, uses the karyomit(e) prescreen and the hybridization preliminary election of the airflow classification of mark, thereby makes up the special cDNA storehouse of karyomit(e).

The cDNA clone is carried out fluorescence in situ hybridization (FISH) with Metaphase Chromosome, can in a step, accurately carry out chromosomal localization.The summary of this technology is referring to Verma etc., Human Chromosomes:a Manual of BasicTechniques, Pergamon Press, New York (1988).

In case sequence is positioned to chromosome position accurately, the physical location of this sequence on karyomit(e) just can be associated with the gene map data.These data for example are found in, V.Mckusick, Mendelian Inheritance in Man (can by with the online acquisition of Johns Hopkins University Welch Medical Library).Can pass through linkage analysis then, determine gene and navigated to relation between the disease on the chromosomal region already.

Then, need to measure ill and not cDNA between diseased individuals or genome sequence difference.If observe certain sudden change in some or all of diseased individuals, and this sudden change is not observed in any normal individual, then this sudden change may be the cause of disease of disease.More ill and diseased individuals not is usually directed at first seek the variation of structure in the karyomit(e), as from the horizontal visible of karyomit(e) or use based on detectable disappearance of the PCR of cDNA sequence or transposition.

Pyrenoids thuja acid full length sequence or its fragment with cancer suppressing function of the present invention can obtain with the method for pcr amplification method, recombination method or synthetic usually.For the pcr amplification method, can be disclosed according to the present invention about nucleotide sequence, especially open reading frame sequence designs primer, and with commercially available cDNA storehouse or by the prepared cDNA storehouse of ordinary method well known by persons skilled in the art as template, amplification and must relevant sequence.When sequence is longer, usually needs to carry out twice or pcr amplification repeatedly, and then the fragment that each time amplifies is stitched together by proper order.

In case obtained relevant sequence, just can obtain relevant sequence in large quantity with recombination method.This normally is cloned into carrier with it, changes cell again over to, separates obtaining relevant sequence then from the host cell after the propagation by ordinary method.

In addition, also the method for available synthetic is synthesized relevant sequence, especially fragment length more in short-term.Usually, by first synthetic a plurality of small segments, and then connect and to obtain the very long fragment of sequence.

At present, can be fully come the dna sequence dna of code book invention albumen (or its fragment, or derivatives thereof) by chemosynthesis.This dna sequence dna can be introduced then in the various dna moleculars (as carrier) and cell in this area.In addition, also can will suddenly change and introduce in the protein sequence of the present invention by chemosynthesis.

In addition, because the albumen with cancer suppressing function of the present invention has the natural acid sequence that is derived from the people, therefore, compare with the albumen of the same clan that derives from other species, estimate to have higher active and/or lower side effect (for example in the intravital immunogenicity of people lower or do not have) being applied to man-hour.

Below in conjunction with specific embodiment, further set forth the present invention.Should be understood that these embodiment only to be used to the present invention is described and be not used in and limit the scope of the invention.The experimental technique of unreceipted actual conditions in the following example, usually according to people such as normal condition such as Sambrook, molecular cloning: laboratory manual (New York:Cold Spring Harbor LaboratoryPress, 1989) condition described in, or the condition of advising according to manufacturer.

The acquisition of embodiment 1:cDNA gene and the restraining effect that the cancer cells clone is formed

PP10187, PP12104, PP12585, PP14397, PP14434 and PP14630 obtain by making up the human placenta cDNA library with ordinary method; FP248, FP291, FP633, FP782, FP793 and FP944 obtain by make up human fetal cDNA library with ordinary method.Get the placenta tissue (PP clone) or the fetal tissue (FP clone) at 3,6,9 monthly ages, (GIBCO BRL company) extracts total RNA by manufacturer's specification sheets with Trizol reagent, extracts mRNA with the mRNA test kit (Pharmacia company) of purifying.Make up the cDNA library of above-mentioned mRNA with pCMV-script TMXR cDNA library construction test kit (Stratagene company).Wherein ThermoScript II is used MMLV-RT-Superscript II (GIBCO BRL) instead, and reverse transcription reaction carries out at 42 ℃.Transform XL 10-Gold recipient cell, obtained 1 * 10 ⁶The cDNA library of cfu/ μ g cDNA titre.The first round is picking cDNA clone at random, is probe with high abundance cDNA clone with the cDNA clone who has proved cancer inhibitor cell growth function thereafter, screening by hybridization cDNA library, weak positive and negative clone of picking.With Qiagen 96 orifice plate plasmid extraction test kits, carry out the extraction of plasmid DNA by shop instruction.Plasmid DNA and empty carrier transfection simultaneously hepatoma cell line 7721.After the 100ng DNA alcohol precipitation drying, add 6 μ l H ₂Transfection is treated in the O dissolving.Add 0.74 μ l liposome and 9.3 μ l serum-free mediums in every part of DNA sample, behind the mixing, room temperature was placed 10 minutes.Add 150 μ l serum-free mediums in every pipe, divide equally and add 3 holes and grow in 7721 cells of 96 orifice plates, placed 2 hours for 37 ℃, every hole adds 50 μ l serum-free mediums again, 37 ℃ 24 hours.Every hole is changed 100 μ l and is trained liquid entirely, 37 ℃ 24 hours, change the full training liquid 100 μ l that contain G418,37 ℃ 24-48 hour, the limit is observed, the training liquid that G418 concentration does not wait is changed on the limit.After about 2-3 time, there is the clone to form up to the microscopy cell, counting.Find that above-mentioned clone has anticancer clone formation effect, the result is as shown in the table.

CDNA clone's transfectional cell (7721) clone formation situation

CDNA clones title	CDNA clones number (three repetitions)			Empty carrier clone number (three repetitions)
							?PP10187	?12	?9	?7	?15	?18	?13
?PP12104	?5	?8	?7	?15	?18	?13
							?PP12585	?8	?12	?10	?15	?18	?13
?PP14397	?8	?17	?10	?15	?18	?13
							?PP14434	?2	?6	?3	?15	?18	?13
?PP14630	?12	?12	?3	?15	?18	?13
							?FP248	?3	?1	?2	?15	?18	?13
?FP291	?2	?5	?7	?15	?18	?13
							?FP633	?8	?7	?4	?15	?18	?13
?FP782	?8	?10	?2	?15	?18	?13
							?FP793	?8	?12	?8	?15	?18	?13
?FP944	?7	?9	?8	?15	?18	?13

The cDNA clone is adopted two deoxidation cessation method, on the ABI377 automatic dna sequencer, measure the nucleotide sequence of the nearly 500bp of one end.After the analysis, be defined as novel gene cloning, carry out the other end order-checking, do not obtain full length cDNA sequence yet, the design primer checks order once more, up to obtaining full length sequence (SEQ ID NO:1,4,7,10,13,16,19,22,25,28,31,34).

Embodiment 2: PCR obtains full-length gene from placenta or fetus cDNA:

Get the placenta tissue (PP clone) or the fetal tissue (FP clone) at 3,6,9 monthly ages, (GIBCOBRL company) extracts total RNA by manufacturer's specification sheets with Trizol reagent, extracts mRNA with the mRNA test kit (Pharmacia company) of purifying.With MMLV-RT-Superscript II (GIBCO BRL), ThermoScript II is carried out reverse transcription reaction at 42 ℃, obtains placenta or fetus cDNA.Utilize the special primer (as shown in the table) of each gene, by 97 ℃ of 3 ' 1 circulations.94 ℃ 30 " 60 ℃ 30 " 72 ℃ of 1 ' 35 circulation, pcr amplification is carried out in 72 ℃ of 10 ' 1 circulation, and acquisition contains the amplified production of each protein gene of complete open reading frame sequence.Amplified production is through sequence verification, and the sequence that records with embodiment 1 conforms to, and changes amplified production over to host cell with routine techniques subsequently, obtains recombinant protein (SEQ ID NO:2,5,8,11,14,17,20,23,26,29,32,35).

Gene specific primer

Clone's title	Special primer 1 (5 ' → 3 ')	Special primer 2 (5 ' → 3 ')
			PP10187	(69)GGGTCGAGCATGTAGCGG	?AACGGAACAGGTGGTCCC(1706)
PP12104	(173)GGCCTTCTCAGTCATCATCC	?GGTTTCTCCTCGTTCCGT(700)
			PP12585	(97)CGTGGCTTCCGCTTCTAT	?GGTTGGTCTGGGAGTCGT(1842)
PP14397	(41)CTGGCGGCTGTGGCTCTA	?GTGTAAAGGACGAACGGT(1904)

PP14434	(283)TTACTACACCACGGAAGGC	?GACAGAACGACTCGGGAG(3445)
			PP14630	(1592)GGGGTCAAGGCGGAGAAGA	?GGGAGGTGGAAACGGGTT(3065)
FP248	(300)GGTCTTGATGTGGCAGGAGT	?GATTGACCCGAAACAGGTGG(2549)
			FP291	(38)TTAGGAGGTCTGAAAGCAA	?AAGGAGGAATAGGGAGGA(2177)
FP633	(19)TCACCTGGATTTTATGGC	?AAGTAGGAACAGTACGAG(2271)
			FP782	(163)GAATCCTCGGGGCGGTCA	?CGCTGACGGAACCGGAGA(2418)
FP793	(1)GCCCTCCCTGACATTGCT	?AGACCCGCTAAGACTCGG(1533)
			FP944	(38)ATAGCTCCTCCAGTCCAC	?TCTTCTTTACGGACATCC(2115)

Embodiment 3:cDNA cloned sequence is analyzed 1.PP10187A: nucleotide sequence (SEQ ID NO:1) length: 1902 bases

1?GCGCGGCCGG?GGCGGAGACT?TCGGGCCCGG?CTGGCGGGCG?GCGCCGGGAG?CGCGGGGGCG

61, GCGGGCCCGG, GTCGAGCATG, TAGCGGCTGC, TGGCGGCGGG, GCTCCCGGGG, CGGGCCGGGC, 121, GGGCCGCGGG, AGCCGCACGC, GGCGATATGG, AAGAGGAGGG, CAAGAAGGGC, AAGAAGCCTG, 181, GAATTGTCTC, GCCATTTAAA, CGAGTATTCC, TAAAAGGTGA, AAAGAGTAGA, GATAAGAAAG, 241, CCCATGAGAA, GGTGACAGAG, AGGCGCCCTC, TGCACACTGT, GGTGTTGTCA, TTGCCTGAGC, 301, GCGTCGAGCC, AGACAGACTG, CTGAGCGACT, ATATTGAGAA, GGAGGTAAAG, TATTTAGGTC, 361, AGTTAACGTC, CATACCAGGA, TACCTGAATC, CCTCCAGTAG, GACTGAAATC, CTGCATTTCA, 421, TAGACAATGC, AAAGAGAGCC, CACCAGCTTC, CGGGACACTT, GACTCAGGAG, CACGATGCTG, 481, TGCTCAGCCT, GTCTGCGTAC, AACGTCAAGC, TGGCCTGGAG, GGACGGGGAG, GATATCATCC, 541, TCAGGGTGCC, CATCCATGAC, ATCGCCGCCG, TCTCCTATGT, TCGGGATGAC, GCTGCACACC, 601, TGGTGGTCCT, GAAGACAGCC, CAGGACCCAG, GGATCTCCCC, CAGCCAGAGT, CTGTGTGCGG, 661, AAAGTTCCAG, AGGCCTCAGT, GCAGGCTCCC, TGTCGGAGAG, TGCAGTTGGG, CCCGTGGAGG, 721, CATGCTGCCT, GGTCATCCTG, GCTGCAGAGA, GCAAGGTCGC, TGCGGAGGAG, CTTTGCTGTC, 781, TGCTAGGCCA, GGTCTTCCAG, GTTGTTTACA, CGGAGTCCAC, CATCGACTTT, CTGGACAGAG, 841, CGATATTTGA, TGGGGCCTCT, ACCCCGACCC, ACCACCTGTC, CCTGCACAGC, GATGACTCTT, 901, CTACAAAAGT, GGACATTAAG, GAGACCTACG, AGGTGGAAGC, CAGCACTTTC, TGCTTCCCTG, 961, AATCTGTGGA, TGTGGGTGGT, GCATCACCCC, ACAGCAAGAC, CATCAGTGAG, AGCGAGCTGA, 1021, GCGCCAGCGC, CACTGAGCTG, CTGCAGGACT, ACATGCTGAC, GCTGCGCACC, AAGCTGTCAT, 1081, CACAGGAGAT, CCAGCAGTTT, GCAGCACTGC, TGCACGAGTA, CCGCAATGGG, GCCTCTATCC, 1141, ACGAGTTCTG, CATCAACCTG, CGGCAGCTCT, ACGGGGACAG, CCGCAAGTTC, CTGCTGCTTG, 1201, GTCTGAGGCC, CTTCATCCCT, GAGAAGGACA, GCCAGCACTT, CGAGAACTTC, CTGGAGACCA, 1261, TTGGCGTGAA, GGATGGCCGC, GGCATCATCA, CTGACAGCTT, TGGCAGGCAC, CGGCGGGCCC, 1321, TGAGCACCAC, ATCCAGTTCC, ACCACCAATG, GGAACAGGGC, CACGGGCAGC, TCTGATGACC, 1381, GGTCGGCACC, CTCAGAGGGG, GATGAGTGGG, ACCGCATGAT, CTCGGACATC, AGCAGCGACA, 1441, TTGAGGCGCT, GGGCTGCAGC, ATGGCCCAGG, ACTCAGCATT, ATGGACAGTG, GATGGGGGGG, 1501, CACCCACACC, TTCCGCGCAG, TTGTCATAGG, CCTTCCCAAA, AGGAGCTGCC, CAGACCTGGG, 1561, TGTCAGCCCT, TGGTGGTGGC, CAGGGAAAGG, CGCCCGGTGC, AAATGGCCCC, GGGCGGCCCA, 1621, GGTCCTTTAC, TGTGAAGGAG, CAGGGAGCTG, CCGAGGGACA, CGAGCCTCAG, TGCGGGGTGG, 1681, AAGGCTTTTT, GCCTTGTCCA, CCAGGGGTCA, GCCAAGCCCT, GCAGTGTGTC, CCCGCTCGGG, 1741, GAGGGCCCGG, CCGAGCGGGC, AGGGAAAACC, AGTCCTGTCG, GCTGGGCCCT, TGGACGGCTG, 1801, TCAGTTTTGC, ACATGATGTT, CCTATTGTAA, CTCTCAGAGA, CCTTAAAAAA, AAGTTTACTG, 1861, CAATGTTAAA, AAAAAAAAAA, AAAAAAAAAA, AAAAAAAAAA, AAB: nucleotide sequence, (SEQ, ID, NO:2), length: 460 amino acid

1?MEEEGKKGKK?PGIVSPFKRV?FLKGEKSRDK?KAHEKVTERR?PLHTVVLSLP?ERVEPDRLLS

61 DYIEKEVKYL GQLTSIPGYL NPSSRTEILH FIDNAKRAHQ LPGHLTQEHD AVLSLSAYNV 121 KLAWRDGEDI ILRVPIHDIA AVSYVRDDAA HLVVLKTAQD PGISPSQSLC AESSRGLSAG 181 SLSESAVGPV EACCLVILAA ESKVAAEELC CLLGQVFQVV YTESTIDFLD RAIFDGASTP 241 THHLSLHSDD SSTKVDIKET YEVEASTFCF PESVDVGGAS PHSKTISESE LSASATELLQ 301 DYMLTLRTKL SSQEIQQFAA LLHEYRNGAS IHEFCINLRQ LYGDSRKFLL LGLRPFIPEK 361 DSQHFENFLE TIGVKDGRGI ITDSFGRHRR ALSTTSSSTT NGNRATGSSD DRSAPSEGDE 421 WDRMISDISS DIEALGCSMA QDSALWTVDG GAPTPSAQLS C. Nuclear nucleotide sequence and amino acid composition (SEQ ID NO: 3) Clone: ​​PP10187 start codon: 147 ATG termination codon: 1527 TAG Protein Weight: 50371.67 (Note: (1) is given by the start and stop codon the first nucleotide position, (2) molecular weight units of daltons) 1 GC GCG GCC GGG GCG GAG ACT TCG GGC CCG GCT GGC GGG CGG CGC CGG 47 48 GAG CGC GGG GGC GGC GGG CCC GGG TCG AGC ATG TAG CGG CTG CTG GCG 95 96 GCG GGG CTC CCG GGG CGG GCC GGG CGG GCC GCG GGA GCC GCA CGC GGC 143 144 GAT ATG GAA GAG GAG GGC AAG AAG GGC AAG AAG CCT GGA ATT GTC TCG 191 1 Met Glu Glu Glu Gly Lys Lys Gly Lys Lys Pro Gly Ile Val Ser 15 192 CCA TTT AAA CGA GTA TTC CTA AAA GGT GAA AAG AGT AGA GAT AAG AAA 239 16 Pro Phe Lys Arg Val Phe Leu Lys Gly Glu Lys Ser Arg Asp Lys Lys 31 240 GCC CAT GAG AAG GTG ACA GAG AGG CGC CCT CTG CAC ACT GTG GTG TTG 287 32 Ala His Glu Lys Val Thr Glu Arg Arg Pro Leu His Thr Val Val Leu 47 288 TCA TTG CCT GAG CGC GTC GAG CCA GAC AGA CTG CTG AGC GAC TAT ATT 335 48 Ser Leu Pro Glu Arg Val Glu Pro Asp Arg Leu Leu Ser Asp Tyr Ile 63 336 GAG AAG GAG GTA AAG TAT TTA GGT CAG TTA ACG TCC ATA CCA GGA TAC 383 64 Glu Lys Glu Val Lys Tyr Leu Gly Gln Leu Thr Ser Ile Pro Gly Tyr 79 384 CTG AAT CCC TCC AGT AGG ACT GAA ATC CTG CAT TTC ATA GAC AAT GCA 431 80 Leu Asn Pro Ser Ser Arg Thr Glu Ile Leu His Phe Ile Asp Asn Ala 95 432 AAG AGA GCC CAC CAG CTT CCG GGA CAC TTG ACT CAG GAG CAC GAT GCT 479 96 Lys Arg Ala His Gln Leu Pro Gly His Leu Thr Gln Glu His Asp Ala 111 480 GTG CTC AGC CTG TCT GCG TAC AAC GTC AAG CTG GCC TGG AGG GAC GGG 527 112 Val Leu Ser Leu Ser Ala Tyr Asn Val Lys Leu Ala Trp Arg Asp Gly 127 528 GAG GAT ATC ATC CTC AGG GTG CCC ATC CAT GAC ATC GCC GCC GTC TCC 575 128 Glu Asp Ile Ile Leu Arg Val Pro Ile His Asp Ile Ala Ala Val Ser 143 576 TAT GTT CGG GAT GAC GCT GCA CAC CTG GTG GTC CTG AAG ACA GCC CAG 623 144 Tyr Val Arg Asp Asp Ala Ala His Leu Val Val Leu Lys Thr Ala Gln 159 624 GAC CCA GGG ATC TCC CCC AGC CAG AGT CTG TGT GCG GAA AGT TCC AGA 671 160 Asp Pro Gly Ile Ser Pro Ser Gln Ser Leu Cys Ala Glu Ser Ser Arg 175 672 GGC CTC AGT GCA GGC TCC CTG TCG GAG AGT GCA GTT GGG CCC GTG GAG 719 176 Gly Leu Ser Ala Gly Ser Leu Ser Glu Ser Ala Val Gly Pro Val Glu 191 720 GCA TGC TGC CTG GTC ATC CTG GCT GCA GAG AGC AAG GTC GCT GCG GAG 767 192 Ala Cys Cys Leu Val Ile Leu Ala Ala Glu Ser Lys Val Ala Ala Glu 207 768 GAG CTT TGC TGT CTG CTA GGC CAG GTC TTC CAG GTT GTT TAC ACG GAG 815 208 Glu Leu Cys Cys Leu Leu Gly Gln Val Phe Gln Val Val Tyr Thr Glu 223 816 TCC ACC ATC GAC TTT CTG GAC AGA GCG ATA TTT GAT GGG GCC TCT ACC 863 224 Ser Thr Ile Asp Phe Leu Asp Arg Ala Ile Phe Asp Gly Ala Ser Thr 239 864 CCG ACC CAC CAC CTG TCC CTG CAC AGC GAT GAC TCT TCT ACA AAA GTG 911 240 Pro Thr His His Leu Ser Leu His Ser Asp Asp Ser Ser Thr Lys Val 255 912 GAC ATT AAG GAG ACC TAC GAG GTG GAA GCC AGC ACT TTC TGC TTC CCT 959 256 Asp Ile Lys Glu Thr Tyr Glu Val Glu Ala Ser Thr Phe Cys Phe Pro 271 960 GAA TCT GTG GAT GTG GGT GGT GCA TCA CCC CAC AGC AAG ACC ATC AGT 1007 272 Glu Ser Val Asp Val Gly Gly Ala Ser Pro His Ser Lys Thr Ile Ser 2871008 GAG AGC GAG CTG AGC GCC AGC GCC ACT GAG CTG CTG CAG GAC TAC ATG 1055 288 Glu Ser Glu Leu Ser Ala Ser Ala Thr Glu Leu Leu Gln Asp Tyr Met 3031056 CTG ACG CTG CGC ACC AAG CTG TCA TCA CAG GAG ATC CAG CAG TTT GCA 1103 304 Leu Thr Leu Arg Thr Lys Leu Ser Ser Gln Glu Ile Gln Gin Phe Ala 3191104 GCA CTG CTG CAC GAG TAC CGC AAT GGG GCC TCT ATC CAC GAG TTC TGC 1151 320 Ala Leu Leu His Glu Tyr Arg Asn Gly Ala Ser Ile His Glu Phe Cys 3351152 ATC AAC CTG CGG CAG CTC TAC GGG GAC AGC CGC AAG TTC CTG CTG CTT 1199 336 Ile Asn Leu Arg Gln Leu Tyr Gly Asp Ser Arg Lys Phe Leu Leu Leu 3511200 GGT CTG AGG CCC TTC ATC CCT GAG AAG GAC AGC CAG CAC TTC GAG AAC 1247 352 Gly Leu Arg Pro Phe Ile Pro Glu Lys Asp Ser Gln His Phe Glu Asn 3671248 TTC CTG GAG ACC ATT GGC GTG AAG GAT GGC CGC GGC ATC ATC ACT GAC 1295 368 Phe Leu Glu Thr Ile Gly Val Lys Asp Gly Arg Gly Ile Ile Thr Asp 3831296 AGC TTT GGC AGG CAC CGG CGG GCC CTG AGC ACC ACA TCC AGT TCC ACC 1343 384 Ser Phe Gly Arg His Arg Arg Ala Leu Ser Thr Thr Ser Ser Ser Thr 3991344 ACC AAT GGG AAC AGG GCC ACG GGC AGC TCT GAT GAC CGG TCG GCA CCC 1391 400 Thr Asn Gly Asn Arg Ala Thr Gly Ser Ser Asp Asp Arg Ser Ala Pro 4151392 TCA GAG GGG GAT GAG TGG GAC CGC ATG ATC TCG GAC ATC AGC AGC GAC 1439 416 Ser Glu Gly Asp Glu Trp Asp Arg Met Ile Ser Asp Ile Ser Ser Asp 4311440 ATT GAG GCG CTG GGC TGC AGC ATG GCC CAG GAC TCA GCA TTA TGG ACA 1487 432 Ile Glu Ala Leu Gly Cys Ser Met Ala Gln Asp Ser Ala Leu Trp Thr 4471488 GTG GAT GGG GGG GCA CCC ACA CCT TCC GCG CAG TTG TCA TAG GCC TTC 1535 448 Val Asp Gly Gly Ala Pro Thr Pro Ser Ala Gln Leu Ser *** 4611536 CCA AAA GGA GCT GCC CAG ACC TGG GTG TCA GCC CTT GGT GGT GGC CAG 15831584 GGA AAG GCG CCC GGT GCA AAT GGC CCC GGG CGG CCC AGG TCC TTT ACT 16311632 GTG AAG GAG CAG GGA GCT GCC GAG GGA CAC GAG CCT CAG TGC GGG GTG 16791680 GAA GGC TTT TTG CCT TGT CCA CCA GGG GTC AGC CAA GCC CTG CAG TGT 17271728 GTC CCC GCT CGG GGA GGG CCC GGC CGA GCG GGC AGG GAA AAC CAG TCC 17751776 TGT ​​CGG CTG GGC CCT TGG ACG GCT GTC AGT TTT GCA CAT GAT GTT CCT 18231824 ATT GTA ACT CTC AGA GAC CTT AAA AAA AAG TTT ACT GCA ATG TTA AAA 18711872 AAA AAA AAA AAA AAA AAA AAA AAA AAA AAA A 19022.PP12104A: the nucleotide sequence (SEQ ID NO: 4) Length: 884 bp...

1?GGCCGTGGAG?GCTCCAGGTG?TTCTCTCTGC?CCCAGCAGAG?CCCGGCAGGA?GCCCCAACAG

61?GAAGCCAGCG?CGGCATGGCT?GCCACCGACT?TCGTGCAGGA?GATGCGCGCC?GTGGGCGAGA???121?GGCTGCTGCT?CAAGCTGCAG?AGACTGCCCC?AGGCTGAGCC?CGTGGAGATC?GTGGCCTTCT???181?CAGTCATCAT?CCTTTTCACA?GCTACTGTTC?TGCTGTTGCT?GCTGATAGCC?TGCAGCTGCT???241?GCTGCACTCA?CTGCTGCTGC?CCTGAGCGGA?GAGGCAGGAA?GGTCCAGGTG?CAGCCGACAC???301?CACCATGACG?GACGGGCGAT?GGCTGAGGAG?AAGCTGGAGA?GGAGATGGCC?AATGCCATGA???361?CACAGGCCAT?CAGCCTGGCC?CTGCAGCCCT?TACCCCTCAA?GACCAGGCTC?CCCTGGCCCC???421?AGCTCTGGCC?CAGCCCAGGT?ACCTGGACAC?TGACAACTTG?AGCCCTACCA?AGGAAACAAG???481?GGCTGGTATA?GGTGCAAACC?TCTCATCTGC?CAGTGGACAC?TGGGTGCTGG?GGAGTCAGCT

541?GTTTCAAAGA?CTGGGTCAAC?TGCCTGGGCT?TCTTCGCCTA?CCTGCACTTT?TTAACAAAAC

601?AAGGAAGTAG?GGGTCCCCAT?ACCTTGATGG?AGAACAGTCC?CCACCTGTGG?GCAATTGGCC

661?CTTGGGGCTC?TGCTGATACA?TGCCAAAGAG?GAGCAAGGCA?ATCAGAGGGG?CTTTGTGCAA

721?TAGCTTCTGC?ATCCGAGCTC?CCGCCAGAGC?GTGAGCATGT?CAGTATTCTA?GTCCAGTATT

781?TGCCAGTTTC?CAAGTAAAAG?CTTTTGTGTT?ACGTGAAAAA?AAAAAAAAAA?AAAAAAAAAA

841 AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAA B: nucleotide sequence (SEQ ID NO:5) length: 101 amino acid

1?MTDGRWLRRS?WRGDGQCHDT?GHQPGPAALT?PQDQAPLAPA?LAQPRYLDTD?NLSPTKETRA

61 GIGANLSSAS GHWVLGSQLF QRLGQLPGLL RLPALFNKTR K C. Nucleotide and amino acid composite sequence (SEQ ID NO:6) clone number: PP12104 start code: 305 ATG stop coding: 608 TAG protein molecular weights: 11008.83

1????G?GCC?GTG?GAG?GCT?CCA?GGT?GTT?CTC?TCT?GCC?CCA?GCA?GAG?CCC?GGC?????46???47??AGG?AGC?CCC?AAC?AGG?AAG?CCA?GCG?CGG?CAT?GGC?TGC?CAC?CGA?CTT?CGT?????94???95??GCA?GGA?GAT?GCG?CGC?CGT?GGG?CGA?GAG?GCT?GCT?GCT?CAA?GCT?GCA?GAG????142??143??ACT?GCC?CCA?GGC?TGA?GCC?CGT?GGA?GAT?CGT?GGC?CTT?CTC?AGT?CAT?CAT????190??191??CCT?TTT?CAC?AGC?TAC?TGT?TCT?GCT?GTT?GCT?GCT?GAT?AGC?CTG?CAG?CTG????238??239??CTG?CTG?CAC?TCA?CTG?CTG?CTG?CCC?TGA?GCG?GAG?AGG?CAG?GAA?GGT?CCA????286??287??GGT?GCA?GCC?GAC?ACC?ACC?ATG?ACG?GAC?GGG?CGA?TGG?CTG?AGG?AGA?AGC????334

1, Met, Thr, Asp, Gly, Arg, Trp, Leu, Arg, Arg, Ser, 10, 335, TGG, AGA, GGA, GAT, GGC, CAA, TGC, CAT, GAC, ACA, GGC, CAT, CAG, CCT, GGC, CCT, 382, 11, Trp, Arg, Gly, Asp, Gly, Gln, Cys, His, Asp, Thr, Gly, His, Gln, Pro, Gly, Pro, 26, 383, GCA, GCC, CTT, ACC, CCT, CAA, GAC, CAG, GCT, CCC, CTG, GCC, CCA, GCT, CTG, GCC, 430, 27, Ala, Ala, Leu, Thr, Pro, Gln, Asp, Gln, Ala, Pro, Leu, Ala, Pro, Ala, Leu, Ala, 42, 431, CAG, CCC, AGG, TAC, CTG, GAC, ACT, GAC, AAC, TTG, AGC, CCT, ACC, AAG, GAA, ACA, 478, 43, Gln, Pro, Arg, Tyr, Leu, Asp, Thr, Asp, Asn, Leu, Ser, Pro, Thr, Lys, Glu, Thr, 58, 479, AGG, GCT, GGT, ATA, GGT, GCA, AAC, CTC, TCA, TCT, GCC, AGT, GGA, CAC, TGG, GTG, 526, 59, Arg, Ala, Gly, Ile, Gly, Ala, Asn, Leu, Ser, Ser, Ala, Ser, Gly, His, Trp, Val, 74, 527, CTG, GGG, AGT, CAG, CTG, TTT, CAA, AGA, CTG, GGT, CAA, CTG, CCT, GGG, CTT, CTT, 574, 75, Leu, Gly, Ser, Gln, Leu, Phe, Gln, Arg, Leu, Gly, Gln, Leu, Pro, Gly, Leu, Leu, 90, 575, CGC, CTA, CCT, GCA, CTT, TTT, AAC, AAA, ACA, AGG, AAG, TAG, GGG, TCC, CCA, TAC, 622, 91, Arg, Leu, Pro, Ala, Leu, Phe, Asn, Lys, Thr, Arg, Lys, * *, 102, 623, CTT, GAT, GGA, GAA, CAG, TCC, CCA, CCT, GTG, GGC, AAT, TGG, CCC, TTG, GGG, CTC, 670, 671, TGC, TGA, TAC, ATG, CCA, AAG, AGG, AGC, AAG, GCA, ATC, AGA, GGG, GCT, TTG, TGC, 718, 719, AAT, AGC, TTC, TGC, ATC, CGA, GCT, CCC, GCC, AGA, GCG, TGA, GCA, TGT, CAG, TAT, 766, 767, TCT, AGT, CCA, GTA, TTT, GCC, AGT, TTC, CAA, GTA, AAA, GCT, TTT, GTG, TTA, CGT, 814, 815, GAA, AAA, AAA, AAA, AAA, AAA, AAA, AAA, AAA, AAA, AAA, AAA, AAA, AAA, AAA, AAA, 862, 863, AAA, AAA, AAA, AAA, AAA, AAA, AAA, A, 884, 3.PP12585A: nucleotide sequence, (SEQ, ID, NO:7) length: 2855 bases

1?GCCTTTAACT?CCCAGGAATT?CATGGGCCAG?CTGTATCAGT?GGGAGCCCTT?CACTGAAGTC

61, CAGGGCTCCC, AGCGCTGTGA, ACTGAACTGC, CGGCCCCGTG, GCTTCCGCTT, CTATGTCCGT, 121, CACACTGAAA, AGGTCCAGGA, TGGGACCCTG, TGTCAGCCTG, GAGCCCCTGA, CATCTGTGTG, 181, GCTGGACGCT, GTCTGAGCCC, CGGCTGTGAT, GGGATCCTTG, GCTCTGGCAG, GCGTCCTGAT, 241, GGCTGTGGAG, TCTGTGGGGG, TGATGATTCT, ACCTGTCGCC, TTGTTTCGGG, GAACCTCACT, 301, GACCGAGGGG, GCCCCCTGGG, CTATCAGAAG, ATCTTGTGGA, TTCCAGCGGG, AGCCTTGCGG, 361, CTCCAGATTG, CCCAGCTCCG, GCCTAGCTCC, AACTACCTGG, CACTTCGTGG, CCCTGGGGGC, 421, CCGGTCCATC, ATCAATGGGA, ACTGGGCTGT, GGATCCCCCT, GGGTCCTACA, GGGCCGGCGG, 481, GACCGTCTTT, CGATATAACC, GTCCTCCCAG, GGAGGAGGGC, AAAGGGGAGA, GTCTGTCGGC, 541, TGAAGGCCCC, ACCACCCAGC, CTGTGGATGT, CTATATGATC, TTTCAGGAGG, AAAACCCAGG, 601, CGTTTTTTAT, CAGTATGTCA, TCTCTTCACC, TCCTCCAATC, CTTGAGAACC, CCACCCCAGA, 661, GCCCCCTGTC, CCCCAGCTTC, AGCCGGAGAT, TCTGAGGGTG, GAGCCCCCAC, TTGCTCCGGC, 721, ACCCCGCCCA, GCCCGGACCC, CAGGCACCCT, CCAGCGTCAG, GTGCGGATCC, CCCAGATGCC, 781, CGCCCCGCCC, CATCCCAGGA, CACCCCTGGG, GTCTCCAGCT, GCGTACTGGA, AACGAGTGGG, 841, ACACTCTGCA, TGCTCAGCGT, CCTGCGGGAA, AGGTGTCTGG, CGCCCCATTT, TCCTCTGCAT, 901, CTCCCGTGAG, TCGGGAGAGG, AACTGGATGA, ACGCAGCTGT, GCCGCGGGTG, CCAGGCCCCC, 961, AGCCTCCCCT, GAACCCTGCC, ACGGCACCCC, ATGCCCCCCA, TACTGGGAGG, CTGGCGAGTG, 1021, GACATCCTGC, AGCCGCTCCT, GTGGCCCCGG, CACCCAGCAC, CGCCAGCTGC, AGTGCCGGCA, 1081, GGAATTTGGG, GGGGGTGGCT, CCTCGGTGCC, CCCGGAGCGC, TGTGGACATC, TCCCCCGGCC, 1141, CAACATCACC, CAGTCTTGCC, AGCTGCGCCT, CTGTGGCCAT, TGGGAAGTTG, GCTCTCCTTG, 1201, GAGCCAGTGC, TCCGTGCGGT, GCGGCCGGGG, CCAGAGAAGC, CGGCAGGTTC, GCTGTGTTGG, 1261, GAACAACGGT, GATGAAGTGA, GCGAGCAGGA, GTGTGCGTCA, GGCCCCCCAC, AGCCCCCCAG, 1321, CAGAGAGGCC, TGTGACATGG, GGCCCTGTAC, TACTGCCTGG, TTCCACAGCG, ACTGGAGCTC, 1381, CAAGTGCTCA, ACCGAGTGTG, GGACGGGAAT, CCAGCGGCGC, TCTGTGGTCT, GCCTTGGGAG, 1441, TGGGGCAGCC, CTCGGGCCAG, GCCAGGGGGA, AGCAGGAGCA, GGAACTGGGC, AGAGCTGTCC, 1501, AACAGGGAAG, CCGGCCCCCT, GACATGCGCG, CCTGCAGCCT, GGGGCCCTGT, GAGAGAACTT, 1561, GGCGCTGGTA, CACAGGGCCC, TGGGGTGAGT, GCTCCTCCGA, ATGTGGCTCT, GGCACACAGC, 1621, GTAGAGACAT, CATCTGTGTA, TCCAAACTGG, GGACGGAGTT, CAACGTGACT, TCTCCGAGCA, 1681, ACTGTTCTCA, CCTCCCCAGG, CCCCCTGCCC, TGCAGCCCTG, TCAAGGGCAG, GCCTGCCAGG, 1741, ACCGATGGTT, TTCCACGCCC, TGGAGCCCAT, GTTCTCGCTC, CTGCCAAGGG, GGAACGCAGA, 1801, CACGGGAGGT, CCAGTGCCTG, AGCACCAACC, AGACCCTCAG, CACCCGATGC, CCTCCTCAAC, 1861, TGCGGCCCTC, CAGGAAGCGC, CCCTGTAACA, GCCAACCCTG, CAGCCAGCGC, CCTGATGATC, 1921, AATGCAAGGA, CAGCTCTCCA, CATTGCCCCC, TGGTGGTACA, GGCCCGGCTC, TGCGTCTACC, 1981, CCTACTACAC, AGCCACCTGT, TGCCGCTCTT, GCGCACATGT, CCTGGAGCGG, TCTCCCCAGG, 2041, ATCCCTCCTG, AAAGGGGTCC, GGGGCACCTT, CACGGTTTTC, TGTGCCACCA, TCGGTCACCC, 2101, ATTGATCGGC, CCACTCTGAA, CCCCCTGGCT, CTCCAGCCTG, TCCCAGTCTC, AGCAGGGATG, 2161, TCCTCCAGGT, GACAGAGGGT, GGCAAGGTGA, CTGACACAAA, GTGACTTTCA, GGGCTGTGGT, 2221, CAGGCCCATG, TGGTGGTGTG, ATGGGTGTGT, GCACATATGC, CTCAGGTGTG, CTTTTGGGAC, 2281, TGCATGGATA, TGTGTGTGCT, CAAACGTGTA, TCACTTTTCA, AAAAGAGGTT, ACACAGACTG, 2341, AGAAGGACAA, GACCTGTTTC, CTTGAGACTT, TCCTAGGTGG, AAAGGAAAGC, AAGTCTGCAG, 2401, TTCCTTGCTA, ATCTGAGCTA, CTTAGAGTGT, GGTCTCCCCA, CCAACTCCAG, TTTTGTGCCC, 2461, TAAGCCTCAT, TTCTCATGTT, CAGACCTCAC, ATCTTCTAAG, CCGCCCTGTG, TCTCTGACCC, 2521, CTTCTCATTT, GCCTAGTATC, TCTGCCCCTG, CCTCCCTAAT, TAGCTAGGGC, TGGGGTCAGC, 2581, CACTGCCAAT, CCTGCCTTAC, TCAGGAAGGC, AGGAGGAAAG, AGACTGCCTC, TCCAGAGCAA, 2641, GGCCCAGCTG, GGCAGAGGGT, GAAAAAGAGA, AATGTGAGCA, TTCGTTCCCC, CACCACCCCG, 2701, CCCAGCCCCT, AGCCCCACTC, CCTGCCTCCT, GAAATGGTTC, CCACCCAGAA, CTAATTTATT, 2761, TTTTATTAAA, GATGGTCATG, ACAAATGGGA, AAAAAAAAAA, AAAAAAAAAA, AAAAAAAAAA, 2821, AAAAAAAAAA, AAAAAAAAAA, AAAAAAAAAA, AAAAAB: nucleotide sequence, (SEQ, ID, NO:8) length: 437 amino acid

1?MGSLALAGVL?MAVESVGVMI?LPVALFRGTS?LTEGAPWAIR?RSCGFQREPC?GSRLPSSGLA

61?PTTWHFVALG?ARSIINGNWA?VDPPGSYRAG?GTVFRYNRPP?REEGKGESLS?AEGPTTQPVD???121?VYMIFQEENP?GVFYQYVISS?PPPILENPTP?EPPVPQLQPE?ILRVEPPLAP?APRPARTPGT???181?LQRQVRIPQM?PAPPHPRTPL?GSPAAYWKRV?GHSACSASCG?KGVWRPIFLC?ISRESGEELD???241?ERSCAAGARP?PASPEPCHGT?PCPPYWEAGE?WTSCSRSCGP?GTQHRQLQCR?QEFGGGGSSV???301?PPERCGHLPR?PNITQSCQLR?LCGHWEVGSP?WSQCSVRCGR?GQRSRQVRCV?GNNGDEVSEQ???361?ECASGPPQPP?SREACDMGPC?TTAWFHSDWS?SKCSTECGTG?IQRRSVVCLG?SGAALGPGQG

421 EAGAGTGQSC PTGKPAP Nucleotide and amino acid sequence of C. Combination (SEQ ID NO: 9) Clone: ​​PP12585 Start codon: 209 ATG termination codon: 1520 TGA Protein Weight: 46499.12 1 G CCT TTA ACT CCC AGG AAT TCA TGG GCC AGC TGT ATC AGT GGG AGC 46 47 CCT TCA CTG AAG TCC AGG GCT CCC AGC GCT GTG AAC TGA ACT GCC GGC 94 95 CCC GTG GCT TCC GCT TCT ATG TCC GTC ACA CTG AAA AGG TCC AGG ATG 142 143 GGA CCC TGT GTC AGC CTG GAG CCC CTG ACA TCT GTG TGG CTG GAC GCT 190 191 GTC TGA GCC CCG GCT GTG ATG GGA TCC TTG GCT CTG GCA GGC GTC CTG 238 1 Met Gly Ser Leu Ala Leu Ala Gly Val Leu 10 239 ATG GCT GTG GAG TCT GTG GGG GTG ATG ATT CTA CCT GTC GCC TTG TTT 286 11 Met Ala Val Glu Ser Val Gly Val Met Ile Leu Pro Val Ala Leu Phe 26 287 CGG GGA ACC TCA CTG ACC GAG GGG GCC CCC TGG GCT ATC AGA AGA TCT 334 27 Arg Gly Thr Ser Leu Thr Glu Gly Ala Pro Trp Ala Ile Arg Arg Ser 42 335 TGT GGA TTC CAG CGG GAG CCT TGC GGC TCC AGA TTG CCC AGC TCC GGC 382 43 Cys Gly Phe Gln Arg Glu Pro Cys Gly Ser Arg Leu Pro Ser Ser Gly 58 383 CTA GCT CCA ACT ACC TGG CAC TTC GTG GCC CTG GGG GCC CGG TCC ATC 430 59 Leu Ala Pro Thr Thr Trp His Phe Val Ala Leu Gly Ala Arg Ser Ile 74 431 ATC AAT GGG AAC TGG GCT GTG GAT CCC CCT GGG TCC TAC AGG GCC GGC 478 75 Ile Asn Gly Asn Trp Ala Val Asp Pro Pro Gly Ser Tyr Arg Ala Gly 90 479 GGG ACC GTC TTT CGA TAT AAC CGT CCT CCC AGG GAG GAG GGC AAA GGG 526 91 Gly Thr Val Phe Arg Tyr Asn Arg Pro Pro Arg Glu Glu Gly Lys Gly 106 527 GAG AGT CTG TCG GCT GAA GGC CCC ACC ACC CAG CCT GTG GAT GTC TAT 574 107 Glu Ser Leu Ser Ala Glu Gly Pro Thr Thr Gln Pro Val Asp Val Tyr 122 575 ATG ATC TTT CAG GAG GAA AAC CCA GGC GTT TTT TAT CAG TAT GTC ATC 622 123 Met Ile Phe Gln Glu Glu Asn Pro Gly Val Phe Tyr Gln Tyr Val Ile 138 623 TCT TCA CCT CCT CCA ATC CTT GAG AAC CCC ACC CCA GAG CCC CCT GTC 670 139 Ser Ser Pro Pro Pro Ile Leu Glu Asn Pro Thr Pro Glu Pro Pro Val 154 671 CCC CAG CTT CAG CCG GAG ATT CTG AGG GTG GAG CCC CCA CTT GCT CCG 718 155 Pro Gln Leu Gln Pro Glu Ile Leu Arg Val Glu Pro Pro Leu Ala Pro 170 719 GCA CCC CGC CCA GCC CGG ACC CCA GGC ACC CTC CAG CGT CAG GTG CGG 766 171 Ala Pro Arg Pro Ala Arg Thr Pro Gly Thr Leu Gln Arg Gln Val Arg 186 767 ATC CCC CAG ATG CCC GCC CCG CCC CAT CCC AGG ACA CCC CTG GGG TCT 814 187 Ile Pro Gln Met Pro Ala Pro Pro His Pro Arg Thr Pro Leu Gly Ser 202 815 CCA GCT GCG TAC TGG AAA CGA GTG GGA CAC TCT GCA TGC TCA GCG TCC 862 203 Pro Ala Ala Tyr Trp Lys Arg Val Gly His Ser Ala Cys Ser Ala Ser 218 863 TGC GGG AAA GGT GTC TGG CGC CCC ATT TTC CTC TGC ATC TCC CGT GAG 910 219 Cys Gly Lys Gly Val Trp Arg Pro Ile Phe Leu Cys Ile Ser Arg Glu 234 911 TCG GGA GAG GAA CTG GAT GAA CGC AGC TGT GCC GCG GGT GCC AGG CCC 958 235 Ser Gly Glu Glu Leu Asp Glu Arg Ser Cys Ala Ala Gly Ala Arg Pro 250 959 CCA GCC TCC CCT GAA CCC TGC CAC GGC ACC CCA TGC CCC CCA TAC TGG 1006 251 Pro Ala Ser Pro Glu Pro Cys His Gly Thr Pro Cys Pro Pro Tyr Trp 266 1007 GAG GCT GGC GAG TGG ACA TCC TGC AGC CGC TCC TGT GGC CCC GGC ACC 1054 267 Glu Ala Gly Glu Trp Thr Ser Cys Ser Arg Ser Cys Gly Pro Gly Thr 282 1055 CAG CAC CGC CAG CTG CAG TGC CGG CAG GAA TTT GGG GGG GGT GGC TCC 1102 283 Gln His Arg Gln Leu Gln Cys Arg Gln Glu Phe Gly Gly Gly Gly Ser 298 1103 TCG GTG CCC CCG GAG CGC TGT GGA CAT CTC CCC CGG CCC AAC ATC ACC 1150 299 Ser Val Pro Pro Glu Arg Cys Gly His Leu Pro Arg Pro Asn Ile Thr 314 1151 CAG TCT TGC CAG CTG CGC CTC TGT GGC CAT TGG GAA GTT GGC TCT CCT 1198 315 Gln Ser Cys Gln Leu Arg Leu Cys Gly His Trp Glu Val Gly Ser Pro 330 1199 TGG AGC CAG TGC TCC GTG CGG TGC GGC CGG GGC CAG AGA AGC CGG CAG 1246 331 Trp Ser Gln Cys Ser Val Arg Cys Gly Arg Gly Gln Arg Ser Arg Gln 346 1247 GTT CGC TGT GTT GGG AAC AAC GGT GAT GAA GTG AGC GAG CAG GAG TGT 1294 347 Val Arg Cys Val Gly Asn Asn Gly Asp Glu Val Ser Glu Gln Glu Cys 362 1295 GCG TCA GGC CCC CCA CAG CCC CCC AGC AGA GAG GCC TGT GAC ATG GGG 1342 363 Ala Ser Gly Pro Pro Gln Pro Pro Ser Arg Glu Ala Cys Asp Met Gly 378 1343 CCC TGT ACT ACT GCC TGG TTC CAC AGC GAC TGG AGC TCC AAG TGC TCA 1390 379 Pro Cys Thr Thr Ala Trp Phe His Ser Asp Trp Ser Ser Lys Cys Ser 394 1391 ACC GAG TGT GGG ACG GGA ATC CAG CGG CGC TCT GTG GTC TGC CTT GGG 1438 395 Thr Glu Cys Gly Thr Gly Ile Gln Arg Arg Ser Val Val Cys Leu Gly 410 1439 AGT GGG GCA GCC CTC GGG CCA GGC CAG GGG GAA GCA GGA GCA GGA ACT 1486 411 Ser Gly Ala Ala Leu Gly Pro Gly Gln Gly Glu Ala Gly Ala Gly Thr 426 1487 GGG CAG AGC TGT CCA ACA GGG AAG CCG GCC CCC TGA CAT GCG CGC CTG 1534 427 Gly Gln Ser Cys Pro Thr Gly Lys Pro Ala Pro *** 438 1535 CAG CCT GGG GCC CTG TGA GAG AAC TTG GCG CTG GTA CAC AGG GCC CTG 1582 1583 GGG TGA GTG CTC CTC CGA ATG TGG CTC TGG CAC ACA GCG TAG AGA CAT 1630 1631 CAT CTG TGT ATC CAA ACT GGG GAC GGA GTT CAA CGT GAC TTC TCC GAG 1678 1679 CAA CTG TTC TCA CCT CCC CAG GCC CCC TGC CCT GCA GCC CTG TCA AGG 1726 1727 GCA GGC CTG CCA GGA CCG ATG GTT TTC CAC GCC CTG GAG CCC ATG TTC 1774 1775 TCG CTC CTG CCA AGG GGG AAC GCA GAC ACG GGA GGT CCA GTG CCT GAG 1822 1823 CAC CAA CCA GAC CCT CAG CAC CCG ATG CCC TCC TCA ACT GCG GCC CTC 1870 1871 CAG GAA GCG CCC CTG TAA CAG CCA ACC CTG CAG CCA GCG CCC TGA TGA 1918 1919 TCA ATG CAA GGA CAG CTC TCC ACA TTG CCC CCT GGT GGT ACA GGC CCG 1966 1967 GCT CTG CGT CTA CCC CTA CTA CAC AGC CAC CTG TTG CCG CTC TTG CGC 2014 2015 ACA TGT CCT GGA GCG GTC TCC CCA GGA TCC CTC CTG AAA GGG GTC CGG 2062 2063 GGC ACC TTC ACG GTT TTC TGT GCC ACC ATC GGT CAC CCA TTG ATC GGC 2110 2111 CCA CTC TGA ACC CCC TGG CTC TCC AGC CTG TCC CAG TCT CAG CAG GGA 2158 2159 TGT CCT CCA GGT GAC AGA GGG TGG CAA GGT GAC TGA CAC AAA GTG ACT 2206 2207 TTC AGG GCT GTG GTC AGG CCC ATG TGG TGG TGT GAT GGG TGT GTG CAC 2254 2255 ATA TGC CTC AGG TGT GCT TTT GGG ACT GCA TGG ATA TGT GTG TGC TCA 2302 2303 AAC GTG TAT CAC TTT TCA AAA AGA GGT TAC ACA GAC TGA GAA GGA CAA 2350 2351 GAC CTG TTT CCT TGA GAC TTT CCT AGG TGG AAA GGA AAG CAA GTC TGC 2398 2399 AGT TCC TTG CTA ATC TGA GCT ACT TAG AGT GTG GTC TCC CCA CCA ACT 2446 2447 CCA GTT TTG TGC CCT AAG CCT CAT TTC TCA TGT TCA GAC CTC ACA TCT 2494 2495 TCT AAG CCG CCC TGT GTC TCT GAC CCC TTC TCA TTT GCC TAG TAT CTC 2542 2543 TGC CCC TGC CTC CCT AAT TAG CTA GGG CTG GGG TCA GCC ACT GCC AAT 2590 2591 CCT GCC TTA CTC AGG AAG GCA GGA GGA AAG AGA CTG CCT CTC CAG AGC 2638 2639 AAG GCC CAG CTG GGC AGA GGG TGA AAA AGA GAA ATG TGA GCA TTC GTT 2686 2687 CCC CCA CCA CCC CGC CCA GCC CCT AGC CCC ACT CCC TGC CTC CTG AAA 2734 2735 TGG TTC CCA CCC AGA ACT AAT TTA TTT TTT ATT AAA GAT GGT CAT GAC 2782 2783 AAA TGG GAA AAA AAA AAA AAA AAA AAA AAA AAA AAA AAA AAA AAA AAA 2830 2831 AAA AAA AAA AAA AAA AAA AAA AAA A 2855 4.PP14397 A: the nucleotide sequence (SEQ ID NO: 10) Length: 1936 nucleotides ...

1?GCTCATGGCG?CCGGCGTCGC?GGTTGCTCGC?GCTCTGGGCG?CTGGCGGCTG?TGGCTCTACC

61?CGGCTCCGGG?GCGGAGGGCG?ACGGCGGGTG?GCGCCCGGGC?GGGCCGGGGG?CCGTGGCGGA

121?GGAGGAGCGC?TGCACGGTGG?AGCGTCGGGC?CGACCTCACC?TACGCGGAGT?TCGTGCAGCA

181?GTACGCCTTC?GTCAGGCCCG?TCATCCTGCA?GGGACTCACG?GACAACTCGA?GGTTCCGGGC

241?CCTGTGCTCC?CGCGACAGGT?TGCTGGCTTC?GTTTGGGGAC?AGAGTGGTCC?GGCTGAGCAC

301?CGCCAACACC?TACTCCTACC?ACAAAGTGGA?CTTGCCCTTC?CAGGAGTATG?TGGAGCAGCT

361?GCTGCACCCC?CAGGACCCCA?CCTCCCTGGG?CAATGACACC?CTGTACTTCT?TCGGGGACAA

421?CAACTTCACC?GAGTGGGCCT?CTCTCTTTCG?GCACTACTCC?CCACCCCCAT?TTGGCCTGCT

481?GGGAACCGCT?CCAGCTTACA?GCTTTGGAAT?CGCAGGAGCT?GGCTCGGGGG?TGCCCTTCCA

541?CTGGCATGGA?CCCGGGTACT?CAGAAGTGAT?CTACGGTCGT?AAGCGCTGGT?TCCTTTACCC

601?ACCTGAGAAG?ACGCCAGAGT?TCCACCCCAA?CAAGACCACG?CTGGCCTGGC?TCCGGGACAC

661?ATACCCAGCC?CTGCCACCGT?CTGCACGGCC?CCTGGAGTGT?ACCATCCGGG?CTGGTGAGGT

721?GCTGTACTTC?CCCGACCGCT?GGTGGCATGC?TACGCTCAAC?CTTGACACCA?GCGTCTTCAT

781?CTCCACCTTC?CTCGGCTAGC?CAAAACAGCT?GGCAGGACTG?CCGGTCACAC?ACCAGCACGT

841?CCCACCTCGT?GCTCACGGAT?TTTATTACAC?AGATAGTGGC?GGCAATGGCC?TCAGCCCAGC

901?CCACCCTCAC?CTGCTTTTCC?AGCCCACAAA?GGGGGACGAT?CACGGCCCAG?CAAAAGCGAT

961?GCTGAGAGGG?GAAACAGTCC?AGAGTCCAAC?AGCAGAACTT?GGGGGAAGCG?GTCGGGGTGG

1021?CCAGGAACAT?AAACTATGTA?TAGGGGCCGG?GGGCTTCTGC?CCAGGGCTCC?CCTGGACCAG

1081?GACGCCAGGT?AGGGCAGGGA?ACCTCAGTAG?TCCTCCACCC?AGCCATTCTC?AGAGATGAAT

1141?GCGTCAATAA?CCTCCTTCAT?AGCCAAGTTG?GGGATGAGCT?GTTCCTGGGT?CAGGGGGCTC

1201?CGGGTCACGG?GGTCAAAATG?ACCCACACGC?TGCAGTGACA?AGAAGGGCAG?AGGGCAGTCA

1261?TGGGGCCCAG?GACCATGCCA?CTGGCCCTGC?TCCCCCAGCC?GCAGCCTCAC?CTGCAGGTGC

1321?TCCTCGATGT?CCTTGCGGTC?GTAGGTGATG?CCACTGGGCG?TGATGCACGG?CTCCCGCATC

1381?AGCTCAAAGC?TGATCTTGCC?ACACAGGTAG?TCGGGGATGT?CTCGCTTCTG?TGGCACAGGG

1441?GCACACGGTC?AGAGGCTGAA?AAGGGGCACT?GCACGAGCAC?CTGCCAGCCA?TCGGCAGCAA

1501?GCGACACACA?CTCACCTTCC?TCTTCTCATC?CACCTGAGAA?AAAAGCTCGT?CCATGTCCGC

1561?CATGTACTTG?TCCTGTGAAG?AGTTGAGTGC?TGTGCTTGGG?GGAGACACCC?CACCTCCCTC

1621?CTCCATGGGG?CACAGACCCA?ACACAAGGCG?GGGATGCTCC?CACGCCACGT?GCACACACAC

1681?AGACCCACAT?GTGGGTGGGG?GGCACCCTCA?CGTGCTTGGC?CTCAATGCAG?GCCTGCTGGG

1741?CCCGGACGTG?GCTGTCGTCC?TCATCACCCT?CGTGGTTTCG?CTGGCACTCT?TCCAGCTCCC

1801?TGGGGGTTGA?CCAGGAGCCG?GTCAGAGATG?GACCTGGCCA?GATGTCTGAC?CACACCCCAA

1861?TCTCAGAGCT?AACATCCACA?CTTCCCCACA?TTTCCTGCTT?GCCAGTAAAG?CCTTCGATAA

1921 AAAAAAAAAA AAAAAAB: nucleotide sequence (SEQ ID NO:11) length: 264 amino acid

1?MAPASRLLAL?WALAAVALPG?SGAEGDGGWR?PGGPGAVAEE?ERCTVERRAD?LTYAEFVQQY

61?AFVRPVILQG?LTDNSRFRAL?CSRDRLLASF?GDRVVRLSTA?NTYSYHKVDL?PFQEYVEQLL

121?HPQDPTSLGN?DTLYFFGDNN?FTEWASLFRH?YSPPPFGLLG?TAPAYSFGIA?GAGSGVPFHW

181?HGPGYSEVIY?GRKRWFLYPP?EKTPEFHPNK?TTLAWLRDTY?PALPPSARPL?ECTIRAGEVL

241 YFPDRWWHAT LNLDTSVFIS TFLG C. Nucleotide and amino acid composite sequence (SEQ ID NO:12) clone number: PP14397 start code: 5 ATG stop coding: 797 TAG protein molecular weights: 29507.63

1????G?CTC?ATG?GCG?CCG?GCG?TCG?CGG?TTG?CTC?GCG?CTC?TGG?GCG?CTG?GCG????46

1, Met, Ala, Pro, Ala, Ser, Arg, Leu, Leu, Ala, Leu, Trp, Ala, Leu, Ala, 14, 47, GCT, GTG, GCT, CTA, CCC, GGC, TCC, GGG, GCG, GAG, GGC, GAC, GGC, GGG, TGG, CGC, 94, 15, Ala, Val, Ala, Leu, Pro, Gly, Ser, Gly, Ala, Glu, Gly, Asp, Gly, Gly, Trp, Arg, 30, 95, CCG, GGC, GGG, CCG, GGG, GCC, GTG, GCG, GAG, GAG, GAG, CGC, TGC, ACG, GTG, GAG, 142, 31, Pro, Gly, Gly, Pro, Gly, Ala, Val, Ala, Glu, Glu, Glu, Arg, Cys, Thr, Val, Glu, 46, 143, CGT, CGG, GCC, GAC, CTC, ACC, TAC, GCG, GAG, TTC, GTG, CAG, CAG, TAC, GCC, TTC, 190, 47, Arg, Arg, Ala, Asp, Leu, Thr, Tyr, Ala, Glu, Phe, Val, Gln, Gln, Tyr, Ala, Phe, 62, 191, GTC, AGG, CCC, GTC, ATC, CTG, CAG, GGA, CTC, ACG, GAC, AAC, TCG, AGG, TTC, CGG, 238, 63, Val, Arg, Pro, Val, Ile, Leu, Gln, Gly, Leu, Thr, Asp, Ash, Ser, Arg, Phe, Arg, 78, 239, GCC, CTG, TGC, TCC, CGC, GAC, AGG, TTG, CTG, GCT, TCG, TTT, GGG, GAC, AGA, GTG, 286, 79, Ala, Leu, Cys, Ser, Arg, Asp, Arg, Leu, Leu, Ala, Ser, Phe, Gly, Asp, Arg, Val, 94, 287, GTC, CGG, CTG, AGC, ACC, GCC, AAC, ACC, TAC, TCC, TAC, CAC, AAA, GTG, GAC, TTG, 334, 95, Val, Arg, Leu, Ser, Thr, Ala, Asn, Thr, Tyr, Ser, Tyr, His, Lys, Val, Asp, Leu, 110, 335, CCC, TTC, CAG, GAG, TAT, GTG, GAG, CAG, CTG, CTG, CAC, CCC, CAG, GAC, CCC, ACC, 382, 111, Pro, Phe, Gln, Glu, Tyr, Val, Glu, Gln, Leu, Leu, His, Pro, Gln, Asp, Pro, Thr, 126, 383, TCC, CTG, GGC, AAT, GAC, ACC, CTG, TAC, TTC, TTC, GGG, GAC, AAC, AAC, TTC, ACC, 430, 127, Ser, Leu, Gly, Asn, Asp, Thr, Leu, Tyr, Phe, Phe, Gly, Asp, Asn, Asn, Phe, Thr, 142, 431, GAG, TGG, GCC, TCT, CTC, TTT, CGG, CAC, TAC, TCC, CCA, CCC, CCA, TTT, GGC, CTG, 478, 143, Glu, Trp, Ala, Ser, Leu, Phe, Arg, His, Tyr, Ser, Pro, Pro, Pro, Phe, Gly, Leu, 158, 479, CTG, GGA, ACC, GCT, CCA, GCT, TAC, AGC, TTT, GGA, ATC, GCA, GGA, GCT, GGC, TCG, 526, 159, Leu, Gly, Thr, Ala, Pro, Ala, Tyr, Ser, Phe, Gly, Ile, Ala, Gly, Ala, Gly, Ser, 174, 527, GGG, GTG, CCC, TTC, CAC, TGG, CAT, GGA, CCC, GGG, TAC, TCA, GAA, GTG, ATC, TAC, 574, 175, Gly, Val, Pro, Phe, His, Trp, His, Gly, Pro, Gly, Tyr, Ser, Glu, Val, Ile, Tyr, 190, 575, GGT, CGT, AAG, CGC, TGG, TTC, CTT, TAC, CCA, CCT, GAG, AAG, ACG, CCA, GAG, TTC, 622, 191, Gly, Arg, Lys, Arg, Trp, Phe, Leu, Tyr, Pro, Pro, Glu, Lys, Thr, Pro, Glu, Phe, 206, 623, CAC, CCC, AAC, AAG, ACC, ACG, CTG, GCC, TGG, CTC, CGG, GAC, ACA, TAC, CCA, GCC, 670, 207, His, Pro, Asn, Lys, Thr, Thr, Leu, Ala, Trp, Leu, Arg, Asp, Thr, Tyr, Pro, Ala, 222, 671, CTG, CCA, CCG, TCT, GCA, CGG, CCC, CTG, GAG, TGT, ACC, ATC, CGG, GCT, GGT, GAG, 718, 223, Leu, Pro, Pro, Ser, Ala, Arg, Pro, Leu, Glu, Cys, Thr, Ile, Arg, Ala, Gly, Glu, 238, 719, GTG, CTG, TAC, TTC, CCC, GAC, CGC, TGG, TGG, CAT, GCT, ACG, CTCAAC, CTT, GAC, 766, 239, Val, Leu, Tyr, Phe, Pro, Asp, Arg, Trp, Trp, His, Ala, Thr, Leu, Asn, Leu, Asp, 254, 767, ACC, AGC, GTC, TTC, ATC, TCC, ACC, TTC, CTC, GGC, TAG, CCA, AAA, CAG, CTG, GCA, 814, 255, Thr, Ser, Val, Phe, Ile, Ser, Thr, Phe, Leu, Gly, * *, 265, 815, GGA, CTG, CCG, GTC, ACA, CAC, CAG, CAC, GTC, CCA, CCT, CGT, GCT, CAC, GGA, TTT, 862, 863, TAT, TAC, ACA, GAT, AGT, GGC, GGC, AAT, GGC, CTC, AGC, CCA, GCC, CAC, CCT, CAC, 910, 911, CTG, CTT, TTC, CAG, CCC, ACA, AAG, GGG, GAC, GAT, CAC, GGC, CCA, GCA, AAA, GCG, 958, 959, ATG, CTG, AGA, GGG, GAA, ACA, GTC, CAG, AGT, CCA, ACA, GCA, GAA, CTT, GGG, GGA, 10061007, AGC, GGT, CGG, GGT, GGC, CAG, GAA, CAT, AAA, CTA, TGT, ATA, GGG, GCC, GGG, GGC, 10541055, TTC, TGC, CCA, GGG, CTC, CCC, TGG, ACC, AGG, ACG, CCA, GGT, AGG, GCA, GGG, AAC, 11021103, CTC, AGT, AGT, CCT, CCA, CCC, AGC, CAT, TCT, CAG, AGA, TGA, ATG, CGT, CAA, TAA, 11501151, CCT, CCT, TCA, TAG, CCA, AGT, TGG, GGA, TGA, GCT, GTT, CCT, GGG, TCA, GGG, GGC, 11981199, TCC, GGG, TCA, CGG, GGT, CAA, AAT, GAC, CCA, CAC, GCT, GCA, GTG, ACA, AGA, AGG, 12461247, GCA, GAG, GGC, AGT, CAT, GGG, GCC, CAG, GAC, CAT, GCC, ACT, GGC, CCT, GCT, CCC, 12941295, CCA, GCC, GCA, GCC, TCA, CCT, GCA, GGT, GCT, CCT, CGA, TGT, CCT, TGC, GGT, CGT, 13421343, AGG, TGA, TGC, CAC, TGG, GCG, TGA, TGC, ACG, GCT, CCC, GCA, TCA, GCT, CAA, AGC, 13901391, TGA, TCT, TGC, CAC, ACA, GGT, AGT, CGG, GGA, TGT, CTC, GCT, TCT, GTG, GCA, CAG, 14381439, GGG, CAC, ACG, GTC, AGA, GGC, TGA, AAA, GGG, GCA, CTG, CAC, GAG, CAC, CTG, CCA, 1486, 1487, GCC, ATC, GGC, AGC, AAG, CGA, CAC, ACA, CTC, ACC, TTC, CTC, TTC, TCA, TCC, ACC, 1534, 1535, TGA, GAA, AAA, AGC, TCG, TCC, ATG, TCC, GCC, ATG, TAC, TTG, TCC, TGT, GAA, GAG, 1582, 1583, TTG, AGT, GCT, GTG, CTT, GGG, GGA, GAC, ACC, CCA, CCT, CCC, TCC, TCC, ATG, GGG, 1630, 1631, CAC, AGA, CCC, AAC, ACA, AGG, CGG, GGA, TGC, TCC, CAC, GCC, ACG, TGC, ACA, CAC, 1678, 1679, ACA, GAC, CCA, CAT, GTG, GGT, GGG, GGG, CAC, CCT, CAC, GTG, CTT, GGC, CTC, AAT, 1726, 1727, GCA, GGC, CTG, CTG, GGC, CCG, GAC, GTG, GCT, GTC, GTC, CTC, ATC, ACC, CTC, GTG, 1774, 1775, GTT, TCG, CTG, GCA, CTC, TTC, CAG, CTC, CCT, GGG, GGT, TGA, CCA, GGA, GCC, GGT, 1822, 1823, CAG, AGA, TGG, ACC, TGG, CCA, GAT, GTC, TGA, CCA, CAC, CCC, AAT, CTC, AGA, GCT, 1870, 1871, AAC, ATC, CAC, ACT, TCC, CCA, CAT, TTC, CTG, CTT, GCC, AGT, AAA, GCC, TTC, GAT, 1918, 1919, AAA, AAA, AAA, AAA, AAA, AAA, 1936, 5.PP14434A: nucleotide sequence, (SEQ, ID, NO:13) length: 4130 bases

1?GCTGAGTCGT?CTTGGTCCCA?GGAGCCAGTA?GTGAAGGCAA?CAGTCTGCCC?ACCTGTGGAC

61?ACCAGATCCT?GGGAGCTCCT?GGTTAGCAAG?TGAGATCTCT?GGGATGTCAG?TGAGGCTGGT

121?TGAAGACCAG?AGGTAAACTG?CAGAGGTCAC?CACCCCCACC?ATGTCCCAGG?TGATGTCCAG

181?CCCACTGCTG?GCAGGAGGCC?ATGCTGTCAG?CTTGGCGCCT?TGTGATGAGC?CCAGGAGGAC

241?CCTGCACCCA?GCACCCAGCC?CCAGCCTGCC?ACCCCAGTGT?TCTTACTACA?CCACGGAAGG

301?CTGGGGAGCC?CAGGCCCTGA?TGGCCCCCGT?GCCCTGCATG?GGGCCCCCTG?GCCGACTCCA

361?GCAAGCCCCA?CAGGTGGAGG?CCAAAACCAC?CTGCTTCCTG?CCGTCCCCTG?GTGAGAAAGG

421?CCTTGGGGAC?CCCAGAGGAC?CTTGACTCCT?ACATTGACTT?CTCACTGGAG?AGCCTCAATC

481?AGATGATCCT?GGAACTGGAC?CCCACCTTCC?AGCTGCTTCC?CCCAGGGACT?GGGGGCTCCC

541?AGGCTGAGCT?GGCCCAGAGC?ACCATGTCAA?TGAGAAAGAA?GGAGGAATCT?GAAGCCTTGG

601?ACATAAAGTA?CATCGAGGTG?ACCTCCGCCA?GATCAAGGTG?CCACGATGGC?CCCCAGCACT

661?GCTCCAGCCC?CTCTGTCACC?CCGCCCTTCG?GCTCCCTTCG?CAGTGGTGGC?CTCCTCCTTT

721?CCAGAGACGT?CCCCCGAGAG?ACACGAAGCA?GCAGTGAGAG?CCTCATCTTC?TCTGGGAACC

781?AGGGCAGGGG?GCACCAGCGC?CCTCTGCCCC?CCTCAGAGGG?TCTCTCCCCT?CGACCCCCAA

841?ATTCCCCCAG?CATCTCAATC?CCTTGCATGG?GGAGCAAGGC?CTCGAGCCCC?CATGGTTTGG

901?GCTCCCCGCT?GGTGGCTTCT?CCAAGACTGG?AGAAGCGGCT?GGGAGGCCTG?GCCCCACAGC

961?GGGGCAGCAG?GATCTCTGTG?CTGTCAGCCA?GCCCAGTGTC?TGATGTCAGC?TATATGTTTG

1021?GAAGCAGCCA?GTCCCTTCTG?CACTCAGCAA?CTCCAGCCAT?CAGTCATCTT?CCAGATCCTT

1081?GGAAAGTCCA?GCCAACTCTT?CCTCCAGCCT?CCACAGCCTT?GGCTCAGTGT?CCCTGTGTAC

1141?AAGACCCAGT?GACTTCCAGG?CTCCCAGAAA?CCCCACCCTA?ACCATGGGCC?AACCCAGAAC

1201?ACCCCACTCT?CCACCACTGG?CCAAAGAACA?TGCCAGCAGC?TGCCCCCCAT?CCATCACCAA

1261?CTCCATGGTG?GACATACCCA?TTGTGCTGAT?CAACGGCTGG?CCAGAACCAG?GGTCTTCTCC

1321?ACCCCAGCGG?ACCCCAGGAC?ACCAGAACTC?CGTTCAACCT?GGAGCTGCTT?CTCCCAGCAA

1381?CCCCTGTCCA?GCCACCAGGA?GCAACAGCCA?GACCCTGTCA?GATGCCCCCT?TTACCACATG

1441?CCCAGAGGGT?CCCGCCAGGG?ACATGCAGCC?CACCATGAAG?TTCGTGATGG?ACACATCTAA

1501?ATACTGGTTT?AAGCCAAACA?TCACCCGAGA?GCAAGCAATC?GAGCTGCTGA?GGAAGGAGGA

1561?GCCAGGGGCT?TTTTGTCATA?AGGGACAGCT?CTTCATACCG?AGGCTCCTTC?GGCCTGGCCC

1621?TGAAGGTGCA?GGAGGTTCCC?GCGTCTGCTC?AGAGTCGACC?AGGTGAGGAC?AGCAATGACC

1681?TCATCCGACA?CTTCCTCATC?GAGTCGTCTG?CCAAAGGAGT?GCATCTCAAA?GGAGCAGATG

1741?AGGAGCCCTA?CTTTGGGAGC?CTCTCTGCCT?TCGTGTGCCA?GCATTCCATC?ATGGCCCTGG

1801?CCCTGCCCTG?CAAACTCACC?ATCCCACAGA?GAGAACTGGG?AGGTGCAGAT?GGGGCCTCGG

1861?ACTCTACAGA?CAGCCCAGCC?TCCTGCCAGA?AGAAATCTGC?GGGCTGCCAC?ACCCTGTACC

1921?TGAGCTCAGT?GAGCGTGGAG?ACCCTGACTG?GAGCCCTGGC?CGTCAGAAAG?CCATCTCCAC

1981?CACCTTTGAG?AGGGACATCC?TCCCCACGCC?CACCGTGGTC?CACTTCAAAG?TCACAGAGCA

2041?GGGCATCACT?CTGACTGATG?TCCAGAGGAA?GGTGTTTTTC?CGGCGCCATT?ACCCACTCAC

2101?CACCCTCCGC?TTCTGTGGTA?TGGACCCTGA?GCAACGGAAG?TGGCAGAAGT?ACTGCAAACC

2161?CTCCTGGATC?TTTGGGTTTG?TGGCCAAGAG?CCAGACAGAG?CCTCAGGAGA?ACGTATGCCA

2221, CCTCTTTGCG, GAGTATGACA, TGGTCCAGCC, AGCCTCGCAG, GTCATCGGCC, TGGTGACTGC, 2281, TCTGCTGCAG, GACGCAGAAA, GGATGTAGGG, GAGAGACTGC, CTGTGCACCT, AACCAACACC, 2341, TCCAGGGGCT, CGCTAAGGAG, CCCCCCTCCA, CCCCCTGAAT, GGGTGTGGCT, TGTGGCATAT, 2401, TGACAGACCA, ATCTATGGGA, CTAGGGGGAT, TGGCATCAAG, TTGACACCCT, TGAACCTGCT, 2461, ATGGCCTTCA, GCAGTCACCA, TCATCCAGAC, CCCCCGGGCC, TCAGTTTCCT, CAATCATAGA, 2521, AGAAGACCAA, TAGACAAGAT, CAGCTGTTCT, TAGATGCTGG, TGGGCATTTG, AACATGCTCC, 2581, TCCATGATTC, TGAAGCATGC, ACACCTCTGA, AGACCCCTGC, ATGAAAATAA, CCTCCAAGGA, 2641, CCCTCTGACC, CCATCGACCT, GGGCCCTGCC, ACACAACAGT, CTGAGCAAGA, GACCTGCAGC, 2701, CCCTGTTTCG, TGGCAGACAG, CAGGTGCCTG, GCGGTGACCC, ACGGGGCTCC, TGGCTTGCAG, 2761, CTGGTGATGG, TCAAGAACTG, ACTACAAAAC, AGGAATGGAT, AGACTCTATT, TCCTTCCATA, 2821, TCTGTTCCTC, TGTTCCTTTT, CCCACTTTCT, GGGTGGCTTT, TTGGGTCCAC, CCAGCCAGGA, 2881, TGCTGCAGGC, CAAGCTGGGT, GTGGTATTTA, GGGCAGCTCA, GCAGGGGGAA, CTTGTCCCCA, 2941, TGGTCAGAGG, AGACCCAGCT, GTCCTGCACC, CCCTTGCAGA, TGAGTATCAC, CCCATCTTTT, 3001, CTTTCCACTT, GGTTTTTATT, TTTATTTTTT, TTTGAGACAG, AGTCTCACTG, TCACCCAGGC, 3061, TGAACTGCAG, TGGTGTGATC, TAGGCTCACT, GCAACCTCCA, CCTCCCAGGT, TCAAGCAATT, 3121, ATCCTGCCTC, AGGCTCCCAA, GTAGCTGGGA, TTACAGGCAT, GTGCAACTCA, CCCAGCTAAT, 3181, TTTGTATTTT, TAGTAGAGAC, AGGGTTTCAC, CATGTTGGCC, AGGCTGGTCT, TGAACTCCTG, 3241, ACCGCAGTAA, TCCACCTGCT, TCGGCCTCCC, AAAGTGCTGG, GATTACAGGC, GCAACGACCC, 3301, AGCCCAGCTT, CTTTCCATTC, CTTGATAGGC, GAGTATTCCA, AAGCTGGTAT, CGTAGCTGCC, 3361, CTAATGTTGC, ATATTAGGCG, GCGGGGGCAG, AGATAAGGGC, CATCTCTCTG, TGATTCTGCC, 3421, TCAGCTCCTG, TCTTGCTGAG, CCCTCCCCCA, ACCCACGCTC, CAACACACAC, ACACACACAC, 3481, ACACACACAC, ACACACACAC, ACACACACAC, ACACACACGC, CCCTCTACTG, CTATGTGGCT, 3541, TCAACCAGCC, TCACAGCCAC, ACGGGGGAAG, CAGAGAGTCA, AGAATGCAAA, GAGGCCGCTT, 3601, CCCTAAGAGG, CTTGGAGGAG, CTGGGCTCTA, TCCCACACCC, ACCCCCACCC, CACCCCCACC, 3661, CAGCCTCCAG, AAGCTGGAAC, CATTTCTCCC, GCAGCCTGAG, TTCCTAAGGA, AACCACCCTA, 3721, CCGGGGTGGA, AGGGAGGGTC, AGGGAAGAAA, CCCACTCTTG, CTCTACGAGG, AGCAAGTGCC, 3781, TGCCCCCTCC, CAGCAGCCAG, CCCTGCCAAA, GTTGCATTAT, CTTTGGCCAA, GGCTGGGCCT, 3841, GACGGTTATG, ATTTCAGCCC, TGGGCCTGCA, GGAGAGGCTG, AGACCAGCCC, ACCCAGCCAG, 3901, TGGTCGAGCA, CTGCCCCGCC, GCCAAAGTCT, GCAGAATGTG, AGATGAGGTT, CTCAAGGTCA, 3961, CAGGCCCCAG, TCCCAGCCTG, GGGGCTGCAG, AGGCCCCCAT, ATACTCTGCT, ACAGCTCCTA, 4021, TCATGAAAAA, TAAAATGTTT, GTCTTTGCAA, AACAGTAAAA, AAAAAAAAAA, AAAAAAAAAA, 4081, AAAAAAAAAA, AAAAAAAAAA, AAAAAAAAAA, AAAAAAAAAA, AAAAAAAAAAB: nucleotide sequence, (SEQ, ID, NO:14), length: 232 amino acid

1?MILELDPTFQ?LLPPGTGGSQ?AELAQSTMSM?RKKEESEALD?IKYIEVTSAR?SRCHDGPQHC

61 SSPSVTPPFG SLRSGGLLLS RDVPRETRSS SESLIFSGNQ GRGHQRPLPP SEGLSPRPPN 121 SPSISIPCMG SKASSPHGLG SPLVASPRLE KRLGGLAPQR GSRISVLSAS PVSDVSYMFG 181 SSQSLLHSAT PAISHLPDPW KVQPTLPPAS TALAQCPCVQ DPVTSRLPET PP Nucleotide and amino acid sequence of C. Combination (SEQ ID NO: 15) Clone: ​​PP14434 Start codon: 483 ATG termination codon: 1179 TAA Protein Weight: 24467.33 1 GC TGA GTC GTC TTG GTC CCA GGA GCC AGT AGT GAA GGC AAC AGT CTG 47 48 CCC ACC TGT GGA CAC CAG ATC CTG GGA GCT CCT GGT TAG CAA GTG AGA 95 96 TCT CTG GGA TGT CAG TGA GGC TGG TTG AAG ACC AGA GGT AAA CTG CAG 143 144 AGG TCA CCA CCC CCA CCA TGT CCC AGG TGA TGT CCA GCC CAC TGC TGG 191 192 CAG GAG GCC ATG CTG TCA GCT TGG CGC CTT GTG ATG AGC CCA GGA GGA 239 240 CCC TGC ACC CAG CAC CCA GCC CCA GCC TGC CAC CCC AGT GTT CTT ACT 287 288 ACA CCA CGG AAG GCT GGG GAG CCC AGG CCC TGA TGG CCC CCG TGC CCT 335 336 GCA TGG GGC CCC CTG GCC GAC TCC AGC AAG CCC CAC AGG TGG AGG CCA 383 384 AAA CCA CCT GCT TCC TGC CGT CCC CTG GTG AGA AAG GCC TTG GGG ACC 431 432 CCA GAG GAC CTT GAC TCC TAC ATT GAC TTC TCA CTG GAG AGC CTC AAT 479 480 CAG ATG ATC CTG GAA CTG GAC CCC ACC TTC CAG CTG CTT CCC CCA GGG 527 1 Met Ile Leu Glu Leu Asp Pro Thr Phe Gln Leu Leu Pro Pro Gly 15 528 ACT GGG GGC TCC CAG GCT GAG CTG GCC CAG AGC ACC ATG TCA ATG AGA 575 16 Thr Gly Gly Ser Gln Ala Glu Leu Ala Gln Ser Thr Met Ser Met Arg 31 576 AAG AAG GAG GAA TCT GAA GCC TTG GAC ATA AAG TAC ATC GAG GTG ACC 623 32 Lys Lys Glu Glu Ser Glu Ala Leu Asp Ile Lys Tyr Ile Glu Val Thr 47 624 TCC GCC AGA TCA AGG TGC CAC GAT GGC CCC CAG CAC TGC TCC AGC CCC 671 48 Ser Ala Arg Ser Arg Cys His Asp Gly Pro Gln His Cys Ser Ser Pro 63 672 TCT GTC ACC CCG CCC TTC GGC TCC CTT CGC AGT GGT GGC CTC CTC CTT 719 64 Ser Val Thr Pro Pro Phe Gly Ser Leu Arg Ser Gly Gly Leu Leu Leu 79 720 TCC AGA GAC GTC CCC CGA GAG ACA CGA AGC AGC AGT GAG AGC CTC ATC 767 80 Ser Arg Asp Val Pro Arg Glu Thr Arg Ser Ser Ser Glu Ser Leu Ile 95 768 TTC TCT GGG AAC CAG GGC AGG GGG CAC CAG CGC CCT CTG CCC CCC TCA 815 96 Phe Ser Gly Asn Gln Gly Arg Gly His Gln Arg Pro Leu Pro Pro Ser 111 816 GAG GGT CTC TCC CCT CGA CCC CCA AAT TCC CCC AGC ATC TCA ATC CCT 863 112 Glu Gly Leu Ser Pro Arg Pro Pro Asn Ser Pro Ser Ile Ser Ile Pro 127 864 TGC ATG GGG AGC AAG GCC TCG AGC CCC CAT GGT TTG GGC TCC CCG CTG 911 128 Cys Met Gly Ser Lys Ala Ser Ser Pro His Gly Leu Gly Ser Pro Leu 143 912 GTG GCT TCT CCA AGA CTG GAG AAG CGG CTG GGA GGC CTG GCC CCA CAG 959 144 Val Ala Ser Pro Arg Leu Glu Lys Arg Leu Gly Gly Leu Ala Pro Gln 159 960 CGG GGC AGC AGG ATC TCT GTG CTG TCA GCC AGC CCA GTG TCT GAT GTC 1007 160 Arg Gly Ser Arg Ile Ser Val Leu Ser Ala Ser Pro Val Ser Asp Val 175 1008 AGC TAT ATG TTT GGA AGC AGC CAG TCC CTT CTG CAC TCA GCA ACT CCA 1055 176 Ser Tyr Met Phe Gly Ser Ser Gln Ser Leu Leu His Ser Ala Thr Pro 191 1056 GCC ATC AGT CAT CTT CCA GAT CCT TGG AAA GTC CAG CCA ACT CTT CCT 1103 192 Ala Ile Ser His Leu Pro Asp Pro Trp Lys Val Gln Pro Thr Leu Pro 207 1104 CCA GCC TCC ACA GCC TTG GCT CAG TGT CCC TGT GTA CAA GAC CCA GTG 1151 208 Pro Ala Ser Thr Ala Leu Ala Gln Cys Pro Cys Val Gln Asp Pro Val 223 1152 ACT TCC AGG CTC CCA GAA ACC CCA CCC TAA CCA TGG GCC AAC CCA GAA 1199 224 Thr Ser Arg Leu Pro Glu Thr Pro Pro *** 233 1200 CAC CCC ACT CTC CAC CAC TGG CCA AAG AAC ATG CCA GCA GCT GCC CCC 1247 1248 CAT CCA TCA CCA ACT CCA TGG TGG ACA TAC CCA TTG TGC TGA TCA ACG 1295 1296 GCT GGC CAG AAC CAG GGT CTT CTC CAC CCC AGC GGA CCC CAG GAC ACC 1343 1344 AGA ACT CCG TTC AAC CTG GAG CTG CTT CTC CCA GCA ACC CCT GTC CAG 1391 1392 CCA CCA GGA GCA ACA GCC AGA CCC TGT CAG ATG CCC CCT TTA CCA CAT 1439 1440 GCC CAG AGG GTC CCG CCA GGG ACA TGC AGC CCA CCA TGA AGT TCG TGA 1487 1488 TGG ACA CAT CTA AAT ACT GGT TTA AGC CAA ACA TCA CCC GAG AGC AAG 1535 1536 CAA TCG AGC TGC TGA GGA AGG AGG AGC CAG GGG CTT TTT GTC ATA AGG 1583 1584 GAC AGC TCT TCA TAC CGA GGC TCC TTC GGC CTG GCC CTG AAG GTG CAG 1631 1632 GAG GTT CCC GCG TCT GCT CAG AGT CGA CCA GGT GAG GAC AGC AAT GAC 1679 1680 CTC ATC CGA CAC TTC CTC ATC GAG TCG TCT GCC AAA GGA GTG CAT CTC 1727 1728 AAA GGA GCA GAT GAG GAG CCC TAC TTT GGG AGC CTC TCT GCC TTC GTG 1775 1776 TGC CAG CAT TCC ATC ATG GCC CTG GCC CTG CCC TGC AAA CTC ACC ATC 1823 1824 CCA CAG AGA GAA CTG GGA GGT GCA GAT GGG GCC TCG GAC TCT ACA GAC 1871 1872 AGC CCA GCC TCC TGC CAG AAG AAA TCT GCG GGC TGC CAC ACC CTG TAC 1919 1920 CTG AGC TCA GTG AGC GTG GAG ACC CTG ACT GGA GCC CTG GCC GTC AGA 1967 1968 AAG CCA TCT CCA CCA CCT TTG AGA GGG ACA TCC TCC CCA CGC CCA CCG 2015 2016 TGG TCC ACT TCA AAG TCA CAG AGC AGG GCA TCA CTC TGA CTG ATG TCC 2063 2064 AGA GGA AGG TGT TTT TCC GGC GCC ATT ACC CAC TCA CCA CCC TCC GCT 2111 2112 TCT GTG GTA TGG ACC CTG AGC AAC GGA AGT GGC AGA AGT ACT GCA AAC 2159 2160 CCT CCT GGA TCT TTG GGT TTG TGG CCA AGA GCC AGA CAG AGC CTC AGG 2207 2208 AGA ACG TAT GCC ACC TCT TTG CGG AGT ATG ACA TGG TCC AGC CAG CCT 2255 2256 CGC AGG TCA TCG GCC TGG TGA CTG CTC TGC TGC AGG ACG CAG AAA GGA 2303 2304 TGT AGG GGA GAG ACT GCC TGT GCA CCT AAC CAA CAC CTC CAG GGG CTC 2351 2352 GCT AAG GAG CCC CCC TCC ACC CCC TGA ATG GGT GTG GCT TGT GGC ATA 2399 2400 TTG ACA GAC CAA TCT ATG GGA CTA GGG GGA TTG GCA TCA AGT TGA CAC 2447 2448 CCT TGA ACC TGC TAT GGC CTT CAG CAG TCA CCA TCA TCC AGA CCC CCC 2495 2496 GGG CCT CAG TTT CCT CAA TCA TAG AAG AAG ACC AAT AGA CAA GAT CAG 2543 2544 CTG TTC TTA GAT GCT GGT GGG CAT TTG AAC ATG CTC CTC CAT GAT TCT 2591 2592 GAA GCA TGC ACA CCT CTG AAG ACC CCT GCA TGA AAA TAA CCT CCA AGG 2639 2640 ACC CTC TGA CCC CAT CGA CCT GGG CCC TGC CAC ACA ACA GTC TGA GCA 2687 2688 AGA GAC CTG CAG CCC CTG TTT CGT GGC AGA CAG CAG GTG CCT GGC GGT 2735 2736 GAC CCA CGG GGC TCC TGG CTT GCA GCT GGT GAT GGT CAA GAA CTG ACT 2783 2784 ACA AAA CAG GAA TGG ATA GAC TCT ATT TCC TTC CAT ATC TGT TCC TCT 2831 2832 GTT CCT TTT CCC ACT TTC TGG GTG GCT TTT TGG GTC CAC CCA GCC AGG 2879 2880 ATG CTG CAG GCC AAG CTG GGT GTG GTA TTT AGG GCA GCT CAG CAG GGG 2927 2928 GAA CTT GTC CCC ATG GTC AGA GGA GAC CCA GCT GTC CTG CAC CCC CTT 2975 2976 GCA GAT GAG TAT CAC CCC ATC TTT TCT TTC CAC TTG GTT TTT ATT TTT 3023 3024 ATT TTT TTT TGA GAC AGA GTC TCA CTG TCA CCC AGG CTG AAC TGC AGT 3071 3072 GGT GTG ATC TAG GCT CAC TGC AAC CTC CAC CTC CCA GGT TCA AGC AAT 3119 3120 TAT CCT GCC TCA GGC TCC CAA GTA GCT GGG ATT ACA GGC ATG TGC AAC 3167 3168 TCA CCC AGC TAA TTT TGT ATT TTT AGT AGA GAC AGG GTT TCA CCA TGT 3215 3216 TGG CCA GGC TGG TCT TGA ACT CCT GAC CGC AGT AAT CCA CCT GCT TCG 3263 3264 GCC TCC CAA AGT GCT GGG ATT ACA GGC GCA ACG ACC CAG CCC AGC TTC 3311 3312 TTT CCA TTC CTT GAT AGG CGA GTA TTC CAA AGC TGG TAT CGT AGC TGC 3359 3360 CCT AAT GTT GCA TAT TAG GCG GCG GGG GCA GAG ATA AGG GCC ATC TCT 3407 3408 CTG TGA TTC TGC CTC AGC TCC TGT CTT GCT GAG CCC TCC CCC AAC CCA 3455 3456 CGC TCC AAC ACA CAC ACA CAC ACA CAC ACA CAC ACA CAC ACA CAC ACA 3503 3504 CAC ACA CAC ACA CAC GCC CCT CTA CTG CTA TGT GGC TTC AAC CAG CCT 3551 3552 CAC AGC CAC ACG GGG GAA GCA GAG AGT CAA GAA TGC AAA GAG GCC GCT 3599 3600 TCC CTA AGA GGC TTG GAG GAG CTG GGC TCT ATC CCA CAC CCA CCC CCA 3647 3648 CCC CAC CCC CAC CCA GCC TCC AGA AGC TGG AAC CAT TTC TCC CGC AGC 3695 3696 CTG AGT TCC TAA GGA AAC CAC CCT ACC GGG GTG GAA GGG AGG GTC AGG 3743 3744 GAA GAA ACC CAC TCT TGC TCT ACG AGG AGC AAG TGC CTG CCC CCTCCC 3791 3792 AGC AGC CAG CCC TGC CAA AGT TGC ATT ATC TTT GGC CAA GGC TGG GCC 3839 3840 TGA CGG TTA TGA TTT CAG CCC TGG GCC TGC AGG AGA GGC TGA GAC CAG 3887 3888 CCC ACC CAG CCA GTG GTC GAG CAC TGC CCC GCC GCC AAA GTC TGC AGA 3935 3936 ATG TGA GAT GAG GTT CTC AAG GTC ACA GGC CCC AGT CCC AGC CTG GGG 3983 3984 GCT GCA GAG GCC CCC ATA TAC TCT GCT ACA GCT CCT ATC ATG AAA AAT 4031 4032 AAA ATG TTT GTC TTT GCA AAA CAG TAA AAA AAA AAA AAA AAA AAA AAA 4079 4080 AAA AAA AAA AAA AAA AAA AAA AAA AAA AAA AAA AAA AAA AAA AAA AAA 4127 4128 AAA 4130 6.PP14630 A: the nucleotide sequence (SEQ ID NO: 16) Length: 3128 nucleotides ...

1?GTTGACCGCA?GCCCAGGAGC?CCATGCCGAA?GAGAGCCACC?AGCAGGGCCA?GACACGCTTT

61, GGCTCTCCTG, GGAAGTGAAG, ACTTCTTCTA, GCTTGGAAGA, AACAGAGAAA, CAGATAGGAT, 121, GCAGAGCCGG, AGTCAGAACA, GGGTGAGACC, AGGGGAACTG, GGGGAGCCCC, GGGCAGGAGC, 181, GCAGATGGGG, AGGATTGGCT, AAAACGTACC, CAGCGGGACC, GCCGGCAGGC, AGGGAAGCAG, 241, GAAGCCGGCC, CGAGTCGCTG, CGGCCCCAGG, GGAGGAGGCC, GAAGGAGCGA, GTGGAGCCCT, 301, CCTCTCCAGG, GAGAGGCGGG, GCTGGAGTCA, ACGCCACCAC, CACCCCAAGC, CGGACGCCGG, 361, GAAAGGGCGC, CTACCAGGAG, GAGCCACGCA, CACCCCAGGG, CTTCACGGTG, CCCGCGACCG, 421, CAAGAGCCAA, GTCAGATCCC, AGGGGAGTGG, CCGGGACGGC, TCTGCTCGGA, GGGGCGCCGC, 481, CCTCTCGGTA, CCGTCAGGTG, GGCGACTCGG, GAGCCGTCCG, GTCCCTGCGC, CTCCCGGTCC, 541, CGCGCCCAGT, GCGCTCCCGC, TCCAGTGCCG, GCTTCCCGCC, ACGCCGGGAC, ACCGCCGTCC, 601, GGCCCAGGGA, CGCCACCTCA, GTCCGGAGCG, CGCAGGACCC, GGCAGCAGCC, ACGACCCGAC, 661, TCACCCGTGG, CGGTTCCGGG, CCCGCCCCCG, GCATGGCCCA, CGACCGGAAG, TCCCGCCCCG, 721, GAAGCTGGTC, GGCGGGCGGG, CGGGCGTTGA, GAGGAACCGG, GGGGTTGTCG, GTCTATAAGC, 781, CTCGCCCGTT, CCGCTCCCTG, GGGCTTCCCC, GAGCGCCGTC, GGTGGTCATG, GCTGCCCCAG, 841, CCTCCCGGCA, GGTCCGACGC, AGAGCCCGGG, CAGCGCCGCG, GGCCCCGCTC, GGCCGAGGAC, 901, TGGTGGTGGG, ACCGGCTGGC, GCCGAGGGGC, TCGGGGTACC, ACCTGCTGCA, GTCCGACAGC, 961, ATGCTGCTGG, TGCTGTCCGA, ACCCGGCCCC, GCCCGGCCCC, GCGCACAGCG, CGCGCTTCCC1021, GCCGCACTCC, CCGGCAGCCG, CCCCGGGGCC, CCAGCGCCGC, GGCCAAGCCC, AAGGCCGGGC1081, TCAGGTCCGA, GGCGGCGGCC, GCGCCCGCAC, CCGCACCGGC, ACCCACGCCC, ACGCCCGAGG1141, AAGGGCCCGA, CGCGGGCTGG, GGAGACCGCA, TTCCCTTGGA, AATCCTGGTG, CAGATTTTCG1201, GGTTGTTGGT, GGCGGCGGAC, GGCCCCATGC, CCTTCCTGGG, CAGGTAACGC, TGGTGCCGGG1261, CCCGCCGCCG, AGCGTAGCGG, CTTGGGCCAG, ACGTGGTCCG, AGCGGTGGCC, CGGGCGGGGG1321, CGGAGGGCGA, AAGCATCGGA, GCGCGCACCG, CTCAGTCCGA, GAGCGCAGCC, CCTTAGGTGC1381, CCAGTTGGAG, TCCCAGGAGC, CCGGCTTTGA, GCCGGGGTGT, CTACTGCGCT, GCGAGAGGGG1441, GGCATCGCCT, ACGGAGGGGC, CGGCACCCTC, AGCACGCTGT, CCTCCCAGGG, CTGCGCGCGT1501, GTGCCGCCGC, TGGCAGGAGG, CCGCTTCCCA, ACCCGCGCTC, TGGCACACCG, TGACCCTGTC1561, GTCCCCGCTG, GTCGGCCGGC, CTGCCAAGGG, CGGGGTCAAG, GCGGAGAAGA, AGCTCCTTGC1621, TTCCCTGGAG, TGGCTTATGC, CCAATCGGTT, TTCACAGCTC, CAGAGGCTGA, CCCTCATCCA1681, CTGGAAGTCT, CAGGTACACC, CCGTGTTGAA, GGTGAGAGCT, CCAGGCTGTC, CTGCACATCA1741, GCTGTGACAC, TCTGGGACTG, TTCAGTACTC, TAGGAAGTGG, GTCAGGCACC, TTGGGGGCCC1801, AACGCTGCTC, CGTGGGGATG, TCTGCCTGCC, TGCCTGGTTC, TCTTTTCCTG, CTGTTTCCTC1861, CAGCAGGGAG, GTATCAGAGG, CGGGGACACC, CAAGTAGGCC, TGGCATGGGC, AGAAAGGAGG1921, TCACAGCTAA, GGCGGTAGAG, TGGGGTTGGC, ACCAGCCACT, TGTCTGTTTC, CCTTGTGGAT1981, CTTAGCCTGT, CGTCTCCCAA, CCCCAGCTGC, CCCTCTGTCT, CCCCGCAGCT, GGTAGGTGAG2041, TGCTGTCCTC, GGCTCACTTT, CCTCAAGCTC, TCCGGCTGCC, ACGGTGTGAC, TGCTGACGCT2101, CTGGTCATGC, TAGCCAAAGC, CTGCTGCCAG, CTCCATAGCC, TGGACCTACA, GCACTCCATG2161, GTGGAGTCCA, CAGCTGTGGT, GAGCTTCTTG, GAGGAGGCAG, GGTCCCGAAT, GCGCAAGTTG2221, TGGCTGACCT, ACAGCTCCCA, GACGACAGCC, ATCCTGGGCG, CACTGCTGGG, CAGCTGCTGC2281, CCCCAGCTCC, AGGTCCTGGA, GGTGAGCACC, GGCATCAACC, GTAATAGCAT, TCCCCTTCAG2341, CTGCCTGTCG, AGGCTCTGCA, GAAAGGCTGC, CCTCAGCTCC, AGGTGCTGCG, GCTGTTGAAC2401, CTGATGTGGC, TGCCCAAGCC, TCCGGGACGA, GGGGTGGCTC, CCGGACCAGG, CTTCCCTAGC2461, CTAGAGGAGC, TCTGCCTGGC, GAGCTCAACC, TGCAACTTTG, TGAGCAACGA, GGTCCTGGGC2521, CGCCTACTCC, ACGGCTCTCC, CAACCTGCGC, TTACTGGATC, TTCGTGGCTG, TGCGCGCATC2581, ACGCCGGCTG, GCCTTCAGGA, TCTGCCATGT, CGGGAGCTGG, AGCAGCTTCA, TCTGGGCCTG2641, TATGGCACGT, CAGACCGGCT, GACTCTAGCC, AAGGAGGGCA, GCCCCTTTTT, GACCCAGAAG2701, TGGTGCCATA, CACTGCGAGA, ACTGGACTTG, AGTGGCCAGG, GGTTCAGTGA, GAAGGACCTG2761, GAGCAGGCCC, TGGCTGCCTT, CTTAAGCACC, CCTGGGGGCT, CACACCCAGC, CCTGTGCTCT2821, CTTAACCTCA, GGGGCACCCG, GGTCACACCA, AGCACTGTCA, GCTCTGTGAT, CAGCAGCTGC2881, CCGGGCCTGC, TCTACCTCAA, CCTGGAGTCC, TGCCGCTGCC, TTCCCCGGGG, TCTGAAGCGG2941, GCCTACCGGG, GCCTGGAGGA, AGTCCAGTGG, TGTCTGGAGC, AGCTGCTCAC, CAGCCCCTCA3001, CCCAGCTAGG, CAGCCACAGA, CCTGGGACAC, CTCAGCCAGC, TTGCCCACCC, TCCACCTTTG3061, CCCAATTTCA, GATATTTGAG, CATTTTGTTA, AAATAAAACA, TTTTTAGGAA, AAAAAAAAAA3121, AAAAAAAAB: nucleotide sequence, (SEQ, ID, NO:17) length: 300 amino acid

1?MLAKACCGLH?SLDLQHSMVE?STAVVSFLEE?AGSRMRKLWL?TYSSQTTAIL?GALLGSCCPQ

61?LQVLEVSTGI?NRNSIPLQLP?VEALQKGCPQ?LQVLRLLNLM?WLPKPPGRGV?APGPGFPSLE

121?ELCLASSTCN?FVSNEVLGRL?LHGSPNLRLL?DLRGCARITP?AGLQDLPCRE?LEQLHLGLYG

181?TSDRLTLAKE?GSPFLTQKWC?HTLRELDLSG?QGFSEKDLEQ?ALAAFLSTPG?GSHPALCSLN

241 LRGTRVTPST VSSVISSCPG LLYLNLESCR CLPRGLKRAY RGLEEVQWCL EQLLTSPSPS Nucleotide and amino acid sequence of C. Combination (SEQ ID NO: 18) Clone: ​​PP14630 Start codon: 2107 ATG termination codon: 3007 TAG Protein Weight: 32570.05 1 GTT GAC CGC AGC CCA GGA GCC CAT GCC GAA GAG AGC CAC CAG CAG GGC 48 49 CAG ACA CGC TTT GGC TCT CCT GGG AAG TGA AGA CTT CTT CTA GCT TGG 96 97 AAG AAA CAG AGA AAC AGA TAG GAT GCA GAG CCG GAG TCA GAA CAG GGT 144 145 GAG ACC AGG GGA ACT GGG GGA GCC CCG GGC AGG AGC GCA GAT GGG GAG 192 193 GAT TGG CTA AAA CGT ACC CAG CGG GAC CGC CGG GAG GCA GGG AAG CAG 240 241 GAA GCC GGC CCG AGT CGC TGC GGC CCC AGG GGA GGA GGC CGA AGG AGC 288 289 GAG TGG AGC CCT CCT CTC CAG GGA GAG GCG GGG CTG GAG TCA ACG CCA 336 337 CCA CCA CCC CAA GCC GGA CGC CGG GAA AGG GCG CCT ACC AGG AGG AGC 384 385 CAC GCA CAC CCC AGG GCT TCA CGG TGC CCG CGA CCG CAA GAG CCA AGT 432 433 CAG ATC CCA GGG GAG TGG CCG GGA CGG CTC TGC TCG GAG GGG CGC CGC 480 481 CCT CTC GGT ACC GTC AGG TGG GCG ACT CGG GAG CCG TCC GGT CCC TGC 528 529 GCC TCC CGG TCC CGC GCC CAG TGC GCT CCC GCT CCA GTG CCG GCT TCC 576 577 CGC CAC GCC GGG ACA CCG CCG TCC GGC CCA GGG ACG CCA CCT CAG TCC 624 625 GGA GCG CGC AGG ACC CGG CAG CAG CCA CGA CCC GAC TCA CCC GTG GCG 672 673 GTT CCG GGC CCG CCC CCG GCA TGG CCC ACG ACC GGA AGT CCC GCC CCG 720 721 GAA GCT GGT CGG CGG GCG GGC GGG CGT TGA GAG GAA CCG GGG GGT TGT 768 769 CGG TCT ATA AGC CTC GCC CGT TCC GCT CCC TGG GGC TTC CCC GAG CGC 816 817 CGT CGG TGG TCA TGG CTG CCC CAG CCT CCC GGC AGG TCC GAC GCA GAG 864 865 CCC GGG CAG CGC CGC GGG CCC CGC TCG GCC GAG GAC TGG TGG TGG GAC 912 913 CGG CTG GCG CCG AGG GGC TCG GGG TAC CAC CTG CTG CAG TCC GAC AGC 960 961 ATG CTG CTG GTG CTG TCC GAA CCC GGC CCC GCC CGG CCC CGC GCA CAG 1008 1009 CGC GCG CTT CCC GCC GCA CTC CCC GGC AGC CGC CCC GGG GCC CCA GCG 1056 1057 CCG CGG CCA AGC CCA AGG CCG GGC TCA GGT CCG AGG CGG CGG CCG CGC 1104 1105 CCG CAC CCG CAC CGG CAC CCA CGC CCA CGC CCG AGG AAG GGC CCG ACG 1152 1153 CGG GCT GGG GAG ACC GCA TTC CCT TGG AAA TCC TGG TGC AGA TTT TCG 1200 1201 GGT TGT TGG TGG CGG CGG ACG GCC CCA TGC CCT TCC TGG GCA GGT AAC 1248 1249 GCT GGT GCC GGG CCC GCC GCC GAG CGT AGC GGC TTG GGC CAG ACG TGG 1296 1297 TCC GAG CGG TGG CCC GGG CGG GGG CGG AGG GCG AAA GCA TCG GAG CGC 1344 1345 GCA CCG CTC AGT CCG AGA GCG CAG CCC CTT AGG TGC CCA GTT GGA GTC 1392 1393 CCA GGA GCC CGG CTT TGA GCC GGG GTG TCT ACT GCG CTG CGA GAG GGG 1440 1441 GGC ATC GCC TAC GGA GGG GCC GGC ACC CTC AGC ACG CTG TCC TCC CAG 1488 1489 GGC TGC GCG CGT GTG CCG CCG CTG GCA GGA GGC CGC TTC CCA ACC CGC 1536 1537 GCT CTG GCA CAC CGT GAC CCT GTC GTC CCC GCT GGT CGG CCG GCC TGC 1584 1585 CAA GGG CGG GGT CAA GGC GGA GAA GAA GCT CCT TGC TTC CCT GGA GTG 1632 1633 GCT TAT GCC CAA TCG GTT TTC ACA GCT CCA GAG GCT GAC CCT CAT CCA 1680 1681 CTG GAA GTC TCA GGT ACA CCC CGT GTT GAA GGT GAG AGC TCC AGG CTG 1728 1729 TCC TGC ACA TCA GCT GTG ACA CTC TGG GAC TGT TCA GTA CTC TAG GAA 1776 1777 GTG GGT CAG GCA CCT TGG GGG CCC AAC GCT GCT CCG TGG GGA TGT CTG 1824 1825 CCT GCC TGC CTG GTT CTC TTT TCC TGC TGT TTC CTC CAG CAG GGA GGT 1872 1873 ATC AGA GGC GGG GAC ACC CAA GTA GGC CTG GCA TGG GCA GAA AGG AGG 1920 1921 TCA CAG CTA AGG CGG TAG AGT GGG GTT GGC ACC AGC CAC TTG TCT GTT 1968 1969 TCC CTT GTG GAT CTT AGC CTG TCG TCT CCC AAC CCC AGC TGC CCC TCT 2016 2017 GTC TCC CCG CAG CTG GTA GGT GAG TGC TGT CCT CGG CTC ACT TTC CTC 2064 2065 AAG CTC TCC GGC TGC CAC GGT GTG ACT GCT GAC GCT CTG GTC ATG CTA 2112 1 Met Leu 2 2113 GCC AAA GCC TGC TGC CAG CTC CAT AGC CTG GAC CTA CAG CAC TCC ATG 2160 3 Ala Lys Ala Cys Cys Gln Leu His Ser Leu Asp Leu Gln His Ser Met 18 2161 GTG GAG TCC ACA GCT GTG GTG AGC TTC TTG GAG GAG GCA GGG TCC CGA 2208 19 Val Glu Ser Thr Ala Val Val Ser Phe Leu Glu Glu Ala Gly Ser Arg 34 2209 ATG CGC AAG TTG TGG CTG ACC TAC AGC TCC CAG ACG ACA GCC ATC CTG 2256 35 Met Arg Lys Leu Trp Leu Thr Tyr Ser Ser Gln Thr Thr Ala Ile Leu 50 2257 GGC GCA CTG CTG GGC AGC TGC TGC CCC CAG CTC CAG GTC CTG GAG GTG 2304 51 Gly Ala Leu Leu Gly Ser Cys Cys Pro Gln Leu Gln Val Leu Glu Val 66 2305 AGC ACC GGC ATC AAC CGT AAT AGC ATT CCC CTT CAG CTG CCT GTC GAG 2352 67 Ser Thr Gly Ile Asn Arg Asn Ser Ile Pro Leu Gln Leu Pro Val Glu 82 2353 GCT CTG CAG AAA GGC TGC CCT CAG CTC CAG GTG CTG CGG CTG TTG AAC 2400 83 Ala Leu Gln Lys Gly Cys Pro Gln Leu Gln Val Leu Arg Leu Leu Asn 98 2401 CTG ATG TGG CTG CCC AAG CCT CCG GGA CGA GGG GTG GCT CCC GGA CCA 2448 99 Leu Met Trp Leu Pro Lys Pro Pro Gly Arg Gly Val Ala Pro Gly Pro 114 2449 GGC TTC CCT AGC CTA GAG GAG CTC TGC CTG GCG AGC TCA ACC TGC AAC 2496 115 Gly Phe Pro Ser Leu Glu Glu Leu Cys Leu Ala Ser Ser Thr Cys Asn 130 2497 TTT GTG AGC AAC GAG GTC CTG GGC CGC CTA CTC CAC GGC TCT CCC AAC 2544 131 Phe Val Ser Asn Glu Val Leu Gly Arg Leu Leu His Gly Ser Pro Asn 146 2545 CTG CGC TTA CTG GAT CTT CGT GGC TGT GCG CGC ATC ACG CCG GCT GGC 2592 147 Leu Arg Leu Leu Asp Leu Arg Gly Cys Ala Arg Ile Thr Pro Ala Gly 162 2593 CTT CAG GAT CTG CCA TGT CGG GAG CTG GAG CAG CTT CAT CTG GGC CTG 2640 163 Leu Gln Asp Leu Pro Cys Arg Glu Leu Glu Gln Leu His Leu Gly Leu 178 2641 TAT GGC ACG TCA GAC CGG CTG ACT CTA GCC AAG GAG GGC AGC CCC TTT 2688 179 Tyr Gly Thr Ser Asp Arg Leu Thr Leu Ala Lys Glu Gly Ser Pro Phe 194 2689 TTG ACC CAG AAG TGG TGC CAT ACA CTG CGA GAA CTG GAC TTG AGT GGC 2736 195 Leu Thr Gln Lys Trp Cys His Thr Leu Arg Glu Leu Asp Leu Ser Gly 210 2737 CAG GGG TTC AGT GAG AAG GAC CTG GAG CAG GCC CTG GCT GCC TTC TTA 2784 211 Gln Gly Phe Ser Glu Lys Asp Leu Glu Gln Ala Leu Ala Ala Phe Leu 226 2785 AGC ACC CCT GGG GGC TCA CAC CCA GCC CTG TGC TCT CTT AAC CTC AGG 2832 227 Ser Thr Pro Gly Gly Ser His Pro Ala Leu Cys Ser Leu Asn Leu Arg 242 2833 GGC ACC CGG GTC ACA CCA AGC ACT GTC AGC TCT GTG ATC AGC AGC TGC 2880 243 Gly Thr Arg Val Thr Pro Ser Thr Val Ser Ser Val Ile Ser Ser Cys 258 2881 CCG GGC CTG CTC TAC CTC AAC CTG GAG TCC TGC CGC TGC CTT CCC CGG 2928 259 Pro Gly Leu Leu Tyr Leu Asn Leu Glu Ser Cys Arg Cys Leu Pro Arg 274 2929 GGT CTG AAG CGG GCC TAC CGG GGC CTG GAG GAA GTC CAG TGG TGT CTG 2976 275 Gly Leu Lys Arg Ala Tyr Arg Gly Leu Glu Glu Val Gln Trp Cys Leu 290 2977 GAG CAG CTG CTC ACC AGC CCC TCA CCC AGC TAG GCA GCC ACA GAC CTG 3024 291 Glu Gln Leu Leu Thr Ser Pro Ser Pro Ser *** 301 3025 GGA CAC CTC AGC CAG CTT GCC CAC CCT CCA CCT TTG CCC AAT TTC AGA 3072 3073 TAT TTG AGC ATT TTG TTA AAA TAA AAC ATT TTT AGG AAA AAA AAA AAA 3120 3121 AAA AAA AA 3128 7.FP248 A: the nucleotide sequence (SEQ ID NO: 19) Length: 2978 nucleotides ...

1?GGCTTACTGC?GGAACAGCAG?GTTGGTGTCC?ACAGCATTCA?GCATCTGGAA?CACGGCCTGG

61?GGGTGGTAGC?AGATGGTGTG?GCCTGTGTAA?CAGACGGGCA?GCTGGTGGCT?CAGGGCTCCC

121?TGTCTCCTGG?GGGGCTGTAG?CCCACCCCTG?CCCCTCTTCA?GCCCCAAGCT?CCTCCTCATC

181?CACCCCCTTT?CCTCTCTTGT?GGGTGGTGAG?TCAGGGAGGG?TCAAGGGTGC?TTGGGTGGGG

241?GCAGGCCTGG?GGGTCTTTAA?GCCCGGCCTC?GCCCTCCCAC?CTATGAAGAG?TGTCACCCAG

301?GTCTTGATGT?GGCAGGAGTG?GCTGTGCAGG?TAGCTGAGGG?CCTGTGACAA?GTGGATGCTG

361?AATTCCTCCT?GGCTGCGGGT?CATCTGGCCG?GAGGAGAGCA?CACCTGGCTG?GGACGGGCTG

421?GGGGCCCTGG?GCATACCAGG?GTCCTCCAGC?CCCAGTTTGC?CTTGCCCAGC?CCCTGGAGCT

481?GCTATAGCAG?CTGTGTGTGA?GACGGGAGTG?AATGGGGGAG?CCGCAAGCCT?GGTCTCCCCC

541?ACTCCCTGGC?CCTGTTCCTC?CCCACCGATC?CCAGGCCTCT?CACCAGGCAG?GTCCAGAGGA

601?AGTGGCGGGC?GCTGAGGCCC?CTCTCCCAGG?CCAGCGTGCA?GAAGAGGGTG?TGCAGTAGCC

661?GCCAGCGGAG?CAGCACAGCA?CAGCGGTAGA?AGGTGAACTT?GGCCTGCTGC?AGGGACAGGC

721?GTGGAGGGTC?ACCCACCGCC?TATGTCTGAG?CCCTTTCCCC?TAGAGGCCAC?AGGCCTCCAT

781?GGGCACTGGA?GGCAGCCTGC?TGTGCGGGTG?TTCCCTGGTT?CTGTCCTGCT?TGTGCCCCTC

841?GGCAAGCCTC?CCCGACCCTG?GCAACAGCAC?CTGGCCCCCC?GGAGCCCAGG?CTGGTCTGCC

901?CGCGGCCCTG?GCCCTGCCCC?TTCCACGGTT?GCCCCGTATC?CTTTTCCCCA?TGGCAGGGAG

961?ACCCGCGAGG?CCAAGCTCTG?ACTTCGTGGG?CTGTGCACAG?GGCATGTGCT?GCCACGGCAG

1021?GCAGGGCACA?GTCCATATTC?ACACAAGCTC?TGTGAGCTGC?TGGACCCCCT?GCCCCGTTAC

1081?AGGGACTGGG?GGCACAGCAG?TGAGCAGAAA?AGACCGGGTC?CTGCCGCATC?GACGGCAAGT

1141?CTCGCTCGCA?TGCGTGTGCG?CAGTGGGGGA?GCGGGCAGGC?CAACTGTGGT?CACAGAAACC

1201?AGTGCAGATG?GCCAGACCCT?CTGCCCGCCA?CTTGCTGCCC?CGTGGGAGCT?CCCCCAACTC

1261?TCAGGCAGTG?CTGCTGCCAT?CCGTCTGCCC?CGTACCCTGG?CCTCCTGTGG?GTCCCAGCCC

1321?TGGCCAAGGT?GAAGGCCTAT?CACCTGCCTT?TCCTGGGGTG?GGCACTGACC?GTGGCGACAG

1381?CTGGGCATTG?GTCCTTCAGG?TGTAGGAGCA?GGGGCACCAT?GCTCTGGTGC?ACCTGGGTCC

1441?GCAGCCGCTC?AGCTCCCTGT?CTGCCATGGC?CGCCACCAGG?TCCCCGAACA?GTGCCATGGC

1501?TGCCGCCCGA?ATCCCGTCCG?CTCCTGCAAG?GCAGAGGCTC?AGAGGCACGG?CCAGACCTGT

1561?CCAGGGGTCC?CAGCTTTGGT?CCAAGTTGGG?ACCCCACACC?TTGTAGGGGT?ACAACTCAGT

1621?TCTTTCTGCA?GGATTCCTTC?ACCCAGGCTC?TCGGCTCCCG?GGGAAGGGAA?GGGCTGGGGC

1681?TCCCCCCTCA?CACAGGGCTC?TCTGGTGTCC?CTGAGGATGT?AAGAATCACA?TCTCCCTTCT

1741?ACCCACAACT?GCATCCTGGC?AGCCCAGGCC?TCATGAATGC?ATTTGAGGGG?CGCCTATCCC

1801?CCAGATTCCC?CAGTGAAGGA?AAAACAGCCA?CGCTAACCGT?GCTGACATGT?CAGAAAGCAA

1861?ATCTGGGTAG?GCTGTCGTGG?GGCCGGAGAC?CACTGCACTT?GGAGACTGAA?CGTGAGAACT

1921?AGTTCAGCCC?TGTGGAGAAG?GGGTGAGCGC?CAGGGGCCCA?CCCAGCCCAC?CTGCTCAGTG

1981?CCCACCTCAA?CCGAGGGCCA?CAAGCGGGCA?GCTCCCCAGG?GCCTGGGCCT?CCCTGCTTGC

2041?AGCTTGGGGT?TCCCCCTTTG?GCAGAGGAAG?GGAGCTGGGT?TGGGAGGAGG?GTCCTGGAGG

2101?GCGTGAGCAG?GAGGTAGCCC?CGCCCTGCCC?CAGTGCTCAC?GTCATTAAAG?AAGGAGCGTG

2161?TGCTGATGGC?AACGCCGAGG?CTCTGACTCC?CTGTGCCCTG?CGCGCCCAGG?CGGTGCAGCG

2221?TGTCTGACAC?GGTGCCCATG?ATGCACACGA?TCACCTGGTC?GCTGCTCTGG?AAGAAGCCGT

2281?CGAGCAAGGG?CTGCAGCTGT?CCCTGGAGCA?GGCTTCCCTG?GGGGTGGTGG?CGGCTGGTGG

2341?GCGGAGAGCA?CTAGGACCCG?CTGGCCCCAT?GCCCCCGCCT?CGTTCTCCCA?CTTGACCCCC

2401?TCACCCCATC?TGCACTGGGT?GGGGGGGTGG?GGGGTGGTGA?TTCAGAGCTG?TGGGTCCCGG

2461?CCTGGCCCTT?CCCGCCATGG?GGAGCTGTGG?GTCCCGGCCT?GGCCCTGCCC?ACCGTGGGGA

2521?GCTGTGCCCC?TAACTGGGCT?TTGTCCACCA?GGAGCTGCGT?GGTCTGGACA?GGGTGGCCTC

2581?TTTTCTTTTT?TGAGACAGGG?TCTCACACTG?TCACCCAGGC?TGGAGTACAG?TGGTGTGACC

2641?ATAGCTTACT?GCAGCCTTGA?CCTCCCAGGC?TCAAGCAATC?CTCCCAACAT?AACCTCCTGA

2701?GTAGCTGGGT?CTACAGCCAG?TTCCGTCTTC?TCCACTTGAT?TGCGTGTTTG?CAGTGAGTTC

2761 CTGAGTTATC GGGATGAATG GTCAGAAAGC AGTGTGCCCA CCAATGGATG TTTCCTGCCA 2821 TTGGGCCCCT TAGCAGTGAC TTGGGTGCAA ACCAGGGTGA TTTTTACAAC TTTTAAACAA 2881 GTTTAAAGCA ACTTTGTTGG CTTTCTTAGC TGTTTGCTTT GAAAATATTA AATTCATTTT 2941 CAGCAAGTGA GTCATTCAAC AAAAAAAAAA AAAAAAAAB: nucleotide sequence (SEQ ID NO:20) length: 208 amino acid

1?MGTGGSLLCG?CSLVLSCLCP?SASLPDPGNS?TWPPGAQAGL?PAALALPLPR?LPRILFPMAG

61 RPARPSSDFV GCAQGMCCHG RQGTVHIHTS SVSCWTPCPV TGTGGTAVSR KDRVLPHRRQ 121 VSLACVCAVG ERAGQLWSQK PVQMARPSAR HLLPRGSSPN SQAVLLPSVC PVPWPPVGPS 181 PGQGEGLSPA FPGVGTDRGD SWALVLQV Nucleotide and amino acid sequence of C. Combination (SEQ ID NO: 21) Clone: ​​FP248 Start codon: 779 ATG termination codon: 1403 TAG Protein Weight: 21374.62 1 G GCT TAC TGC GGA ACA GCA GGT TGG TGT CCA CAG CAT TCA GCA TCT 46 47 GGA ACA CGG CCT GGG GGT GGT AGC AGA TGG TGT GGC CTG TGT AAC AGA 94 95 CGG GCA GCT GGT GGC TCA GGG CTC CCT GTC TCC TGG GGG GCT GTA GCC 142 143 CAC CCC TGC CCC TCT TCA GCC CCA AGC TCC TCC TCA TCC ACC CCC TTT 190 191 CCT CTC TTG TGG GTG GTG AGT CAG GGA GGG TCA AGG GTG CTT GGG TGG 238 239 GGG CAG GCC TGG GGG TCT TTA AGC CCG GCC TCG CCC TCC CAC CTA TGA 286 287 AGA GTG TCA CCC AGG TCT TGA TGT GGC AGG AGT GGC TGT GCA GGT AGC 334 335 TGA GGG CCT GTG ACA AGT GGA TGC TGA ATT CCT CCT GGC TGC GGG TCA 382 383 TCT GGC CGG AGG AGA GCA CAC CTG GCT GGG ACG GGC TGG GGG CCC TGG 430 431 GCA TAC CAG GGT CCT CCA GCC CCA GTT TGC CTT GCC CAG CCC CTG GAG 478 479 CTG CTA TAG CAG CTG TGT GTG AGA CGG GAG TGA ATG GGG GAG CCG CAA 526 527 GCC TGG TCT CCC CCA CTC CCT GGC CCT GTT CCT CCC CAC CGA TCC CAG 574 575 GCC TCT CAC CAG GCA GGT CCA GAG GAA GTG GCG GGC GCT GAG GCC CCT 622 623 CTC CCA GGC CAG CGT GCA GAA GAG GGT GTG CAG TAG CCG CCA GCG GAG 670 671 CAG CAC AGC ACA GCG GTA GAA GGT GAA CTT GGC CTG CTG CAG GGA CAG 718 719 GCG TGG AGG GTC ACC CAC CGC CTA TGT CTG AGC CCT TTC CCC TAG AGG 766 767 CCA CAG GCC TCC ATG GGC ACT GGA GGC AGC CTG CTG TGC GGG TGT TCC 814 1 Met Gly Thr Gly Gly Ser Leu Leu Cys Gly Cys Ser 12 815 CTG GTT CTG TCC TGC TTG TGC CCC TCG GCA AGC CTC CCC GAC CCT GGC 862 13 Leu Val Leu Ser Cys Leu Cys Pro Ser Ala Ser Leu Pro Asp Pro Gly 28 863 AAC AGC ACC TGG CCC CCC GGA GCC CAG GCT GGT CTG CCC GCG GCC CTG 910 29 Asn Ser Thr Trp Pro Pro Gly Ala Gln Ala Gly Leu Pro Ala Ala Leu 44 911 GCC CTG CCC CTT CCA CGG TTG CCC CGT ATC CTT TTC CCC ATG GCA GGG 958 45 Ala Leu Pro Leu Pro Arg Leu Pro Arg Ile Leu Phe Pro Met Ala Gly 60 959 AGA CCC GCG AGG CCA AGC TCT GAC TTC GTG GGC TGT GCA CAG GGC ATG 1006 61 Arg Pro Ala Arg Pro Ser Ser Asp Phe Val Gly Cys Ala Gln Gly Met 76 1007 TGC TGC CAC GGC AGG CAG GGC ACA GTC CAT ATT CAC ACA AGC TCT GTG 1054 77 Cys Cys His Gly Arg Gln Gly Thr Val His Ile His Thr Ser Ser Val 92 1055 AGC TGC TGG ACC CCC TGC CCC GTT ACA GGG ACT GGG GGC ACA GCA GTG 1102 93 Ser Cys Trp Thr Pro Cys Pro Val Thr Gly Thr Gly Gly Thr Ala Val 108 1103 AGC AGA AAA GAC CGG GTC CTG CCG CAT CGA CGG CAA GTC TCG CTC GCA 1150 109 Ser Arg Lys Asp Arg Val Leu Pro His Arg Arg Gln Val Ser Leu Ala 124 1151 TGC GTG TGC GCA GTG GGG GAG CGG GCA GGC CAA CTG TGG TCA CAG AAA 1198 125 Cys Val Cys Ala Val Gly Glu Arg Ala Gly Gln Leu Trp Ser Gln Lys 140 1199 CCA GTG CAG ATG GCC AGA CCC TCT GCC CGC CAC TTG CTG CCC CGT GGG 1246 141 Pro Val Gln Met Ala Arg Pro Ser Ala Arg His Leu Leu Pro Arg Gly 156 1247 AGC TCC CCC AAC TCT CAG GCA GTG CTG CTG CCA TCC GTC TGC CCC GTA 1294 157 Ser Ser Pro Asn Ser Gln Ala Val Leu Leu Pro Ser Val Cys Pro Val 172 1295 CCC TGG CCT CCT GTG GGT CCC AGC CCT GGC CAA GGT GAA GGC CTA TCA 1342 173 Pro Trp Pro Pro Val Gly Pro Ser Pro Gly Gln Gly Glu Gly Leu Ser 188 1343 CCT GCC TTT CCT GGG GTG GGC ACT GAC CGT GGC GAC AGC TGG GCA TTG 1390 189 Pro Ala Phe Pro Gly Val Gly Thr Asp Arg Gly Asp Ser Trp Ala Leu 204 1391 GTC CTT CAG GTG TAG GAG CAG GGG CAC CAT GCT CTG GTG CAC CTG GGT 1438 205 Val Leu Gln Val *** 209 1439 CCG CAG CCG CTC AGC TCC CTG TCT GCC ATG GCC GCC ACC AGG TCC CCG 1486 1487 AAC AGT GCC ATG GCT GCC GCC CGA ATC CCG TCC GCT CCT GCA AGG CAG 1534 1535 AGG CTC AGA GGC ACG GCC AGA CCT GTC CAG GGG TCC CAG CTT TGG TCC 1582 1583 AAG TTG GGA CCC CAC ACC TTG TAG GGG TAC AAC TCA GTT CTT TCT GCA 1630 1631 GGA TTC CTT CAC CCA GGC TCT CGG CTC CCG GGG AAG GGA AGG GCT GGG 1678 1679 GCT CCC CCC TCA CAC AGG GCT CTC TGG TGT CCC TGA GGA TGT AAG AAT 1726 1727 CAC ATC TCC CTT CTA CCC ACA ACT GCA TCC TGG CAG CCC AGG CCT CAT 1774 1775 GAA TGC ATT TGA GGG GCG CCT ATC CCC CAG ATT CCC CAG TGA AGG AAA 1822 1823 AAC AGC CAC GCT AAC CGT GCT GAC ATG TCA GAA AGC AAA TCT GGG TAG 1870 1871 GCT GTC GTG GGG CCG GAG ACC ACT GCA CTT GGA GAC TGA ACG TGA GAA 1918 1919 CTA GTT CAG CCC TGT GGA GAA GGG GTG AGC GCC AGG GGC CCA CCC AGC 1966 1967 CCA CCT GCT CAG TGC CCA CCT CAA CCG AGG GCC ACA AGC GGG CAG CTC 2014 2015 CCC AGG GCC TGG GCC TCC CTG CTT GCA GCT TGG GGT TCC CCC TTT GGC 2062 2063 AGA GGA AGG GAG CTG GGT TGG GAG GAG GGT CCT GGA GGG CGT GAG CAG 2110 2111 GAG GTA GCC CCG CCC TGC CCC AGT GCT CAC GTC ATT AAA GAA GGA GCG 2158 2159 TGT GCT GAT GGC AAC GCC GAG GCT CTG ACT CCC TGT GCC CTG CGC GCC 2206 2207 CAG GCG GTG CAG CGT GTC TGA CAC GGT GCC CAT GAT GCA CAC GAT CAC 2254 2255 CTG GTC GCT GCT CTG GAA GAA GCC GTC GAG CAA GGG CTG CAG CTG TCC 2302 2303 CTG GAG CAG GCT TCC CTG GGG GTG GTG GCG GCT GGT GGG CGG AGA GCA 2350 2351 CTA GGA CCC GCT GGC CCC ATG CCC CCG CCT CGT TCT CCC ACT TGA CCC 2398 2399 CCT CAC CCC ATC TGC ACT GGG TGG GGG GGT GGG GGG TGG TGA TTC AGA 2446 2447 GCT GTG GGT CCC GGC CTG GCC CTT CCC GCC ATG GGG AGC TGT GGG TCC 2494 2495 CGG CCT GGC CCT GCC CAC CGT GGG GAG CTG TGC CCC TAA CTG GGC TTT 2542 2543 GTC CAC CAG GAG CTG CGT GGT CTG GAC AGG GTG GCC TCT TTT CTT TTT 2590 2591 TGA GAC AGG GTC TCA CAC TGT CAC CCA GGC TGG AGT ACA GTG GTG TGA 2638 2639 CCA TAG CTT ACT GCA GCC TTG ACC TCC CAG GCT CAA GCA ATC CTC CCA 2686 2687 ACA TAA CCT CCT GAG TAG CTG GGT CTA CAG CCA GTT CCG TCT TCT CCA 2734 2735 CTT GAT TGC GTG TTT GCA GTG AGT TCC TGA GTT ATC GGG ATG AAT GGT 2782 2783 CAG AAA GCA GTG TGC CCA CCA ATG GAT GTT TCC TGC CAT TGG GCC CCT 2830 2831 TAG CAG TGA CTT GGG TGC AAA CCA GGG TGA TTT TTA CAA CTT TTA AAC 2878 2879 AAG TTT AAA GCA ACT TTG TTG GCT TTC TTA GCT GTT TGC TTT GAA AAT 2926 2927 ATT AAA TTC ATT TTC AGC AAG TGA GTC ATT CAA CAA AAA AAA AAA AAA 2974 2975 AAA A 2978 8.FP291 A: the nucleotide sequence (SEQ ID NO: 22) Length: 2350 nucleotides ...

1?GCTTTGCCCT?GCAAGTGGAG?TGGGCTCTGT?TCTGGTCTTA?GGAGGTCTGA?AAGCAATACC

61?AGCCCCTGCG?CGTCTCACGC?AGGCCCCAGC?GTTAATTAAC?CAGCAGTCGC?TCCTGACAGC???121?CAAGCCCCTG?TATCATCTCC?CAGGTCCAGG?ACCCTGTGGG?AGAAAGGGTC?CGGCAAGTCA???181?CAGACCCAGC?CAGCGCAAAG?GGCGATCGAG?GAGAACCTTC?CAGGAACCGT?CCCAGATCCT???241?AAACGTGAGG?GTCTGCTGAG?ATGCCCATCA?TGGTAGATGA?CATCATGAGG?CTTCTGTGCT

301?CCATTTCCCA?GGAGAGGAAG?ATGAAGGCGG?CCGTCAAGCA?CTCTGGAAAG?GGTGCCATGG

361?TTGCGGGGGC?AATGGCCTTC?GTCGGTGGCT?TGGTTGGTGG?CCCACCAGGA?ATAGCTGTTG

421?GGGGGACTGT?TGGGGGCCTG?TTAGGTGCCT?GGATGACGAG?TGGACAGTTC?AAGCCCGTTC

481?CTCAGATCTT?AATGGAGCTG?CCCCCCGCTG?AACAGCGGAA?ACTTGTTAAC?GAAGCCATGG

541?CCATCATCGG?GAACTTGGAC?TGGACAGACG?CTGTGCAGCT?GACTGCTCTG?GTCATGAGCA

601?ACCAGGCCAT?GCAGCAGAGG?CTCTTGGCCA?TGCTAACGAC?CTATGTCACC?AAAGAGCTGC

661?AGGCTGAGAT?CCGCTATGAG?GACTAGGCCC?CACCCCCTGG?GGAGTGGGGC?TCTCATTTTA

721?GATGATTCTA?TGGCTCATTG?AAGGTGACCA?GGGAATGGGG?GAAGCCTGAC?TTCTGGGAAA

781?CTTGTCTATT?ACCAGCATTG?ATTGTAAGCC?GCCATGCTAG?TGCATTGTTG?GACTGTCTTG

841?CTGGAGAGGC?ATCAGCCATG?CCTCTTGGGC?TGTGTGTGCC?ATGGAAAGGT?ACAGGCGTGC

901?CTGCTGTGGG?CATTCACGGA?CAGCTTGGAG?TCCTCCCGAT?GACCATGTGG?GTCTAAAAGG

961?TTCTCATATT?GTTGGCTGGC?CGACCATAGC?AGATGCTTCT?TTTTCTATGA?AGTGTACCTC

1021?CAGGTACCTG?TCACAGGATC?GAATCCCCTT?AGGCTCTGGG?GTCTTGGGGT?TCAGAGCCAG

1081?CTCTTGTCAG?GATTGTGCTA?ACCTGCTGAG?TGTTTCCTTC?CCTTGGCTAA?GGACTTCCCA

1141?GTGGTCTCAT?GGTGACAACT?GTCCCTCCTT?TGAGTGAAGC?CACAGATGCC?AGGCAGGCTC

1201?TATGCTCTGC?TACAGGCTAT?GCCCTAGACG?CTCTTGAGTA?ACTTTAGTTT?AGCTTGTAGG

1261?AGCTTCTTCT?GCCTCCTTAA?GAAAAATCAT?GGCACTTCAT?TATTTTTTAT?TTTCCATGTC

1321?GATTCTGGAT?TCTTTTTGTT?CTCTACACTT?TCGGAGCCTA?AATTCATTTA?GCTCTGTTTT

1381?CTTTTTCTTC?TTACTATGTT?TCCTTGGGCT?AGCCTTGAAG?TCCTGGGCTC?AAGCTACATA

1441?GCTGGGACTG?TAGGCTTGTG?CCACCATACC?TAGCTTTACC?TCAAAGACTG?TTGTCCACTC

1501?TACTTTTCCT?AAGCCCTCCC?GTGCTCTCCT?GTCTGCTGGC?TGCAATCTAT?AATTCATTTG

1561?TGTGAAAAGA?CAAAATTACC?AATGACTTGA?GTTCAGAGAT?CCTAACATAG?CTAGGTGCTG

1621?TGGTGCAGAA?CCATACCCAC?GGTCCCAGAT?AATTGAAAAG?CCGAAGGGGG?AACATCCTTG

1681?GGCCCAGGAA?TCCAAGGACA?ACCGGACATT?GTGGAAGCCA?GGAGATAGGT?GGGGACACAC

1741?ACATCTTCTT?AGTTGGCTTT?TATTGCAGTC?ACAGAATCAA?GAGGCAGCAA?GTGCCCTGGT

1801?GAGACGGAGA?GAGAGGGTGG?ACAAGGGTGA?GCAAGGGAAA?GTGGAAACAG?CAAGAAAACT

1861?AGATTAACCT?CCCGTGACAC?TGGCTGTTTA?TGGATTGGGC?TAGCTTCGCC?TCCATTTCCC

1921?TAAGTGACAG?AGGCTCAAAT?CTGACATTGG?CTTGTTTGTT?TTCCTTGTGT?TGTGGATGGA

1981?AGCTAGGGCC?TTGCATAGGC?TAAGTGCCAC?CCCTGAGCGC?TGCTCCTAGT?CCTCCTCTCT

2041?GCTGATTCCC?GCCCAGCCTG?GTCCCAGCCC?TTGAGTGACT?CAGCTTTGGT?CTGGTCGGTC

2101?GGTCCCAGTG?CTGGAGCTCA?ACATCTAACA?TTGTATCCAT?TTGATTAAGT?ATTTGATAAT

2161?TCCTCCTTAT?CCCTCCTTGG?AGGTGCTCAC?TCACGGAGGG?CAGGAGCTAT?GTGTCTCGGT

2221?CACTTCTCCT?GCCTCCAGCT?TGCTCCTGCC?TGGCACCATG?GCTTTTGTGG?GGTAGACACT

2281?CAATAAATAT?ATATTTTTAA?AGCTAAAAAA?AAAAAAAAAA?AAAAAAAAAA?AAAAAAAAAA

2341 AAAAAAAAAAB: nucleotide sequence (SEQ ID NO:23) length: 141 amino acid

1?MPIMVDDIMR?LLCSISQERK?MKAAVKHSGK?GAMVAGAMAF?VGGLVGGPPG?IAVGGTVGGL

61?LGAWMTSGQF?KPVPQILMEL?PPAEQRKLVN?EAMAIIGNLD?WTDAVQLTAL?VMSNQAMQQR

121, LLAMLTTYVT, KELQAEIRYE, DC. nucleotides and amino acid composite sequence, (SEQ, ID, NO:24), initial coding of clone number: FP291: 261, ATG, stop coding: 684, TAG, protein molecular weight:, 15086.09, 1, GC, TTT, GCC, CTG, CAA, GTG, GAG, TGG, GCT, CTG, TTC, TGG, TCT, TAG, GAG, GTC, 47, 48, TGA, AAG, CAA, TAC, CAG, CCC, CTG, CGC, GTC, TCA, CGC, AGG, CCC, CAG, CGT, TAA, 95, 96, TTA, ACC, AGC, AGT, CGC, TCC, TGA, CAG, CCA, AGC, CCC, TGT, ATC, ATC, TCC, CAG, 143, 144, GTC, CAG, GAC, CCT, GTG, GGA, GAA, AGG, GTC, CGG, CAA, GTC, ACA, GAC, CCA, GCC, 191, 192, AGC, GCA, AAG, GGC, GAT, CGA, GGA, GAA, CCT, TCC, AGG, AAC, CGT, CCC, AGA, TCC, 239, 240, TAA, ACG, TGA, GGG, TCT, GCT, GAG, ATG, CCC, ATC, ATG, GTA, GAT, GAC, ATC, ATG, 287, 1, Met, Pro, Ile, Met, Val, Asp, Asp, Ile, Met, 9, 288, AGG, CTT, CTG, TGC, TCC, ATT, TCC, CAG, GAG, AGG, AAG, ATG, AAG, GCG, GCC, GTC, 335, 10, Arg, Leu, Leu, Cys, Ser, Ile, Ser, Gln, Glu, Arg, Lys, Met, Lys, Ala, Ala, Val, 25, 336, AAG, CAC, TCT, GGA, AAG, GGT, GCC, ATG, GTT, GCG, GGG, GCA, ATG, GCC, TTC, GTC, 383, 26, Lys, His, Ser, Gly, Lys, Gly, Ala, Met, Val, Ala, Gly, Ala, Met, Ala, Phe, Val, 41, 384, GGT, GGC, TTG, GTT, GGT, GGC, CCA, CCA, GGA, ATA, GCT, GTT, GGG, GGG, ACT, GTT, 431, 42, Gly, Gly, Leu, Val, Gly, Gly, Pro, Pro, Gly, Ile, Ala, Val, Gly, Gly, Thr, Val, 57, 432, GGG, GGC, CTG, TTA, GGT, GCC, TGG, ATG, ACG, AGT, GGA, CAG, TTC, AAG, CCC, GTT, 479, 58, Gly, Gly, Leu, Leu, Gly, Ala, Trp, Met, Thr, Ser, Gly, Gln, Phe, Lys, Pro, Val, 73, 480, CCT, CAG, ATC, TTA, ATG, GAG, CTG, CCC, CCC, GCT, GAA, CAG, CGG, AAA, CTT, GTT, 527, 74, Pro, Gln, Ile, Leu, Met, Glu, Leu, Pro, Pro, Ala, Glu, Gln, Arg, Lys, Leu, Val, 89, 528, AAC, GAA, GCC, ATG, GCC, ATC, ATC, GGG, AAC, TTG, GAC, TGG, ACA, GAC, GCT, GTG, 575, 90, Asn, Glu, Ala, Met, Ala, Ile, Ile, Gly, Asn, Leu, Asp, Trp, Thr, Asp, Ala, Val, 105, 576, CAG, CTG, ACT, GCT, CTG, GTC, ATG, AGC, AAC, CAG, GCC, ATG, CAG, CAG, AGG, CTC, 623, 106, Gln, Leu, Thr, Ala, Leu, Val, Met, Ser, Asn, Gln, Ala, Met, Gln, Gln, Arg, Leu, 121, 624, TTG, GCC, ATG, CTA, ACG, ACC, TAT, GTC, ACC, AAA, GAG, CTG, CAG, GCT, GAG, ATC, 671, 122, Leu, Ala, Met, Leu, Thr, Thr, Tyr, Val, Thr, Lys, Glu, Leu, Gln, Ala, Glu, Ile, 137, 672, CGC, TAT, GAG, GAC, TAG, GCC, CCA, CCC, CCT, GGG, GAG, TGG, GGC, TCT, CAT, TTT, 719, 138, Arg, Tyr, Glu, Asp, * *, 142, 720, AGA, TGA, TTC, TAT, GGC, TCA, TTG, AAG, GTG, ACC, AGG, GAA, TGG, GGG, AAG, CCT, 767, 768, GAC, TTC, TGG, GAA, ACT, TGT, CTA, TTA, CCA, GCA, TTG, ATT, GTA, AGC, CGC, CAT, 815, 816, GCT, AGT, GCA, TTG, TTG, GAC, TGT, CTT, GCT, GGA, GAG, GCA, TCA, GCC, ATG, CCT, 863, 864, CTT, GGG, CTG, TGT, GTG, CCA, TGG, AAA, GGT, ACA, GGC, GTG, CCT, GCT, GTG, GGC, 911, 912, ATT, CAC, GGA, CAG, CTT, GGA, GTC, CTC, CCG, ATG, ACC, ATG, TGG, GTC, TAA, AAG, 959, 960, GTT, CTC, ATA, TTG, TTG, GCT, GGC, CGA, CCA, TAG, CAG, ATG, CTT, CTT, TTT, CTA, 10071008, TGA, AGT, GTA, CCT, CCA, GGT, ACC, TGT, CAC, AGG, ATC, GAA, TCC, CCT, TAG, GCT, 10551056, CTG, GGG, TCT, TGG, GGT, TCA, GAG, CCA, GCT, CTT, GTC, AGG, ATT, GTG, CTA, ACC, 11031104, TGC, TGA, GTG, TTT, CCT, TCC, CTT, GGC, TAA, GGA, CTT, CCC, AGT, GGT, CTC, ATG, 11511152, GTG, ACA, ACT, GTC, CCT, CCT, TTG, AGT, GAA, GCC, ACA, GAT, GCC, AGG, CAG, GCT, 11991200, CTA, TGC, TCT, GCT, ACA, GGC, TAT, GCC, CTA, GAC, GCT, CTT, GAG, TAA, CTT, TAG, 12471248, TTT, AGC, TTG, TAG, GAG, CTT, CTT, CTG, CCT, CCT, TAA, GAA, AAA, TCA, TGG, CAC, 12951296, TTC, ATT, ATT, TTT, TAT, TTT, CCA, TGT, CGA, TTC, TGG, ATT, CTT, TTT, GTT, CTC, 13431344, TAC, ACT, TTC, GGA, GCC, TAA, ATT, CAT, TTA, GCT, CTG, TTT, TCT, TTT, TCT, TCT, 13911392, TAC, TAT, GTT, TCC, TTG, GGC, TAG, CCT, TGA, AGT, CCT, GGG, CTC, AAG, CTA, CAT, 14391440, AGC, TGG, GAC, TGT, AGG, CTT, GTG, CCA, CCA, TAC, CTA, GCT, TTA, CCT, CAA, AGA, 14871488, CTG, TTG, TCC, ACT, CTA, CTT, TTC, CTA, AGC, CCT, CCC, GTG, CTC, TCC, TGT, CTG, 15351536, CTG, GCT, GCA, ATC, TAT, AAT, TCA, TTT, GTG, TGA, AAA, GAC, AAA, ATT, ACC, AAT, 15831584, GAC, TTG, AGT, TCA, GAG, ATC, CTA, ACA, TAG, CTA, GGT, GCT, GTG, GTG, CAG, AAC, 16311632, CAT, ACC, CAC, GGT, CCC, AGA, TAA, TTG, AAA, AGC, CGA, AGG, GGG, AAC, ATC, CTT, 16791680, GGG, CCC, AGG, AAT, CCA, AGG, ACA, ACC, GGA, CAT, TGT, GGA, AGC, CAG, GAG, ATA, 17271728, GGT, GGG, GAC, ACA, CAC, ATC, TTC, TTA, GTT, GGC, TTT, TAT, TGC, AGT, CAC, AGA, 17751776, ATC, AAG, AGG, CAG, CAA, GTG, CCC, TGG, TGA, GAC, GGA, GAG, AGA, GGG, TGG, ACA, 18231824, AGG, GTG, AGC, AAG, GGA, AAG, TGG, AAA, CAG, CAA, GAA, AAC, TAG, ATT, AAC, CTC, 18711872, CCG, TGA, CAC, TGG, CTG, TTT, ATG, GAT, TGG, GCT, AGC, TTC, GCC, TCC, ATT, TCC, 19191920, CTA, AGT, GAC, AGA, GGC, TCA, AAT, CTG, ACA, TTG, GCT, TGT, TTG, TTT, TCC, TTG, 19671968, TGT, TGT, GGA, TGG, AAG, CTA, GGG, CCT, TGC, ATA, GGC, TAA, GTG, CCA, CCC, CTG, 20152016, AGC, GCT, GCT, CCT, AGT, CCT, CCT, CTC, TGC, TGA, TTC, CCG, CCC, AGC, CTG, GTC, 20632064, CCA, GCC, CTT, GAG, TGA, CTC, AGC, TTT, GGT, CTG, GTC, GGT, CGG, TCC, CAG, TGC, 21112112, TGG, AGC, TCA, ACA, TCT, AAC, ATT, GTA, TCC, ATT, TGA, TTA, AGT, ATT, TGA, TAA, 2159, 2160, TTC, CTC, CTT, ATC, CCT, CCT, TGG, AGG, TGC, TCA, CTC, ACG, GAG, GGC, AGG, AGC, 2207, 2208, TAT, GTG, TCT, CGG, TCA, CTT, CTC, CTG, CCT, CCA, GCT, TGC, TCC, TGC, CTG, GCA, 2255, 2256, CCA, TGG, CTT, TTG, TGG, GGT, AGA, CAC, TCA, ATA, AAT, ATA, TAT, TTT, TAA, AGC, 2303, 2304, TAA, AAA, AAA, AAA, AAA, AAA, AAA, AAA, AAA, AAA, AAA, AAA, AAA, AAA, AAA, AA, 2350, 9.FP633A: nucleotide sequence, (SEQ, ID, NO:25) length: 2375 bases

1?GCCAAAGGAG?ACAAAGGATC?ACCTGGATTT?TATGGCAAAA?AGGGTGCAAA?AGGTGAAAAG

61?GGGAATGCTG?GCTTCCCTGG?CCTCCCTGGA?CCTGCTGGAG?AACCAGGAAG?ACATGGAAAG

121?GATGGATTAA?TGGGTAGTCC?CGGTTTCAAG?GGAGAAGCAG?GATCCCCTGG?TGCTCCGGGG

181?CAGGATGGAA?CACGGGGAGA?GCCTACATGT?GCATATGAGT?TCAGCCACGT?GAAAGAGTGA

241?CCTGTACTTC?TTTATGTCTC?TTCACAAACT?GTGGTCTTCA?TATTCTTCAT?GATTGCATCA

301?GGAATCCCAG?GATTTCCTGG?AAACCGAGGA?TTAATGGGCC?AAAAGGGAGA?AATTGGGCCT

361?CCAGGACAGC?AAGGAAAAAA?AGGAGCCCCA?GGGATGCCTG?GTTTAATGGG?AAGCAATGGC

421?TCACCAGGCC?AGCCTGGAAC?ACCGGGATCT?AAGGGAAGCA?AAGGTGAACC?TGGAATTCAA

481?GGGATGCCTG?GGGCTTCTGG?GCTCAAGGGA?GAACCAGGAG?CAACGGGTTC?CCCAGGAGAA

541?CCAGGATACA?TGGGTTTACC?CGGGATTCAA?GGAAAAAAGG?GGGACAAAGG?AAATCAAGGT

601?GAAAAAGGTA?TTCAGGGTCA?AAAGGGAGAA?AATGGAAGAC?AGGGAATTCC?AGGGCAACAG

661?GGAATTCAAG?GCCATCATGG?TGCAAAAGGA?GAGAGAGGTG?AAAAGGGAGA?ACCTGGTGTC

721?CGAGGTGCCA?TTGGATCAAA?AGGAGAATCT?GGGGTGGATG?GCTTGATGGG?GCCCGCAGGT

781?CCTAAGGGGC?AACCTGGGGA?TCCAGGTCCT?CAGGGACCCC?CAGGTTTGGA?TGGGAAGCCC

841?GGAAGAGAGT?TTTCAGAACA?ATTTATTCGA?CAAGTTTGCA?CAGATGTAAT?AAGAGGCCCA

901?GAGGGTCCCA?GAGGATTACC?TGGTTTGCCA?GGAAGAGATG?GTGTTCCTGG?ATTAGTGGGT

961?GTCCCTGGAC?GTCCAGGTGT?CAGAGGATTA?AAAGGCCTAC?CAGGAAGAAA?TGGGGAAAAA

1021?GGGAGCCAAG?GGTTTGGGTA?TCCTGGAGAA?CAAGGTCCTC?CTGGTCCCCC?AGGTCCAGAG

1081?GGCCCTCCTG?GAATAAGCAA?AGAAGGTCCT?CCAGGAGACC?CAGGTCTCCC?TGGCAAAGAT

1141?GGAGACCATG?GAAAACCTGG?AATCCAAGGG?CAACCAGGCC?CCCCAGGCAT?CTGCGACCCA

1201?TCACTATGTT?TTAGTGTAAT?TGCCAGAAGA?GATCCGTTCA?GAAAAGGACC?AAACTATTAG

1261?TGTCTGATGC?CTCATTCAGC?AGCCTAGGCA?TGGTGCTTTT?TCTGTGGTCT?TTTGCATCTC

1321?AGGAAGATAA?CCAACAGTAA?TCCCTTGAAA?AGAAACTTAA?GTACCTCGGT?GTTTTTATTT

1381?TTTTTTTCTT?ATGGAAAAAA?ATATAAAAGA?TCACATATAC?TGATTTTAAA?GGCTCCTCAG

1441?TCATTTGGAG?CCCTTGGATT?AGCAGCATTA?ATTAAATCTC?AAGGGTTTCT?TGTAAAGTCC

1501?ATTTATGTTA?ATCAAAGTTG?AATATAAAAA?TCCACCATTG?CCTGTTAGCC?AGTCAGTTTT

1561?AGTCACTGTG?AAATATTTCA?CATTCAGCCT?CCATGCAGTA?GAGATTTGAG?TTTAATTTCA

1621?TGTCCATGTG?ACTTTCATGT?TTCCTATCTC?ATAGCTCATG?CTACTACATA?AGCCAAAACA

1681?TGTATCTCAT?CATTGGAAGT?AAGATCAGGG?CTGATATTCA?CCTGGGATAG?ACAGTATTGG

1741?TGAACTACTC?ATTTACTACA?GTGTCTCAGC?CTTGATAAGG?GGCAGTGGAT?TGCCTGTTGT

1801?TCGGTGTTGT?GAATAGCACC?TCTGAATAAG?ATTAGAGTGT?TTCTTAATTC?ATTTCAAACT

1861?CTAAAATTAG?ATTAATGGTG?GTGCTAAGAA?AGAGTATTAA?TTACTTTGGG?AATGGTCAAA

1921?ATTAACATTA?AAAACATTTT?AGACAAAAAG?TTTCATTGTA?CATTCAAAGA?AAATGTAAGT

1981?TTGGAAGTAC?TAAAAGACTA?TTTTATACTT?GTTGATTAAT?CGGAATGTTT?GTTGTATGCC

2041?TTCATTTTCC?ATTTCACTTA?TATGTGTATG?TCCATATATG?TTAATTTTCA?TTGTAGCAAA

2101?GCTAATGGAA?ATAAAGCTAA?TGCTCTAGTT?GAAAGAAAAG?GAAAACTCCT?GAAATCCTAG

2161?AATGTCTTGT?TATTTTTAGC?TGACTGTAAA?ATATTATGAA?CAGTCTTTGT?GTATTGTGCT

2221?TAATGCTTTT?GTAAGAAACA?GAATTTGAAA?TATTTCATCC?TTGTCATGCT?CAAAATTTTG

2281?TTACATGCTT?GTTATTCAGA?GTATAATAAA?GTTTTGTACA?GGCCTGAAAA?AAAAAAAAAA

2341 AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAA B: nucleotide sequence (SEQ ID NO:26) length: 323 amino acid

1?MIASGIPGFP?GNRGLMGQKG?EIGPPGQQGK?KGAPGMPGLM?GSNGSPGQPG?TPGSKGSKGE

61?PGIQGMPGAS?GLKGEPGATG?SPGEPGYMGL?PGIQGKKGDK?GNQGEKGIQG?QKGENGRQGI

121?PGQQGIQGHH?GAKGERGEKG?EPGVRGAIGS?KGESGVDGLM?GPAGPKGQPG?DPGPQGPPGL

181?DGKPGREFSE?QFIRQVCTDV?IRGPEGPRGL?PGLPGRDGVP?GLVGVPGRPG?VRGLKGLPGR

241?NGEKGSQGFG?YPGEQGPPGP?PGPEGPPGIS?KEGPPGDPGL?PGKDGDHGKP?GIQGQPGPPG

301 ICDPSLCFSV IARRDPFRKG PNY C. Nucleotide sequence and amino acid composition (SEQ ID NO: 27) Clone: ​​FP633 start codon: 289 ATG termination codon: 1258 TAG protein molecular weight: 31648.92 1 GCC AAA GGA GAC AAA GGA TCA CCT GGA TTT TAT GGC AAA AAG GGT GCA 48 49 AAA GGT GAA AAG GGG AAT GCT GGC TTC CCT GGC CTC CCT GGA CCT GCT 96 97 GGA GAA CCA GGA AGA CAT GGA AAG GAT GGA TTA ATG GGT AGT CCC GGT 144 145 TTC AAG GGA GAA GCA GGA TCC CCT GGT GCT CCG GGG CAG GAT GGA ACA 192 193 CGG GGA GAG CCT ACA TGT GCA TAT GAG TTC AGC CAC GTG AAA GAG TGA 240 241 CCT GTA CTT CTT TAT GTC TCT TCA CAA ACT GTG GTC TTC ATA TTC TTC 288 289 ATG ATT GCA TCA GGA ATC CCA GGA TTT CCT GGA AAC CGA GGA TTA ATG 336 1 Met Ile Ala Ser Gly Ile Pro Gly Phe Pro Gly Asn Arg Gly Leu Met 16 337 GGC CAA AAG GGA GAA ATT GGG CCT CCA GGA CAG CAA GGA AAA AAA GGA 384 17 Gly Gln Lys Gly Glu Ile Gly Pro Pro Gly Gln Gln Gly Lys Lys Gly 32 385 GCC CCA GGG ATG CCT GGT TTA ATG GGA AGC AAT GGC TCA CCA GGC CAG 432 33 Ala Pro Gly Met Pro Gly Leu Met Gly Ser Asn Gly Ser Pro Gly Gln 48 433 CCT GGA ACA CCG GGA TCT AAG GGA AGC AAA GGT GAA CCT GGA ATT CAA 480 49 Pro Gly Thr Pro Gly Ser Lys Gly Ser Lys Gly Glu Pro Gly Ile Gln 64 481 GGG ATG CCT GGG GCT TCT GGG CTC AAG GGA GAA CCA GGA GCA ACG GGT 528 65 Gly Met Pro Gly Ala Ser Gly Leu Lys Gly Glu Pro Gly Ala Thr Gly 80 529 TCC CCA GGA GAA CCA GGA TAC ATG GGT TTA CCC GGG ATT CAA GGA AAA 576 81 Ser Pro Gly Glu Pro Gly Tyr Met Gly Leu Pro Gly Ile Gln Gly Lys 96 577 AAG GGG GAC AAA GGA AAT CAA GGT GAA AAA GGT ATT CAG GGT CAA AAG 624 97 Lys Gly Asp Lys Gly Asn Gln Gly Glu Lys Gly Ile Gln Gly Gln Lys 112 625 GGA GAA AAT GGA AGA CAG GGA ATT CCA GGG CAA CAG GGA ATT CAA GGC 672 113 Gly Glu Asn Gly Arg Gln Gly Ile Pro Gly Gln Gln Gly Ile Gln Gly 128 673 CAT CAT GGT GCA AAA GGA GAG AGA GGT GAA AAG GGA GAA CCT GGT GTC 720 129 His His Gly Ala Lys Gly Glu Arg Gly Glu Lys Gly Glu Pro Gly Val 144 721 CGA GGT GCC ATT GGA TCA AAA GGA GAA TCT GGG GTG GAT GGC TTG ATG 768 145 Arg Gly Ala Ile Gly Ser Lys Gly Glu Ser Gly Val Asp Gly Leu Met 160 769 GGG CCC GCA GGT CCT AAG GGG CAA CCT GGG GAT CCA GGT CCT CAG GGA 816 161 Gly Pro Ala Gly Pro Lys Gly Gln Pro Gly Asp Pro Gly Pro Gln Gly 176 817 CCC CCA GGT TTG GAT GGG AAG CCC GGA AGA GAG TTT TCA GAA CAA TTT 864 177 Pro Pro Gly Leu Asp Gly Lys Pro Gly Arg Glu Phe Ser Glu Gln Phe 192 865 ATT CGA CAA GTT TGC ACA GAT GTA ATA AGA GGC CCA GAG GGT CCC AGA 912 193 Ile Arg Gln Val Cys Thr Asp Val Ile Arg Gly Pro Glu Gly Pro Arg 208 913 GGA TTA CCT GGT TTG CCA GGA AGA GAT GGT GTT CCT GGA TTA GTG GGT 960 209 Gly Leu Pro Gly Leu Pro Gly Arg Asp Gly Val Pro Gly Leu Val Gly 224 961 GTC CCT GGA CGT CCA GGT GTC AGA GGA TTA AAA GGC CTA CCA GGA AGA 1008 225 Val Pro Gly Arg Pro Gly Val Arg Gly Leu Lys Gly Leu Pro Gly Arg 2401009 AAT GGG GAA AAA GGG AGC CAA GGG TTT GGG TAT CCT GGA GAA CAA GGT 1056 241 Asn Gly Glu Lys Gly Ser Gln Gly Phe Gly Tyr Pro Gly Glu Gln Gly 256 1057 CCT CCT GGT CCC CCA GGT CCA GAG GGC CCT CCT GGA ATA AGC AAA GAA 1104 257 Pro Pro Gly Pro Pro Gly Pro Glu Gly Pro Pro Gly Ile Ser Lys Glu 272 1105 GGT CCT CCA GGA GAC CCA GGT CTC CCT GGC AAA GAT GGA GAC CAT GGA 1152 273 Gly Pro Pro Gly Asp Pro Gly Leu Pro Gly Lys Asp Gly Asp His Gly 288 1153 AAA CCT GGA ATC CAA GGG CAA CCA GGC CCC CCA GGC ATC TGC GAC CCA 1200 289 Lys Pro Gly Ile Gln Gly Gln Pro Gly Pro Pro Gly Ile Cys Asp Pro 304 1201 TCA CTA TGT TTT AGT GTA ATT GCC AGA AGA GAT CCG TTC AGA AAA GGA 1248 305 Ser Leu Cys Phe Ser Val Ile Ala Arg Arg Asp Pro Phe Arg Lys Gly 320 1249 CCA AAC TAT TAG TGT CTG ATG CCT CAT TCA GCA GCC TAG GCA TGG TGC 1296 321 Pro Asn Tyr *** 324 1297 TTT TTC TGT GGT CTT TTG CAT CTC AGG AAG ATA ACC AAC AGT AAT CCC 1344 1345 TTG AAA AGA AAC TTA AGT ACC TCG GTG TTT TTA TTT TTT TTT TCT TAT 1392 1393 GGA AAA AAA TAT AAA AGA TCA CAT ATA CTG ATT TTA AAG GCT CCT CAG 1440 1441 TCA TTT GGA GCC CTT GGA TTA GCA GCA TTA ATT AAA TCT CAA GGG TTT 1488 1489 CTT GTA AAG TCC ATT TAT GTT AAT CAA AGT TGA ATA TAA AAA TCC ACC 1536 1537 ATT GCC TGT TAG CCA GTC AGT TTT AGT CAC TGT GAA ATA TTT CAC ATT 1584 1585 CAG CCT CCA TGC AGT AGA GAT TTG AGT TTA ATT TCA TGT CCA TGT GAC 1632 1633 TTT CAT GTT TCC TAT CTC ATA GCT CAT GCT ACT ACA TAA GCC AAA ACA 1680 1681 TGT ATC TCA TCA TTG GAA GTA AGA TCA GGG CTG ATA TTC ACC TGG GAT 1728 1729 AGA CAG TAT TGG TGA ACT ACT CAT TTA CTA CAG TGT CTC AGC CTT GAT 1776 1777 AAG GGG CAG TGG ATT GCC TGT TGT TCG GTG TTG TGA ATA GCA CCT CTG 1824 1825 AAT AAG ATT AGA GTG TTT CTT AAT TCA TTT CAA ACT CTA AAA TTA GAT 1872 1873 TAA TGG TGG TGC TAA GAA AGA GTA TTA ATT ACT TTG GGA ATG GTC AAA 1920 1921 ATT AAC ATT AAA AAC ATT TTA GAC AAA AAG TTT CAT TGT ACA TTC AAA 1968 1969 GAA AAT GTA AGT TTG GAA GTA CTA AAA GAC TAT TTT ATA CTT GTT GAT 2016 2017 TAA TCG GAA TGT TTG TTG TAT GCC TTC ATT TTC CAT TTC ACT TAT ATG 2064 2065 TGT ATG TCC ATA TAT GTT AAT TTT CAT TGT AGC AAA GCT AAT GGA AAT 2112 2113 AAA GCT AAT GCT CTA GTT GAA AGA AAA GGA AAA CTC CTG AAA TCC TAG 2160 2161 AAT GTC TTG TTA TTT TTA GCT GAC TGT AAA ATA TTA TGA ACA GTC TTT 2208 2209 GTG TAT TGT GCT TAA TGC TTT TGT AAG AAA CAG AAT TTG AAA TAT TTC 2256 2257 ATC CTT GTC ATG CTC AAA ATT TTG TTA CAT GCT TGT TAT TCA GAG TAT 2304 2305 AAT AAA GTT TTG TAC AGG CCT GAA AAA AAA AAA AAA AAA AAA AAA AAA 2352 2353 AAA AAA AAA AAA AAA AAA AAA AA 2375 10.FP782A: nucleotide sequence (SEQ ID NO: 28) Length: 2630 nucleotides...

1?GGTTTTTATT?CTGTTTATTA?TATGTCTCTG?TCTCTCTCTA?TTGTGTGTGT?GTGTGTGTGT

61?GTGTGTGTGT?GTGTGTGTGT?GTGGTGCAGA?AGTGCCACCC?CCAGGGCCCT?GTCAACCTCT

121?CTTTTCTCCT?CCATGGCTGT?CTGCCTGCGT?ATCTGTCTCT?GAGAATCCTC?GGGGCGGTCA

181?GGGGATGTCA?GGAGGGGAAG?GAACCGCCCT?CCCTATCTTG?CTGCTCCTCT?TGGCACTCAG

241?GGGCACCTTC?CATGGAGCCA?GACCGGGTGG?AGGGGCTTCT?GGGATTTGGT?GTCTGCTGCT

301?GCCAGAGCAG?GAACCCCCAG?TCTAGGACTT?GGGCATTTTA?ACAGGGAGAA?AGTAGTGGCT

361?TCCCTTTTCT?CTCTCTCCTC?CTTTTTCCCT?TTAAGCCCAC?AGATTCAGGT?CATGCCAAAA

421?GCTCTCTGGT?TGTAACCTGG?AGACATGTGG?AGGGGAATGG?CGATGGGATT?ATAGGACTCT

481?CCCCATCTCG?GGCCCTGACC?CTGACCCTTG?CCACCAACCC?AAAGACAGCT?GGTGGGTTTC

541?CCCTTGGAGA?CAATCCTGCG?TTTGCCTGGG?CCGGCCCTGG?CTGCCCTCAG?CTTTCGCTGA

601?TCTGCCCGGC?CTGGAGCCTC?CCATCACCCC?GCTTCTTGTT?GGGCCTCAGG?CACTGGTTAC

661?CAGAAGGGGG?TCTGGGTCTG?CTCAGGATCA?TGTTTTGTAG?CACCTCCTGT?TGGAGGGGTG

721?GAGGGATGTT?CCCCTGAGCC?AGGCTGAGAC?TAGAACCCCA?TCTTCCCTGA?GCCAGGCTGA

781?GACTAGAACC?CCATCTTCCC?CACCACGCCA?CCCCTGTGGC?TGCTACAGGA?GCACAGTAGT

841?GAAGGCCTGA?GCTCCAGGTT?TGAAAGACCC?AACTGGAGCG?TGGGGCGGGC?AGGCAGGGGT

901?TAGTGAAAGG?ACACTTCCAG?GGTTAGGACA?GAGCATTTAG?CCTTCTGGAA?GAACCCCTGC

961?CTGGGGTGGG?ACTGTGCAGG?CCAGAGAAGG?TGGCATGGGC?CTGAACCCAC?CTGGACTGAC

1021?TTCTGCACTG?AAGCCACAGA?TGGAGGGTAG?GCTGGTGGGT?GGGGGTGGTT?CGTTCTCTAG

1081?CCGGGGCAGA?CACCCAGCTG?GCTGGGTCCT?TCCTCAGCCT?TGCCTCCTCC?TGTCCCCAAC

1141?CCTTTCCTTT?CCTCCTGCTT?GCGGACTGCT?TGGTCCCCTC?TCCTTCCCTC?CTTCCAGCTG

1201?TTTCCTAGTT?ACCACCTACC?CCTGGCCGTG?GACTGATCAG?ACCAGCATTC?AAAATAAAAG

1261?TTTGTTCCAA?GTTGACAGTG?TGGTGCTCCC?TGCCCAGCCC?TCCAGGTGGA?GGTGCTGCCA

1321?CGGGAACGCA?GTTCGTCTGC?CTGCCCTGGG?GCCCCTGGCG?ACAGCTGGGA?GCAGGGCAGT

1381?GCTGTGAGGA?GCCCAGCTTT?CCCAGTCAGG?CAGGCATGGC?TTCCGTGTTC?AGGCTCCCTC

1441?ACCAGCTGGT?GACACGGGAC?AAGCTTACAA?ACCTTCTCTG?AACCTCAGTT?TTCTCATTTA

1501?CAAGAGCAAA?GCCATCCATC?ACCTTGTGTG?GATTCAGAGA?ATGTGAGGCC?CTGGGGTGTC

1561?CTACACAAGG?GAAAGGCTTG?CTCAGTGAGC?GGTCTGCACA?CCGTTAGCCA?CCCTGCCACC

1621?TCTGTGCCCT?GGGCATGCTC?CAAAGGAAAG?CTCTGGCTGG?GACTGCCAGG?AGTCTCACAC

1681?GCTCCTGTTG?ACATTCCCAG?CAGCCGCCCC?TGAGGTCGAT?GTTTGTTCTG?TTTTTCTTTT

1741?TCTTTTTTGA?GACGGAGTCT?CGCTGTGTTG?CCAGGCTGGA?GTGCAGTGGT?GTGATCTCTG

1801?CTCACTGCAA?CCTCCGCCTG?CCAGTTTCAA?GTGATTCTCT?GCCTCAGCCT?TCTGAGTAGC

1861?TGGGACTACA?GGTGCACGCC?ACCACGCCCA?GCTAACTTTT?TGTATTTTAG?TAGAGACAGG

1921?GTTTCGCCAT?GTCGGCCAGG?GTGGTCTTGA?TCTCCTGACC?TCATGATCCA?CCCGCCTCAG

1981?CCTCCCAAAG?TGCTGGGATT?ACAGGTATGA?GCCACCGCAC?CGGGCCTGTT?CTATTTTTCT

2041?AGTTAAGGGA?ACTGAAGCTC?AGAGAGGTGT?CACCAGCAGG?TGTTCATTCC?CATGCCAGCC

2101?TTGCCCCCCG?GCTTTTCCCA?GGCAGGCTCC?TGCGTGCCCA?CTGGCTCCAG?CCTGGTCCTC

2161?TGTCTCTTGG?CTGCTTCACT?CCTGCTCTTT?GTCCCGACTC?TGGCCCTGCT?TACAGGGGCC

2221?ACTACCTGCT?GGTGCCTCCA?TAACAAGCGT?CTGGCGTTGA?GACCCCTGGC?ATGGCAGGGG

2281?CTTTGGGGTC?TGGTTTCCAC?AAGGCTTAGC?CATGGCAGAA?CCTCGTTTTA?TTTTAACTCT

2341?TTGCCCCTAC?AAACAAACAG?CAGTACTTGC?CAGAACCATT?CTTGGGATTC?AGGAGCTCGG

2401?GCGACTGCCT?TGGCCTCTGG?CCGCACCCAG?GAGGGTGGGG?TTGGATCTGT?GTAGTTGCCA

2461?GGCCCACACC?TGCCAGCAGG?GGGCTGACTG?GATCCATGCT?TTACTGTGTT?TAATGGGGGT

2521?AACAGGGGTC?CCTACAGCCC?TCCCAGCTAA?ACATTTGGAA?CAAAACACCA?GCCCTTTTGT

2581 AGTGGATGCA GAATAAAATT GTTAATCCAA TCAAAAAAAA AAAAAAAAAAB: nucleotide sequence (SEQ ID NO:29) length: 130 amino acid

1?MGLNPPGLTS?ALKPQMEGRL?VGGGGSFSSR?GRHPAGWVLP?QPCLLLSPTL?SFPPACGLLG

61?PLSFPPSSCF?LVTTYPWPWT?DQTSIQNKSL?FQVDSVVLPA?QPSRWRCCHG?NAVRLPALGP

121, LATAGSRAVLC. nucleotides and amino acid composite sequence, (SEQ, ID, NO:30), initial coding of clone number: FP782: 995, ATG, stop coding: 1385, TGA, protein molecular weight:, 13703.18, 1, G, GTT, TTT, ATT, CTG, TTT, ATT, ATA, TGT, CTC, TGT, CTC, TCT, CTA, TTG, TGT, 46, 47, GTG, TGT, GTG, TGT, GTG, TGT, GTG, TGT, GTG, TGT, GTG, TGT, GGT, GCA, GAA, GTG, 94, 95, CCA, CCC, CCA, GGG, CCC, TGT, CAA, CCT, CTC, TTT, TCT, CCT, CCA, TGG, CTG, TCT, 142, 143, GCC, TGC, GTA, TCT, GTC, TCT, GAG, AAT, CCT, CGG, GGC, GGT, CAG, GGG, ATG, TCA, 190, 191, GGA, GGG, GAA, GGA, ACC, GCC, CTC, CCT, ATC, TTG, CTG, CTC, CTC, TTG, GCA, CTC, 238, 239, AGG, GGC, ACC, TTC, CAT, GGA, GCC, AGA, CCG, GGT, GGA, GGG, GCT, TCT, GGG, ATT, 286, 287, TGG, TGT, CTG, CTG, CTG, CCA, GAG, CAG, GAA, CCC, CCA, GTC, TAG, GAC, TTG, GGC, 334, 335, ATT, TTA, ACA, GGG, AGA, AAG, TAG, TGG, CTT, CCC, TTT, TCT, CTC, TCT, CCT, CCT, 382, 383, TTT, TCC, CTT, TAA, GCC, CAC, AGA, TTC, AGG, TCA, TGC, CAA, AAG, CTC, TCT, GGT, 430, 431, TGT, AAC, CTG, GAG, ACA, TGT, GGA, GGG, GAA, TGG, CGA, TGG, GAT, TAT, AGG, ACT, 478, 479, CTC, CCC, ATC, TCG, GGC, CCT, GAC, CCT, GAC, CCT, TGC, CAC, CAA, CCC, AAA, GAC, 526, 527, AGC, TGG, TGG, GTT, TCC, CCT, TGG, AGA, CAA, TCC, TGC, GTT, TGC, CTG, GGC, CGG, 574, 575, CCC, TGG, CTG, CCC, TCA, GCT, TTC, GCT, GAT, CTG, CCC, GGC, CTG, GAG, CCT, CCC, 622, 623, ATC, ACC, CCG, CTT, CTT, GTT, GGG, CCT, CAG, GCA, CTG, GTT, ACC, AGA, AGG, GGG, 670, 671, TCT, GGG, TCT, GCT, CAG, GAT, CAT, GTT, TTG, TAG, CAC, CTC, CTG, TTG, GAG, GGG, 718, 719, TGG, AGG, GAT, GTT, CCC, CTG, AGC, CAG, GCT, GAG, ACT, AGA, ACC, CCA, TCT, TCC, 766, 767, CTG, AGC, CAG, GCT, GAG, ACT, AGA, ACC, CCA, TCT, TCC, CCA, CCA, CGC, CAC, CCC, 814, 815, TGT, GGC, TGC, TAC, AGG, AGC, ACA, GTA, GTG, AAG, GCC, TGA, GCT, CCA, GGT, TTG, 862, 863, AAA, GAC, CCA, ACT, GGA, GCG, TGG, GGC, GGG, CAG, GCA, GGG, GTT, AGT, GAA, AGG, 910, 911, ACA, CTT, CCA, GGG, TTA, GGA, CAG, AGC, ATT, TAG, CCT, TCT, GGA, AGA, ACC, CCT, 958, 959, GCC, TGG, GGT, GGG, ACT, GTG, CAG, GCC, AGA, GAA, GGT, GGC, ATG, GGC, CTG, AAC, 1006, 1, Met, Gly, Leu, Asn, 41007, CCA, CCT, GGA, CTG, ACT, TCT, GCA, CTG, AAG, CCA, CAG, ATG, GAG, GGT, AGG, CTG, 1054, 5, Pro, Pro, Gly, Leu, Thr, Ser, Ala, Leu, Lys, Pro, Gln, Met, Glu, Gly, Arg, Leu, 201055, GTG, GGT, GGG, GGT, GGT, TCG, TTC, TCT, AGC, CGG, GGC, AGA, CAC, CCA, GCT, GGC, 1102, 21, Val, Gly, Gly, Gly, Gly, Ser, Phe, Ser, Ser, Arg, Gly, Arg, His, Pro, Ala, Gly, 361103, TGG, GTC, CTT, CCT, CAG, CCT, TGC, CTC, CTC, CTG, TCC, CCA, ACC, CTT, TCC, TTT, 1150, 37, Trp, Val, Leu, Pro, Gln, Pro, Cys, Leu, Leu, Leu, Ser, Pro, Thr, Leu, Ser, Phe, 521151, CCT, CCT, GCT, TGC, GGA, CTG, CTT, GGT, CCC, CTC, TCC, TTC, CCT, CCT, TCC, AGC, 1198, 53, Pro, Pro, Ala, Cys, Gly, Leu, Leu, Gly, Pro, Leu, Ser, Phe, Pro, Pro, Ser, Ser, 681199, TGT, TTC, CTA, GTT, ACC, ACC, TAC, CCC, TGG, CCG, TGG, ACT, GAT, CAG, ACC, AGC, 1246, 69, Cys, Phe, Leu, Val, Thr, Thr, Tyr, Pro, Trp, Pro, Trp, Thr, Asp, Gln, Thr, Ser, 841247, ATT, CAA, AAT, AAA, AGT, TTG, TTC, CAA, GTT, GAC, AGT, GTG, GTG, CTC, CCT, GCC, 1294, 85, Ile, Gln, Asn, Lys, Ser, Leu, Phe, Gln, Val, Asp, Ser, Val, Val, Leu, Pro, Ala, 1001295, CAG, CCC, TCC, AGG, TGG, AGG, TGC, TGC, CAC, GGG, AAC, GCA, GTT, CGT, CTG, CCT, 1342, 101, Gln, Pro, Ser, Arg, Trp, Arg, Cys, Cys, His, Gly, Asn, Ala, Val, Arg, Leu, Pro, 1161343, GCC, CTG, GGG, CCC, CTG, GCG, ACA, GCT, GGG, AGC, AGG, GCA, GTG, CTG, TGA, GGA, 1390, 117, Ala, Leu, Gly, Pro, Leu, Ala, Thr, Ala, Gly, Ser, Arg, Ala, Val, Leu, * *, 1311391, GCC, CAG, CTT, TCC, CAG, TCA, GGC, AGG, CAT, GGC, TTC, CGT, GTT, CAG, GCT, CCC, 14381439, TCA, CCA, GCT, GGT, GAC, ACG, GGA, CAA, GCT, TAC, AAA, CCT, TCT, CTG, AAC, CTC, 14861487, AGT, TTT, CTC, ATT, TAC, AAG, AGC, AAA, GCC, ATC, CAT, CAC, CTT, GTG, TGG, ATT, 15341535, CAG, AGA, ATG, TGA, GGC, CCT, GGG, GTG, TCC, TAC, ACA, AGG, GAA, AGG, CTT, GCT, 15821583, CAG, TGA, GCG, GTC, TGC, ACA, CCG, TTA, GCC, ACC, CTG, CCA, CCT, CTG, TGC, CCT, 16301631, GGG, CAT, GCT, CCA, AAG, GAA, AGC, TCT, GGC, TGG, GAC, TGC, CAG, GAG, TCT, CAC, 16781679, ACG, CTC, CTG, TTG, ACA, TTC, CCA, GCA, GCC, GCC, CCT, GAG, GTC, GAT, GTT, TGT, 17261727, TCT, GTT, TTT, CTT, TTT, CTT, TTT, TGA, GAC, GGA, GTC, TCG, CTG, TGT, TGC, CAG, 17741775, GCT, GGA, GTG, CAG, TGG, TGT, GAT, CTC, TGC, TCA, CTG, CAA, CCT, CCG, CCT, GCC, 18221823, AGT, TTC, AAG, TGA, TTC, TCT, GCC, TCA, GCC, TTC, TGA, GTA, GCT, GGG, ACT, ACA, 18701871, GGT, GCA, CGC, CAC, CAC, GCC, CAG, CTA, ACT, TTT, TGT, ATT, TTA, GTA, GAG, ACA, 19181919, GGG, TTT, CGC, CAT, GTC, GGC, CAG, GGT, GGT, CTT, GAT, CTC, CTG, ACC, TCA, TGA, 19661967, TCC, ACC, CGC, CTC, AGC, CTC, CCA, AAG, TGC, TGG, GAT, TAC, AGG, TAT, GAG, CCA, 20142015, CCG, CAC, CGG, GCC, TGT, TCT, ATT, TTT, CTA, GTT, AAG, GGA, ACT, GAA, GCT, CAG, 20622063, AGA, GGT, GTC, ACC, AGC, AGG, TGT, TCA, TTC, CCA, TGC, CAG, CCT, TGC, CCC, CCG, 21102111, GCT, TTT, CCC, AGG, CAG, GCT, CCT, GCG, TGC, CCA, CTG, GCT, CCA, GCC, TGG, TCC, 21582159, TCT, GTC, TCT, TGG, CTG, CTT, CAC, TCC, TGC, TCT, TTG, TCC, CGA, CTC, TGG, CCC, 22062207, TGC, TTA, CAG, GGG, CCA, CTA, CCT, GCT, GGT, GCC, TCC, ATA, ACA, AGC, GTC, TGG, 22542255, CGT, TGA, GAC, CCC, TGG, CAT, GGC, AGG, GGC, TTT, GGG, GTC, TGG, TTT, CCA, CAA, 23022303, GGC, TTA, GCC, ATG, GCA, GAA, CCT, CGT, TTT, ATT, TTA, ACT, CTT, TGC, CCC, TAC, 23502351, AAA, CAA, ACA, GCA, GTA, CTT, GCC, AGA, ACC, ATT, CTT, GGG, ATT, CAG, GAG, CTC, 23982399, GGG, CGA, CTG, CCT, TGG, CCT, CTG, GCC, GCA, CCC, AGG, AGG, GTG, GGG, TTG, GAT, 2446, 2447, CTG, TGT, AGT, TGC, CAG, GCC, CAC, ACC, TGC, CAG, CAG, GGG, GCT, GAC, TGG, ATC, 2494, 2495, CAT, GCT, TTA, CTG, TGT, TTA, ATG, GGG, GTA, ACA, GGG, GTC, CCT, ACA, GCC, CTC, 2542, 2543, CCA, GCT, AAA, CAT, TTG, GAA, CAA, AAC, ACC, AGC, CCT, TTT, GTA, GTG, GAT, GCA, 2590, 2591, GAA, TAA, AAT, TGT, TAA, TCC, AAT, CAA, AAA, AAA, AAA, AAA, AAA, A, 2630, 11.FP793A: nucleotide sequence, (SEQ, ID, NO:31) length: 1694 bases

1?GCCCTCCCTG?ACATTGCTGG?CACACAGGCA?TGATTGCTGG?TTCCATTGGA?TATGGATCTG

61, GATTGTCAGC, GTATTTGAAC, AGTATTAAGG, GAGGGTTTTG, CAGTAGAGAC, AGAAGGTGAC, 121, GTAAGGTGGT, TCCTAAGGTG, GGTTCGGTCA, GTCCCCTAAT, AGTTTGTTTT, CAGTGTATTG, 181, AGACCAGGAG, AATTGATTTA, CTTCAGACCT, ATTTTTTGAA, ACTCCCTGTT, GGTCTGGTGT, 241, CATGCGTTTA, GAGAGACTCT, GAACTTCGTT, TTCTGTTTTC, CTTAGATAAT, GATAGCACTT, 301, CATGAGCACC, ATATGTGAAG, CACACATACG, TTCTGTCTGA, CTCTCAGAAC, AGTGCCACAT, 361, TGGCATTGTC, ATCATTTACA, GATGACATCT, GAGAGCTAGG, GTGACTTGCC, CAAGCCCAAG, 421, CAGCTGGTAG, CAGAGTTGGG, ATCTTAACCC, TCACCACACC, GGTGTTTTCA, AGAGAGAACT, 481, TGGTCGTGGA, GAACTGGAGA, ACAGATACTG, CCTAAGTTAC, ATTTAGTTTT, AGACTAATTT, 541, AATACTCCAT, TTAAGAAACA, AACAGAACAG, CTGTGCAGTT, AGGAAAGTGG, AGGGGATTTG, 601, AATGAGGAGG, AGGCGGGTTA, GAGTTAGAAC, CGTCTTTGCT, GAACAAGTAG, TGTGTTTGCA, 661, GAAAGGGAAG, TTGAAGTTAC, GTTGTCCTAA, AATACAGCAA, GGAAGAGGAG, GTGCTTAATA, 721, CCACGGAAAA, AAGTCTGTGT, CATGTTTCTG, TGAGGTTAAA, AGTAATTTGA, TAGTGTATGT, 781, CATGCTGCTG, ACATATTCCA, TGTGTTTGAT, ATCTTCCCAG, CAAAATAATC, AGCTCTCATT, 841, TTCCCTTACA, GAGTCAACTG, TTCATTTTAT, TTCAAAATTG, GAGCATGTCG, TCATGGAGAC, 901, AGGTGCTCTC, GGTTGCACAA, TAAACCGACG, TTTAGCCAGA, CCATTGCCCT, CTTGAACATT, 961, TACCGTAACC, CTCAAAACTC, TTCCCAGTCT, GCTGACGGTT, TGCGCTGTGC, CGTGAGCGAT, 1021, GTGGAGATGC, AGGAACACTA, TGATGAGTTT, TTTGAGGAGG, TTTTTACAGA, AATGGAGGAG, 1081, AAGTATGGGG, AAGTAGAGGA, GATGAACGTC, TGTGACAACC, TGGGAGACCA, CCTGGTGGGG, 1141, AACGTGTACG, TCAAGTTTCG, CCGTGAGGAA, GATGCGGAAA, AGGCTGTGAT, TGACTTGAAT, 1201, AACCGTTGGT, TTAATGGACA, GCCGATCCAC, GCCGAGCTGT, CACCCGTGAC, GGACTTCAGA, 1261, GAAGCCTGCT, GCCGTCAGTA, TGAGATGGGA, GAATGCACAC, GAGGCGGCTT, CTGCAACTTC, 1321, ATGCATTTGA, AGCCCATTTC, CAGAGAGCTG, CGGCGGGAGC, TGTATGGCCG, CCGTCGCAAG, 1381, AAGCATAGAT, CAAGATCCCG, ATCCCGGGAG, CGTCGTTCTC, GGTCTAGAGA, CCGTGGTCGT, 1441, GGCGGTGGCG, GTGGCGGTGG, TGGAGGTGGC, GGCGGACGGG, AGCGTGACAG, GAGGCGGTCG, 1501, AGAGATCGTG, AAAGATCTGG, GCGATTCTGA, GCCATGCCAT, TTTTACCTTA, TGTCTGCTAG, 1561, AAAGTGTTGT, AGTTGATTGA, CCAAACCAGT, TCATAAGGGG, AATTTTTTTT, AAAAAACAAC, 1621, AAAAAAAAAA, ACATACAAAG, ATGGGTTTCT, GAATAAAATT, TGTAGTGATA, ACAGTAAAAA, 1681, AAAAAAAAAA, AAAAB: nucleotide sequence, (SEQ, ID, NO:32) length: 167 amino acid

1?MQEHYDEFFE?EVFTEMEEKY?GEVEEMNVCD?NLGDHLVGNV?YVKFRREEDA?EKAVIDLNNR

61 WFNGQPIHAE LSPVTDFREA CCRQYEMGEC TRGGFCNFMH LKPISRELRR ELYGRRRKKH 121 RSRSRSRERR SRSRDRGRGG GGGGGGGGGG RERDRRRSRD RERSGRFC. Nucleotide and amino acid composite sequence (SEQ ID NO:33) clone number: FP793 start code: 1027 ATG stop coding: 1528 TGA protein molecular weights: 19713.96

1??GCC?CTC?CCT?GAC?ATT?GCT?GGC?ACA?CAG?GCA?TGA?TTG?CTG?GTT?CCA?TTG?????48???49??GAT?ATG?GAT?CTG?GAT?TGT?CAG?CGT?ATT?TGA?ACA?GTA?TTA?AGG?GAG?GGT?????96???97??TTT?GCA?GTA?GAG?ACA?GAA?GGT?GAC?GTA?AGG?TGG?TTC?CTA?AGG?TGG?GTT????144??145??CGG?TCA?GTC?CCC?TAA?TAG?TTT?GTT?TTC?AGT?GTA?TTG?AGA?CCA?GGA?GAA????192??193??TTG?ATT?TAC?TTC?AGA?CCT?ATT?TTT?TGA?AAC?TCC?CTG?TTG?GTC?TGG?TGT????240??241??CAT?GCG?TTT?AGA?GAG?ACT?CTG?AAC?TTC?GTT?TTC?TGT?TTT?CCT?TAG?ATA????288??289??ATG?ATA?GCA?CTT?CAT?GAG?CAC?CAT?ATG?TGA?AGC?ACA?CAT?ACG?TTC?TGT????336???337??CTG?ACT?CTC?AGA?ACA?GTG?CCA?CAT?TGG?CAT?TGT?CAT?CAT?TTA?CAG?ATG????384???385??ACA?TCT?GAG?AGC?TAG?GGT?GAC?TTG?CCC?AAG?CCC?AAG?CAG?CTG?GTA?GCA????432???433??GAG?TTG?GGA?TCT?TAA?CCC?TCA?CCA?CAC?CGG?TGT?TTT?CAA?GAG?AGA?ACT????480???481??TGG?TCG?TGG?AGA?ACT?GGA?GAA?CAG?ATA?CTG?CCT?AAG?TTA?CAT?TTA?GTT????528???529??TTA?GAC?TAA?TTT?AAT?ACT?CCA?TTT?AAG?AAA?CAA?ACA?GAA?CAG?CTG?TGC????576???577??AGT?TAG?GAA?AGT?GGA?GGG?GAT?TTG?AAT?GAG?GAG?GAG?GCG?GGT?TAG?AGT????624???625??TAG?AAC?CGT?CTT?TGC?TGA?ACA?AGT?AGT?GTG?TTT?GCA?GAA?AGG?GAA?GTT????672???673??GAA?GTT?ACG?TTG?TCC?TAA?AAT?ACA?GCA?AGG?AAG?AGG?AGG?TGC?TTA?ATA????720???721??CCA?CGG?AAA?AAA?GTC?TGT?GTC?ATG?TTT?CTG?TGA?GGT?TAA?AAG?TAA?TTT????768???769??GAT?AGT?GTA?TGT?CAT?GCT?GCT?GAC?ATA?TTC?CAT?GTG?TTT?GAT?ATC?TTC????816???817??CCA?GCA?AAA?TAA?TCA?GCT?CTC?ATT?TTC?CCT?TAC?AGA?GTC?AAC?TGT?TCA????864???865??TTT?TAT?TTC?AAA?ATT?GGA?GCA?TGT?CGT?CAT?GGA?GAC?AGG?TGC?TCT?CGG????912???913??TTG?CAC?AAT?AAA?CCG?ACG?TTT?AGC?CAG?ACC?ATT?GCC?CTC?TTG?AAC?ATT????960???961??TAC?CGT?AAC?CCT?CAA?AAC?TCT?TCC?CAG?TCT?GCT?GAC?GGT?TTG?CGC?TGT???1008??1009??GCC?GTG?AGC?GAT?GTG?GAG?ATG?CAG?GAA?CAC?TAT?GAT?GAG?TTT?TTT?GAG???1056

1??????????????????????????Met?Gln?Glu?His?Tyr?Asp?Glu?Phe?Phe?Glu?????10??1057??GAG?GTT?TTT?ACA?GAA?ATG?GAG?GAG?AAG?TAT?GGG?GAA?GTA?GAG?GAG?ATG???1104

11??Glu?Val?Phe?Thr?Glu?Met?Glu?Glu?Lys?Tyr?Gly?Glu?Val?Glu?Glu?Met?????26??1105??AAC?GTC?TGT?GAC?AAC?CTG?GGA?GAC?CAC?CTG?GTG?GGG?AAC?GTG?TAC?GTC???1152

27??Asn?Val?Cys?Asp?Asn?Leu?Gly?Asp?His?Leu?Val?Gly?Asn?Val?Tyr?Val?????42??1153??AAG?TTT?CGC?CGT?GAG?GAA?GAT?GCG?GAA?AAG?GCT?GTG?ATT?GAC?TTG?AAT???1200

43??Lys?Phe?Arg?Arg?Glu?Glu?Asp?Ala?Glu?Lys?Ala?Val?Ile?Asp?Leu?Asn?????58??1201??AAC?CGT?TGG?TTT?AAT?GGA?CAG?CCG?ATC?CAC?GCC?GAG?CTG?TCA?CCC?GTG???1248

59??Asn?Arg?Trp?Phe?Asn?Gly?Gln?Pro?Ile?His?Ala?Glu?Leu?Ser?Pro?Val?????74??1249??ACG?GAC?TTC?AGA?GAA?GCC?TGC?TGC?CGT?CAG?TAT?GAG?ATG?GGA?GAA?TGC???1296

75??Thr?Asp?Phe?Arg?Glu?Ala?Cys?Cys?Arg?Gln?Tyr?Glu?Met?Gly?Glu?Cys?????90??1297??ACA?CGA?GGC?GGC?TTC?TGC?AAC?TTC?ATG?CAT?TTG?AAG?CCC?ATT?TCC?AGA???1344

91, Thr, Arg, Gly, Gly, Phe, Cys, Asn, Phe, Met, His, Leu, Lys, Pro, Ile, Ser, Arg, 106, 1345, GAG, CTG, CGG, CGG, GAG, CTG, TAT, GGC, CGC, CGT, CGC, AAG, AAG, CAT, AGA, TCA, 1392, 107, Glu, Leu, Arg, Arg, Glu, Leu, Tyr, Gly, Arg, Arg, Arg, Lys, Lys, His, Arg, Ser, 122, 1393, AGA, TCC, CGA, TCC, CGG, GAG, CGT, CGT, TCT, CGG, TCT, AGA, GAC, CGT, GGT, CGT, 1440, 123, Arg, Ser, Arg, Ser, Arg, Glu, Arg, Arg, Ser, Arg, Ser, Arg, Asp, Arg, Gly, Arg, 138, 1441, GGC, GGT, GGC, GGT, GGC, GGT, GGT, GGA, GGT, GGC, GGC, GGA, CGG, GAG, CGT, GAC, 1488, 139, Gly, Gly, Gly, Gly, Gly, Gly, Gly, Gly, Gly, Gly, Gly, Gly, Arg, Glu, Arg, Asp, 154, 1489, AGG, AGG, CGG, TCG, AGA, GAT, CGT, GAA, AGA, TCT, GGG, CGA, TTC, TGA, GCC, ATG, 1536, 155, Arg, Arg, Arg, Ser, Arg, Asp, Arg, Glu, Arg, Ser, Gly, Arg, Phe, * *, 168, 1537, CCA, TTT, TTA, CCT, TAT, GTC, TGC, TAG, AAA, GTG, TTG, TAG, TTG, ATT, GAC, CAA, 1584, 1585, ACC, AGT, TCA, TAA, GGG, GAA, TTT, TTT, TTA, AAA, AAC, AAC, AAA, AAA, AAA, AAC, 1632, 1633, ATA, CAA, AGA, TGG, GTT, TCT, GAA, TAA, AAT, TTG, TAG, TGA, TAA, CAG, TAA, AAA, 1680, 1681, AAA, AAA, AAA, AAA, AA, 1694, 12.FP944A: nucleotide sequence, (SEQ, ID, NO:34) length: 2244 bases

1?GCCCAGTCTT?GTGGCTTCAA?ATGCTATCTG?TGTGTGGATA?GCTCCTCCAG?TCCACACCTC

61, TTTTCTGAAT, CTTTTTTCAA, ATTCACACAT, GTGAATTTGA, ATTCCAGGCT, CATCACATCC, 121, AGGTGTGTTC, CCCACACCTC, CACCTGAATG, TCTATTAGAA, ATCTCACACC, CCTCTTGTCC, 181, AAAACTGAGC, TCTTGATCTT, TAACCAGAAA, CTTTATCTCA, GCTATTGGCA, ACTCCAGGTT, 241, TCTGTTTTGC, TCAGGCCACA, GACTTCAGAG, TCATTCTCAC, ACTGCCTTTT, CTCTCATACA, 301, CCATTATGTA, CCTGTCAGCA, GGTCCCAAAT, ATCTAGAATT, TTGATTGCTT, CACATCCCTA, 361, TAGCAACTCT, CCTGGTTCAA, GCCCATCATC, ATCTGGATTT, TTGGGAAGTG, GTCTTAACTG, 421, GTGTGCTGCC, CTTCCCCTCG, GCTCTCAACC, CTATTTTCAA, CATAGCAGTC, AGAATAATCT, 481, AAAATATAAA, CCAGATCATA, TCACTCCTCT, GCTCAACACC, CCCTCCCAAT, ACCTTCATGT, 541, CATCCTCAGA, GTTATTGTCC, AAGCCTCTAA, CTGTGGTCTA, CAAGTCTTTA, CATGATCTGT, 601, CCTGTTACAT, TTTCCACTCT, CGCTCCAGAC, CTGACCTAAG, AGGCTTTTCT, CTGAACTTGC, 661, TAAACATGCT, CTTACCTGAG, GGTCCATTCC, CACTGCCTCT, GCCTGGAATG, CTCTTCCCCA, 721, GACATGCATC, TGCGTGGATC, ATTTCCATGC, CTCCTCAGGT, CTTTGCCCTC, ATGAAGCCTT, 781, CCCTGACAAC, CCTATTTAAG, ATTGTAATCC, CCTCCCACAG, TGGCCCCTAT, CTGCTAGAGA, 841, CTGAATGTTT, TTGTCCCCCC, CAAAATTCCT, ATGTTGAAGC, CTTAATCTCA, ACATAGGAGG, 901, TTTGGCCTTT, GTGAGTTAGT, TTTAGATGAG, GTCATGTGGG, TAATAGAATT, AGTGCATTTA, 961, TAAGGGCGTG, AAGAGCCCTC, ACTGTGAGGA, AACCAGAATG, TAAGCCTTCA, CCAGAACTTC, 1021, TTCATGCTGG, CACCCTGGTC, TTAGACTTCC, CAGCCACTAG, ATCTGTGAGA, AAGAAATGTT, 1081, TGTTGTTTAA, GCCACCCTGT, CTATGGTACT, CTTGTTACAG, CAACCTGAAC, TAAGACACTA, 1141, TCCCTCTCCC, CTGCTTTCTT, TTTCTGTTAT, CACCATAATT, AATGTTTTAC, TTATATATGA, 1201, TTTGTTAATG, TATGTCTCTT, CCCACTAGAA, ACCGAATTCT, ATGACAGCAA, GGGTTTTTGT, 1261, TTTCATTATT, GTCATATTAC, CTGTGCCTGG, CATGTGATAA, GCCCTAAGTA, CTTGTTGACT, 1321, GAATTAACAT, ATGAGATCTG, TGAGTCTGAA, AAAAGAAGTA, CATCATTCCT, TCACATGTCA, 1381, TTTTGAGCCA, CTGTTAACAG, ATTACATAAC, TGTTATTGGA, AGTGCCTCAC, TACTCCATTT, 1441, GGAAAGTATT, CCTGGAATAC, ACGATGAATG, ACTCAGTAGA, AGTTCTGGCT, ATGGGGGAGT, 1501, GCCATCAATA, AATAAAAATA, ATACCATTGC, CTGTTGGTTA, TAAGTTGCTG, TCACAGACTA, 1561, TGAAGGTATT, TGAATTGTAT, TTTCAGGAAG, AGAAACAGAT, ATGCAACCAA, TCTGATTTGG, 1621, TTCCACACCC, TGCCACAGAA, GTCCCAAAGG, AGAAGCAAAT, GCCACTTGTA, GACTCAAACT, 1681, CTGGACTTCA, TTCTCAGCAC, CATCTCTTAA, CCTACTGAGT, AAATCCTATG, AACCTGACTA, 1741, GGGTGGCAAC, TGAAGTTGTA, GTACTTTCTG, TCTTCAAAGG, AGGGTGAACC, TGGAGTATGT, 1801, TGGAAGAAGT, GTTAGGTTCA, TTAGAGACAC, CTCTTTCATA, ACTGCTGTCA, CCTAGAATGT, 1861, CTATTCTCTA, AGCACCTTCT, TGAAAGAAGC, ACATTCCCCC, AGGAGGAGGA, AATGGTTTGT, 1921, TTTCTTTAGT, GACAGTTGGC, CCAGGATCCT, AAGGTAAAGG, AGTATGGGCA, CTAGACAAAA, 1981, TGAGTTTTAT, AATAGTCGAT, TGGAAGGAAT, GGAAGTTTTT, GAATCACAGG, CTTCTGCCTT, 2041, GAAAGGGCAA, GTCCGTGGTG, GTCATGAACC, ACCCAGAGTG, TGTACAAGGC, TCCTGCCAGA, 2101, AGAAATGCCT, GTAGGATTAA, AAGCAAAACA, GCAGAATCAA, AAAGGAAGGG, CACGATGATG, 2161, CCCAGGTGCA, GCCTATATTA, TTAACAGACA, AGGAAAGAAT, CCAAATAAAA, GTTCTGTAAA, 2221, CCAAAAAAAA, AAAAAAAAAA, AAAAB: nucleotide sequence, (SEQ, ID, NO:35) length: 119 amino acid

1?MSSSELLSKP?LTVVYKSLHD?LSCYIFHSRS?RPDLRGFSLN?LLNMLLPEGP?FPLPLPGMLF

61, PRHASAWIIS, MPPQVFALMK, PSLTTLFKIV, IPSHSGPYLL, ETECFCPPQN, SYVEALISTC. nucleotides and amino acid composite sequence, (SEQ, ID, NO:36) initial coding of clone number: FP944: 537, ATG, stop coding: 894, TAG, protein molecular weight:, 13317.99, 1, GC, CCA, GTC, TTG, TGG, CTT, CAA, ATG, CTA, TCT, GTG, TGT, GGA, TAG, CTC, CTC, 47, 48, CAG, TCC, ACA, CCT, CTT, TTC, TGA, ATC, TTT, TTT, CAA, ATT, CAC, ACA, TGT, GAA, 95, 96, TTT, GAA, TTC, CAG, GCT, CAT, CAC, ATC, CAG, GTG, TGT, TCC, CCA, CAC, CTC, CAC, 143, 144, CTG, AAT, GTC, TAT, TAG, AAA, TCT, CAC, ACC, CCT, CTT, GTC, CAA, AAC, TGA, GCT, 191, 192, CTT, GAT, CTT, TAA, CCA, GAA, ACT, TTA, TCT, CAG, CTA, TTG, GCA, ACT, CCA, GGT, 239, 240, TTC, TGT, TTT, GCT, CAG, GCC, ACA, GAC, TTC, AGA, GTC, ATT, CTC, ACA, CTG, CCT, 287, 288, TTT, CTC, TCA, TAC, ACC, ATT, ATG, TAC, CTG, TCA, GCA, GGT, CCC, AAA, TAT, CTA, 335, 336, GAA, TTT, TGA, TTG, CTT, CAC, ATC, CCT, ATA, GCA, ACT, CTC, CTG, GTT, CAA, GCC, 383, 384, CAT, CAT, CAT, CTG, GAT, TTT, TGG, GAA, GTG, GTC, TTA, ACT, GGT, GTG, CTG, CCC, 431, 432, TTC, CCC, TCG, GCT, CTC, AAC, CCT, ATT, TTC, AAC, ATA, GCA, GTC, AGA, ATA, ATC, 479, 480, TAA, AAT, ATA, AAC, CAG, ATC, ATA, TCA, CTC, CTC, TGC, TCA, ACA, CCC, CCT, CCC, 527, 528, AAT, ACC, TTC, ATG, TCA, TCC, TCA, GAG, TTA, TTG, TCC, AAG, CCT, CTA, ACT, GTG, 575, 1, Met, Ser, Ser, Ser, Glu, Leu, Leu, Ser, Lys, Pro, Leu, Thr, Val, 13, 576, GTC, TAC, AAG, TCT, TTA, CAT, GAT, CTG, TCC, TGT, TAC, ATT, TTC, CAC, TCT, CGC, 623, 14, Val, Tyr, Lys, Ser, Leu, His, Asp, Leu, Ser, Cys, Tyr, Ile, Phe, His, Ser, Arg, 29, 624, TCC, AGA, CCT, GAC, CTA, AGA, GGC, TTT, TCT, CTG, AAC, TTG, CTA, AAC, ATG, CTC, 671, 30, Ser, Arg, Pro, Asp, Leu, Arg, Gly, Phe, Ser, Leu, Asn, Leu, Leu, Asn, Met, Leu, 45, 672, TTA, CCT, GAG, GGT, CCA, TTC, CCA, CTG, CCT, CTG, CCT, GGA, ATG, CTC, TTC, CCC, 719, 46, Leu, Pro, Glu, Gly, Pro, Phe, Pro, Leu, Pro, Leu, Pro, Gly, Met, Leu, Phe, Pro, 61, 720, AGA, CAT, GCA, TCT, GCG, TGG, ATC, ATT, TCC, ATG, CCT, CCT, CAG, GTC, TTT, GCC, 767, 62, Arg, His, Ala, Ser, Ala, Trp, Ile, Ile, Ser, Met, Pro, Pro, Gln, Val, Phe, Ala, 77, 768, CTC, ATG, AAG, CCT, TCC, CTG, ACA, ACC, CTA, TTT, AAG, ATT, GTA, ATC, CCC, TCC, 815, 78, Leu, Met, Lys, Pro, Ser, Leu, Thr, Thr, Leu, Phe, Lys, Ile, Val, Ile, Pro, Ser, 93, 816, CAC, AGT, GGC, CCC, TAT, CTG, CTA, GAG, ACT, GAA, TGT, TTT, TGT, CCC, CCC, CAA, 863, 94, His, Ser, Gly, Pro, Tyr, Leu, Leu, Glu, Thr, Glu, Cys, Phe, Cys, Pro, Pro, Gln, 109, 864, AAT, TCC, TAT, GTT, GAA, GCC, TTA, ATC, TCA, ACA, TAG, GAG, GTT, TGG, CCT, TTG, 911, 110, Asn, Ser, Tyr, Val, Glu, Ala, Leu, Ile, Ser, Thr, * *, 120, 912, TGA, GTT, AGT, TTT, AGA, TGA, GGT, CAT, GTG, GGT, AAT, AGA, ATT, AGT, GCA, TTT, 959, 960, ATA, AGG, GCG, TGA, AGA, GCC, CTC, ACT, GTG, AGG, AAA, CCA, GAA, TGT, AAG, CCT, 10071008, TCA, CCA, GAA, CTT, CTT, CAT, GCT, GGC, ACC, CTG, GTC, TTA, GAC, TTC, CCA, GCC, 10551056, ACT, AGA, TCT, GTG, AGA, AAG, AAA, TGT, TTG, TTG, TTT, AAG, CCA, CCC, TGT, CTA, 11031104, TGG, TAC, TCT, TGT, TAC, AGC, AAC, CTG, AAC, TAA, GAC, ACT, ATC, CCT, CTC, CCC, 11511152, TGC, TTT, CTT, TTT, CTG, TTA, TCA, CCA, TAA, TTA, ATG, TTT, TAC, TTA, TAT, ATG, 11991200, ATT, TGT, TAA, TGT, ATG, TCT, CTT, CCC, ACT, AGA, AAC, CGA, ATT, CTA, TGA, CAG, 12471248, CAA, GGG, TTT, TTG, TTT, TCA, TTA, TTG, TCA, TAT, TAC, CTG, TGC, CTG, GCA, TGT, 12951296, GAT, AAG, CCC, TAA, GTA, CTT, GTT, GAC, TGA, ATT, AAC, ATA, TGA, GAT, CTG, TGA, 13431344, GTC, TGA, AAA, AAG, AAG, TAC, ATC, ATT, CCT, TCA, CAT, GTC, ATT, TTG, AGC, CAC, 13911392, TGT, TAA, CAG, ATT, ACA, TAA, CTG, TTA, TTG, GAA, GTG, CCT, CAC, TAC, TCC, ATT, 14391440, TGG, AAA, GTA, TTC, CTG, GAA, TAC, ACG, ATG, AAT, GAC, TCA, GTA, GAA, GTT, CTG, 14871488, GCT, ATG, GGG, GAG, TGC, CAT, CAA, TAA, ATA, AAA, ATA, ATA, CCA, TTG, CCT, GTT, 15351536, GGT, TAT, AAG, TTG, CTG, TCA, CAG, ACT, ATG, AAG, GTA, TTT, GAA, TTG, TAT, TTT, 15831584, CAG, GAA, GAG, AAA, CAG, ATA, TGC, AAC, CAA, TCT, GAT, TTG, GTT, CCA, CAC, CCT, 16311632, GCC, ACA, GAA, GTC, CCA, AAG, GAG, AAG, CAA, ATG, CCA, CTT, GTA, GAC, TCA, AAC, 16791680, TCT, GGA, CTT, CAT, TCT, CAG, CAC, CAT, CTC, TTA, ACC, TAC, TGA, GTA, AAT, CCT, 17271728, ATG, AAC, CTG, ACT, AGG, GTG, GCA, ACT, GAA, GTT, GTA, GTA, CTT, TCT, GTC, TTC, 17751776, AAA, GGA, GGG, TGA, ACC, TGG, AGT, ATG, TTG, GAA, GAA, GTG, TTA, GGT, TCA, TTA, 18231824, GAG, ACA, CCT, CTT, TCA, TAA, CTG, CTG, TCA, CCT, AGA, ATG, TCT, ATT, CTC, TAA, 18711872, GCA, CCT, TCT, TGA, AAG, AAG, CAC, ATT, CCC, CCA, GGA, GGA, GGA, AAT, GGT, TTG, 19191920, TTT, TCT, TTA, GTG, ACA, GTT, GGC, CCA, GGA, TCC, TAA, GGT, AAA, GGA, GTA, TGG, 19671968, GCA, CTA, GAC, AAA, ATG, AGT, TTT, ATA, ATA, GTC, GAT, TGG, AAG, GAA, TGG, AAG, 20152016, TTT, TTG, AAT, CAC, AGG, CTT, CTG, CCT, TGA, AAG, GGC, AAG, TCC, GTG, GTG, GTC, 20632064, ATG, AAC, CAC, CCA, GAG, TGT, GTA, CAA, GGC, TCC, TGC, CAG, AAG, AAA, TGC, CTG, 21112112, TAG, GAT, TAA, AAG, CAA, AAC, AGC, AGA, ATC, AAA, AAG, GAA, GGG, CAC, GAT, GAT, 21592160, GCC, CAG, GTG, CAG, CCT, ATA, TTA, TTA, ACA, GAC, AAG, GAA, AGA, ATC, CAA, ATA, 22072208, AAA, GTT, CTG, TAA, ACC, AAA, AAA, AAA, AAA, AAA, AAA, AAA, A, 2244

Claims (10)

1. isolating people's albumen with cancer suppressing function is characterized in that, it comprises the polypeptide of the aminoacid sequence with the group of being selected from down: SEQ ID NO:2,5,8,11,14,17,20,23,26,29,32,35;

Or its conservative property variation polypeptide or its active fragments or its reactive derivative.

2. polypeptide as claimed in claim 1 is characterized in that, this polypeptide is the polypeptide with aminoacid sequence of the group of being selected from down: SEQ ID NO:2,5,8,11,14,17,20,23,26,29,32,35.

3. isolating polynucleotide is characterized in that, it comprises a nucleotide sequence, and this nucleotide sequence is shown at least 85% homogeny with a kind of nucleotides sequence that is selected from down group:

(a) coding is as the polynucleotide of polypeptide as described in claim 1 and 2;

(b) with polynucleotide (a) complementary polynucleotide.

4. polynucleotide as claimed in claim 3 is characterized in that, the polypeptide of this polynucleotide encoding has the aminoacid sequence of the group of being selected from down: SEQ ID NO:2,5,8,11,14,17,20,23,26,29,32,35.

5. polynucleotide as claimed in claim 3 is characterized in that, the sequence of these polynucleotide is selected from down group:

SEQ ID NO:3,6,9,12,15,18,21,24,27,30,33,36 coding region sequence or full length sequence.

6. a carrier is characterized in that, it contains the described polynucleotide of claim 3.

7. a genetically engineered host cell is characterized in that, it is a kind of host cell that is selected from down group:

(a) host cell that transforms or transduce with the described carrier of claim 6;

(b) host cell that transforms or transduce with the described polynucleotide of claim 3.

8. the preparation method of the polypeptide of the people's protein-active with cancer suppressing function is characterized in that this method comprises:

(a) have under the proteic condition of people of cancer suppressing function suitable the expression, cultivate the described host cell of claim 7;

(b) from culture, isolate the polypeptide of people's protein-active with cancer suppressing function.

9. energy and the described people's protein-specific bonded antibody of claim 1 with cancer suppressing function.

10. a pharmaceutical composition is characterized in that, it contains the described albumen of claim 1 and the pharmaceutically acceptable carrier of safe and effective amount.